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COFACTOR CONTROL OF A VITAL ENZYMATIC REACTION: THE 
EFFECT OF FACTOR VA ON THROMBIN FORMATION DURING BLOOD 
COAGULATION 
 
JAMILA HIRBAWI 
 
ABSTRACT 
The LONG-TERM goal of our research is to study and analyze the structure and 
function of the factor V molecule in order to understand its regulatory effects on the 
natural process of hemostasis and its role in the life-threatening development of deep 
venous thrombosis. 
The SHORT-TERM goal of our research is to identify the amino acid residue(s) of 
factor V that interact with prothrombin during the assembly and function of the 
prothrombinase complex in order to fully understand its particular role in maintaining the 
integrity of the blood coagulation cascade.  The final goal of the coagulation cascade is 
the formation of a fibrin clot that is catalyzed by the serine protease, thrombin.  The 
proteolytic conversion of prothrombin to thrombin is catalyzed by the prothrombinase 
complex composed of the enzyme, factor Xa, its cofactor, factor Va, assembled on a 
membrane surface in the presence of divalent metal ions.  Although factor Xa alone can 
activate prothrombin, it is at a rate that is not compatible for survival. Incorporation of 
factor Va into the prothrombinase complex results in a 300,000-fold increase in the 
catalytic efficiency of factor Xa for thrombin generation and plays an important role in 
v 
 
regulating prothrombin activation.  Thus, it is crucial to identify which specific amino 
acid residue(s) are responsible for the interaction of factor Va with prothombin and factor 
Xa in the formation of thrombin, which is absolutely vital for maintaining normal 
hemostasis in a healthy individual.   
The specific aims of the present study are; To identify the specific amino acid 
region of the factor Va heavy chain that promotes optimal cofactor function during 
prothrombin activation; To identify key acidic amino acid sequences in the factor Va 
molecule that control the rate of prothrombin cleavage; To identify the specific amino 
acids of the factor V/Va heavy chain that regulate enzyme-substrate interaction during 
prothrombin activation. 
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CHAPTER I 
INTRODUCTION 
 
 An estimated eighty million Americans have one or more forms of cardiovascular 
disease.  Among these numbers are individuals who suffer from high blood pressure, 
coronary heart disease, and ischemic stroke.  An important factor involved in the 
evolution of these disorders, is the process of hemostasis.  Hemostasis is the body’s 
natural mechanism for the control of excessive bleeding after injury, as well as 
prevention of a hypercoagulative state during the coagulation response. This procedure 
involves a series of enzymatic reactions that are all tightly regulated in order for proper 
clot formation to occur at the sight of injury [1, 2].  Without proper control, a range of 
thrombotic and hemorrhagic difficulties can arise.  These tendencies can be attributed to 
genetic disorders or can be acquired through various outside factors.  
 Thrombosis is the formation of a blood clot within the vasculature such as an 
artery or a vein that causes the blockage of blood flow through the circulatory system.  
There are two forms of veins present in an individual’s legs. Superficial veins are located 
just beneath the surface of the skin, while deep veins are found deep within the muscles 
of the leg.  
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Deep venous thrombosis (DVT) is a condition where an unwanted blood clot forms in the 
thigh or lower leg [3].  This pathological state can progress to a more fatal stage once a 
small portion of the clot (embolus) is dislodged, circulates in the system through the heart 
and remains lodged in the lung.  A pulmonary embolism will cause blood supply to the 
lung to be blocked therefore, depleting it of oxygen and carbon dioxide exchange and 
ultimately causing necrosis of the lung tissue followed by death. 
 In contrast, hemophilia is an inherited disorder that involves prolonged bleeding 
after injury [4].  There are two major forms of the disease caused by an x-linked recessive 
trait.  Hemophilia A is caused by a deficiency in the clotting factor, factor VIII and 
hemophilia B is due to a deficiency in factor IX [5].  Individuals affected with these 
deficiencies usually suffer bleeding episodes that range from mild to severe. In addition, 
acquired hemophilia is an autoimmune disorder, in which a person with normal 
haemostatic activity spontaneously develops autoantibodies against the blood clotting 
factors, more frequently factor VIII.  This condition generally occurs as a result of 
various medical issues such as pregnancy, autoimmune disorders, diabetes, respiratory 
disease, and a variety of malignancies.   
 Another frequently seen clotting disorder involves the inability of the coagulation 
response to halt in a timely manner.  APC (activated protein C) is the enzyme responsible 
for the inactivation of the clotting factors, FVa and FVIIIa, when bound to its cofactor, 
protein S [6] .  Factors Va and VIIIa are important facilitators in the formation of a blood 
clot. APC resistance occurs in about 25-40% of patients with a family history of 
thrombotic conditions and in about 3-5% of the normal population [7].  Deficiency in 
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either protein C or protein S will cause the continued accumulation of thrombus 
formation due to inadequate quantities present to inactivate FVa and FVIIIa.   
1.1 Hemostasis 
 Primary hemostasis is the body’s initial response to injury to the endothelial 
surface of a blood vessel.  This initial phase is characterized by constriction of the blood 
vessel, blood platelet adhesion to the surface, and the formation of a “soft plug” [8].  
Once damage occurs, vasoconstriction limits the flow of blood to the damaged area. 
Platelets then become activated by thrombin and soon aggregate at the site of injury. Cell 
adhesion occurs when glycoproteins present on the platelet surface bind to von 
Willebrand (vWD) factor that attaches to the endothelim.  Platelets then clump by 
binding to collagen that is exposed during initial rupture of the blood vessel lining.  
Individuals, who have decreased amounts of circulating vWD factor, suffer from 
bleeding of the skin and mucous membranes due to interruption of primary hemostais.  In 
addition, vWD factor also binds and stabilizes circulating factor VIII, which is involved 
in the intrinsic pathway of secondary hemostasis.  There are three types of von 
Willebrand disease, with type III being the most severe and rare form.  Although the 
initial plug arrests bleeding, it must be stabilized through secondary hemostasis.  This 
process involves a series of reactions induced by coagulation factors that serve as 
enzymes and coenzymes, the presence of calcium, and a phospholipid surface that is 
usually presented by the activated platelets [9]. Defects in this system may lead to serious 
bleeding disorders including internal bleeding of the cavities and subcutaneous 
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hematomas.  In addition, deficiencies in circulating blood factors and/or genetic 
mutations can incur risk of thrombotic episodes.   
1.2 The Coagulation Cascade 
 The coagulation response is of utmost importance in the maintenance of normal 
hemostasis in healthy individuals.  Any slight disruption of this mechanism can lead to 
abnormalities that eventually cause heart disease, stroke, or blood pressure variations.  
The penultimate goal of the coagulation cascade is the generation of thrombin, which in 
turn converts fibrinogen to fibrin to generate a fibrin plug. Thrombin generation is 
divided into three separate segments: the initiation phase where low levels of α-thrombin 
are produced; the propagation phase when a considerable amount of thrombin is created 
and the fibrin plug is formed; and the termination phase where the inhibition of thrombin 
and many of the serine proteases involved in the coagulation cascade takes place due to 
the inhibitors TFPI (tissue factor pathway inhibitor) and AT-III (antithrombin III); and 
inactivation of the cofactors (fVa and fVIIIa) by activated Protein C (APC)/Protein S 
[10].  This response is initiated by cellular and vascular injury and can be initially divided 
into two distinct pathways, followed by the common pathway [11] (Fig.1.1).   
 The extrinsic pathway (tissue factor pathway) is initiated with the exposure of 
tissue factor (TF) after vascular damage.  Tissue factor is a cell surface glycoprotein that 
serves as a cofactor for factor VIIa [12, 13].  TF will bind to factor VIIa to form the 
extrinsic tenase complex that will activate factor X [14].  In addition, factor VII can also 
be activated by factor Xa and thrombin.  Activated factor X (fXa) will then go on to the 
common pathway where the prothrombinase complex is formed with its cofactor, factor  
 4
  
 
 
 
Fig. 1.1: The Blood Coagulation Pathway.  The blood coagulation cascade includes the 
extrinsic and extrinsic pathways, which combine at the common pathway where the 
prothrombinase complex forms to continue prothrombin activation.  This process will 
eventually lead to the formation of the fibrin plug after vascular injury. (from 
www.kingsnake.com) 
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Va, on a membrane surface in the presence of Ca2+ to activate the substrate, prothrombin.  
Consequently, the TF-FVII complex will also activate factor IX that will play a role in 
the intrinsic pathway [15].  The extrinsic pathway is rapidly inhibited by tissue factor 
pathway inhibitor (TFPI), a serine protease inhibitor that is associated to lipoprotein 
molecules.  Although this pathway is inhibited quickly, sufficient quantities of thrombin 
are formed to activate factor XI [12]. Factor XIa will participate in the intrinsic pathway, 
inducing the amplification of the coagulation response.  
  The intrinsic pathway, involves the conversion of factor XI to XIa by factor XIIa.  
Activated factor XII is a key component in the generation of bradykinin and 
implementation of fibrinolysis and is the initial activator of the intrinsic pathway.  Factor 
XIa will convert factor IX to factor IXa. This enzyme will associate on a membrane 
surface with its cofactor, factor VIIIa in the presence of calcium to form the intrinsic 
tenase complex [16].  Intrinsic tenase will activate factor X that will be incorporated into 
prothrombinase for thrombin generation.  The intrinsic pathway is not important for 
initiation of the coagulation cascade.  However, it is responsible for amplification of the 
process due to production of large amounts of factor Xa and thrombin. 
 Once enough factor Xa is generated through the extrinsic and intrinsic pathways, 
the common pathway takes part in the generation of human alpha thrombin through 
conversion of prothrombin by the prothrombinase complex.   This complex is composed 
of the enzyme, factor Xa, with its non-enzymatic cofactor, factor Va, on a phospholipid 
surface, (provided by the activated platelets), in the presence of Calcium ions [17].  
Although factor Xa can activate prothrombin with an initial cleavage at Arg271 followed 
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by cleavage at Arg320 to yield the intermediates Fragment 1.2 and Prethrombin 2, 
incorporation of factor Va into the prothrombinase complex results in a reversal of 
cleavages and a 300,000-fold increase in the catalytic efficiency of factor Xa for 
thrombin generation [18].  Thrombin will proceed to convert fibrinogen to fibrin to 
produce a stable clot. 
1.3 Blood Coagulation Factor V 
 Coagulation factor V circulates in plasma at a concentration of 20 nM, as a single 
chain protein of Mr 330,000 consisting of three protein domains (A, B, & C) that are 
arranged in the order of A1-A2-B-A3-C1-C2 [1] (Fig. 1.2).  In addition, factor V can be 
found in a partially active state in the α-granules of platelets.  It is cleaved by α-thrombin 
(fIIa) at Arg709, Arg1018, and Arg 1545 to release the B domain (containing a large number 
of asparagines-linked oligosaccharides) and generate an active cofactor (fVaIia) composed 
of a light chain of Mr 74 kDa (A3-C1-C2 domains) and a heavy chain of Mr 105 kDa 
(A1-A2 domains) that is involved in prothrombinase complex formation and function 
[19, 20].  The amino-terminal heavy chain (amino acids 1-709) is associated via Ca2+ ions 
to the carboxy-terminal light chain (amino acids 1546-2196).  The B domain has been 
shown to have sequences recognized by α-thrombin for activation of the cofactor [21]. 
While thrombin is a major activator of the human factor V molecule, it also has been 
implicated in the inactivation of the cofactor.  In previous studies, it was determined that 
cleavage at Arg643 of the COOH-terminal region of the heavy chain resulted in a partially 
inactive molecule [22].  In addition to thrombin, various proteases can cleave factor V to  
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Fig. 1.2: Human Factor V.  Schematic of the factor V molecule with various 
modifications and activation/deactivation sites. 
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induce activation.  The procofactor can be activated by Russell’s viper venom (RVV-V) 
through cleavage at Arg1018 and Arg1045, resulting in a cofactor with approximately the 
same activity as factor VaIIa.  Proteolytic cleavage of the procofactor can also be induced 
by the serine proteases found in polymorphonuclear leukocytes (PMN), Cathepsin G and 
Human Neutrophil Elastase (HNE).  These enzymes give result to a cofactor with a 
truncated heavy chain missing vital amino acid residues necessary for interaction with 
prothrombin during thrombin formation.  Cathepsin G will cleave factor V at Phe1031, 
Leu1447, Tyr1518, and Tyr696 to yield a 103 kDa heavy chain and 80 kDa light chain.  
Elastase will activate factor V through cleavage at Ile708, Ile819, Ile1484, and Thr678 to 
produce a 102 kDa heavy chain and 90 kDa light chain.  Other proteases involved in 
factor V cleavage include the protease from the venom of the snake naja naja oxiana, 
factor Xa, and the prothrombin activation intermediate, meizothrombin [18].  
1.4 Factor Va Inactivation 
 Factor Va can be inactivated by the anticoagulant, activated protein C (APC).  
Protein C is a 62,000 Mr protein that circulates in plasma at a concentration of 60 nM.  It 
consists of a heavy chain and light chain, which are held together by a single disulfide 
bridge[23] .  When cleaved at Arg169 of the heavy chain by the thrombin-thrombomodulin 
complex, protein C is converted to the active enzyme, APC.  APC cleaves factor Va 
sequentially at Arg506, Arg306, and Arg679 in the presence of its cofactor protein S to yield 
an inactive factor Va molecule that can no longer bind to factor Xa or prothrombin [24].  
Cleavages at Arg506 and Arg306 occur with the involvement of a phospholipid surface 
with the latter being strictly dependent on the presence of a membrane surface [25].  
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Initial cleavage occurs at Arg506 to yield a factor Va molecule that is partially active and 
has a lower affinity for the enzyme, factor Xa.  Once cleavage at Arg306 takes place, total 
deactivation of the cofactor is obtained [26].  In addition to APC inactivation, factor Va 
can also be cleaved at Arg643 by human alpha thrombin in the presence of endothelial 
cells to yield an inactive product [22].  Factor Va will also be inactivated by plasmin 
which will cleave at Lys309, Lys310, Arg313, and Arg348 in the presence of a membrane 
surface and cause the A2 domain to dissociate from the rest of the molecule [27]. 
1.5 Factor Va interaction with factor Xa. 
 Appropriate binding of factor Va to factor Xa during prothrombinase function is 
crucial to the proper activation of the substrate, prothrombin. Factor Va increases the 
catalytic efficiency of factor Xa for prothrombin activation by a great magnitude.  It has 
been shown that factor Va increases the kcat and decreases the Km of the reaction along 
with inducing sequential cleavages at Arg320 and Arg271 to induce the meizothrombin 
pathway in the presence of phospholipids [28].  The increase in Kcat value is attributed to 
cofactor interaction with the enzyme, while the decrease in Km is due to the γ-
carboxyglutamic acid-dependent (Gla domain) interaction of factor Xa and prothrombin 
with the phospholipid suface .  Factor Va binds to both the light and heavy chains of 
factor Xa including amino acids 211-222 and 254-274 of the catalytic domain of factor 
Xa [29, 30].  Cofactor binding to factor Xa has also been found to expose cryptic exosites 
on fXa that are recognition sites for its substrate, prothrombin [31].   Previous data has 
indicated that amino acids located on various portions of the heavy chain have had 
enormous effects on prothrombinase formation and function.  A nonapeptide (AP4’) with 
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amino acid sequence Glu323-Val331 of the factor Va A2 domain of the heavy chain was 
found to have inhibitory effects on prothrombinase assembly and function by interfering 
in factor Xa-Va interaction [32].  It has also been found that the carboxy-terminus of the 
factor Va heavy chain has a dramatic effect on its’ binding to factor Xa and prothrombin.  
A factor Va molecule lacking the 27 amino acids at the carboxyl end of the heavy chain 
produced by cleavage at Asp683 by the protease purified from the venom of the snake 
Naja naja oxiana experienced a reduction in clotting activity.  Additionally, this factor 
Va variant (factor VaNO) was found to have a lower affinity for factor Xa within the 
prothrombinase complex than wild-type factor Va with KD values of 4 nM and 0.5 nM, 
respectively [33].  A pentapeptide (DYDYQ) consisting of the region Asp695-Gln699 was 
also found to inhibit prothrombinase function by competitively inhibiting the 
prothrombinase complex during thrombin formation with a Ki of 850 nM [34, 35].   
1.6 FVa interaction with prothrombin/thrombin 
 There has been substantiated evidence that there are certain acidic amino acid 
residues in the carboxyl-terminal end of the heavy chain of factor Va that are extremely 
important for cofactor activity.  The region between amino acids 680-709 has been the 
basis for investigation into the functional role of factor Va in prothrombinase complex 
formation and function [34, 36].  These acidic residues may be directly involved in the 
interaction of the cofactor with factor Xa or Thrombin through positively charged amino 
acids.  It was recently demonstrated that there is a thrombin-binding site in the last 13 
amino acids of the heavy chain.  Thrombin contains two electro-positively charged 
binding regions (anion binding exosite I (ABE-I) and anion binding exosite II (ABE II)), 
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which are crucial for protein function [37, 38].  ABE-I is responsible for binding many of 
the proteins involved in the coagulation cascade including factors V, Va, fibrinogen, 
PAR-I (the platelet thrombin receptor), thrombomodulin, and heparin cofactor II [39].  
ABE-II, located just above the active site of the molecule, serves as a heparin-binding site 
[40].  Factor Va will also bind to the second kringle domain of prothrombin to enhance 
prothrombinase function [41].   Additional studies involving factor Va interactions with 
prothrombin (fII) have implied that Cys539 of the heavy chain interacts with residues 473-
487 of the serine protease domain of factor II [42].   A peptide (N42R) consisting of 
amino acid region 307-348 of the heavy chain of factor Va was found to be a good 
inhibitor of prothrombinase with an IC50 value of 1.3 uM, leading to believe that this may 
be a factor Xa and/or prothrombin binding site on factor Va [27].  Previous studies have 
also demonstrated that a factor Va molecule cleaved initially with either cathepsin G 
(fVaCG) or human neurtrophil elastase (fVaHNE) followed by cleavage with thrombin 
giving rise to a factor Va molecule with a truncated heavy chain (fVCG/IIa or fVaHNE/IIa), 
resulted in Kd values of ∼.2nM, similar to fVaIIa and kcat values that were higher than the 
wild-type factor Va [43].  Surprisingly, clotting assays performed with these species in 
the presence of factor V deficient plasma resulted in a loss of clotting activity of about 
60%. 
1.7 Prothrombin Activation 
The activation of prothrombin to α-thrombin by factor Xa alone is not considered a very 
efficient reaction.  Factor Xa will convert prothrombin at a rate of 5 orders of  
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Fig.1.3: Prothrombin Activation Pathway.  Conversion of prothrombin to thrombin 
occurs by two distinct pathways. Prothrombin can be activated by fXa alone, as shown in 
pathway I or it can be converted to thrombin by the prothrombinase complex.  Pathway I 
will initially induce cleavage at Arg271 followed by cleavage at Arg320, to produce the 
intermediates fragment 1.2 and prethrombin 2. Pathway II, which is essential for normal 
clotting in healthy individuals, catalyzes an initial cleavage at Arg320, followed by 
cleavage at Arg271 that produces the intermediate, meizothrombin. 
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magnitude lower than when factor Va is incorporated into the prothrombinase complex 
[44].  Factor Va promotes an increase in catalytic efficiency of prothrombinase along 
with inducing sequential cleavage of Arg320 and Arg271 (Fig. 1.3).  Both cleavages are 
phospholipid-dependent, but only cleavage of Arg320 is dependent on factor Va. [45] [46].  
The catalytic efficiency is highly improved as a result of decreasing Km by 100-fold and 
increasing Kcat values by 3,000-fold, corresponding to substrate concentration and 
enzyme efficiency, respectfully [47].  Kinetic analyses has revealed the Ca2+ dependent 
interaction of factor Va with factor Xa, in solution, has a dissociation constant value (Kd) 
of .8 μM, while the Kd in the presence of a phospholipid surface is decreased to1 nM, 
showing a decrease of 1000-fold [15, 18].   
The Kd value of the calcium-independent factor Va-prothrombin interaction is 1 
μM.  Factor Va provides binding sites for proexosite 1 and the Gla domain of 
prothrombin, explaining one of the possible mechanisms by which the cofactor functions 
to increase enzyme efficiency [48].  It has been demonstrated that a factor V molecule 
activated with the purified protease from the venom of the snake Naja nigricollis 
nigricollis (NN) has reduced clotting activity and an increased Kd value of 4 nM when 
compared to factor V activated with thrombin (fVaIIa) (Kd ∼0.5nM) [27].  When factor 
VIIa is additionally cleaved by NN, cofactor activity is reduced by 60-80%. This reduction 
in activity has been hypothesized to be a direct result from the loss of crucial amino acids 
of the heavy chain that are released when cleaved by NN.  
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1.8 Factor VLeiden  
Disruptions in the coagulation cascade can lead to life-threatening circumstances, such as 
bleeding and clotting disorders.  Factor VLeiden is an autosomal dominant mutation in the 
factor V gene that inhibits degradation of the molecule by APC [25] .  This occurs 
through a substitution of Arg506 by a glutamine that prevents proteolytic cleavage of the 
cofactor by the APC/Protein S complex.  Factor Va is inactivated by APC through three 
sequential cleavages at Arg506, Arg306, and Arg679.  In factor VaLeiden, cleavage of Arg506 
does not occur, but cleavage at Arg306 and Arg679 cause inactivation of the cofactor at a 
slower rate [49].   Studies have shown that cleavage at Arg506 promotes cleavage at the 
other two sites for proper inactivation of the cofactor in order to prevent thrombosis [26].  
Excessive venous clotting occurs from this disorder and eventually leads to a condition 
known as deep venous thrombosis (DVT).  Individuals with this syndrome are at risk of 
pulmonary embolism that occurs when a venous blot clot dislodges and travels to the 
lungs.  Patients who are homozygous for the disease are more likely to suffer from these 
episodes than heterozygous ones who only have one defective gene.   
1.9 Thrombin Inhibition 
 Human alpha-thrombin is the main weapon in the battle to halt excessive 
bleeding, after injury.  In order for this process to be carried out effectively, all aspects of 
the coagulation response must be tightly regulated.  In cases where individuals suffer 
from thrombotic disorders, the inhibition of thrombin is executed.  Thrombin can be 
inhibited directly through its catalytic active site and/or through its exosites [50].   One of 
the main thrombin inhibitors used in medicine is heparin [51].  It indirectly inhibits 
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thrombin by forming the heparin-thrombin-antithrombin complex, which involves 
binding of heparin to exosite II of thrombin [52].  Direct inhibition of thrombin occurs 
when an inhibitor binds to the active site of the enzyme or includes binding of one of the 
exosites.  Hirudin, a leech derived inhibitor, was one of the first discovered inhibitors of 
exosite I.  It leads to the impairment of the enzyme to recognize some of its 
macromolecular substrates by binding to both the active site and exosite I.  Bothrojaracin, 
isolated from a Brazilian snake vanom, is another thrombin inhibitor that will inhibit 
both, exosites I and II [53].  In addition to outside inhibitors, thrombin can be inhibited 
physiologically by antithrombin, once it forms a complex with a heparin sulfate [54].  
Although there are a variety of antithrombotic drugs available, many of them lead to 
undesirable side-effects and levels must constantly be monitored during therapy.  It 
would be of great advantage to develop alternative methods to aid individuals with 
thrombotic tendencies.   
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CHAPTER II 
ROLE OF THE ACIDIC HIRUDIN-LIKE COOH-TERMINAL 
AMINO ACID REGION OF FACTOR VA HEAVY CHAIN IN THE 
ENHANCED FUNCTION OF PROTHROMBINASE 
2.1 Abstract  
Prothrombinase activates prothrombin through initial cleavage at Arg320 followed by 
cleavage at Arg271. This pathway is characterized by the generation of an enzymatically 
active transient intermediate, meizothrombin that has increased chromogenic substrate 
activity but poor coagulant activity.  The heavy chain of factor Va contains an acidic 
region at the COOH-terminus (residues 680-709). We have shown that a pentapeptide 
from this region (DYDYQ) inhibits prothrombin activation by prothrombinase by 
inhibiting meizothrombin generation. To ascertain the function of these regions we have 
created a mutant recombinant factor V molecule that is missing the last 30 amino acids 
from the heavy chain (factor VΔ680-709) and a mutant molecule with the substitution 
695DYDY698→AAAA (factor V4A). The clotting activities of both recombinant mutant 
 27
factor Va molecules were impaired compared to the clotting activity of wild type factor 
Va (factor VaWt).  Using an assay employing purified reagents, we found that 
prothrombinase assembled with factor VaΔ680-709 had a ~39% increase in the kcat, while 
prothrombinase assembled with factor Va4A showed a ~20% increase in kcat for the 
activation of prothrombin as compared to prothrombinase assembled with factor VaWt.  
Gel electrophoresis analyzing prothrombin activation by prothrombinase assembled with 
the mutant molecules revealed a delay in prothrombin activation with persistence of 
meizothrombin.  Our data do demonstrate that the COOH-terminal region of factor Va 
heavy chain is indeed crucial for coordinated prothrombin activation by prothrombinase 
because it regulates meizothrombin cleavage at Arg271 and suggest that this portion of the 
molecule is partially responsible for the enhanced coagulant function of prothrombinase. 
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 2.2 Introduction  
Blood coagulation is initiated at the site of vascular injury and results in the 
activation of prothrombin to thrombin by the prothrombinase complex.  Prothrombinase 
is composed of the enzyme factor Xa bound to its cofactor, factor Va, on a phospholipid 
surface in the presence of Ca2+ (1,2).  Prothrombin and α-thrombin have two distinct 
exosites (anion binding exosite I, ABE-I, and anion binding exosite II, ABE-II) that are 
responsible for the functions of the molecules.  The role of (pro)exosite I of thrombin 
within prothrombinase is dependent on the incorporation of factor Va into the complex 
as independently suggested by several laboratories (3-7).  Two activation pathways for 
prothrombin activation are possible: membrane-bound factor Xa alone activates 
prothrombin following initial cleavage at Arg271 followed by cleavage at Arg320, while 
the fully assembled prothrombinase complex activates prothrombin following the 
opposite pathway, initial cleavage at Arg320 followed by cleavage at Arg271 (8-15).  
Activation of prothrombin via this latter pathway is characterized by the generation of 
an intermediate, meizothrombin, that has proteolytic activity and results in a significant 
increase in the catalytic efficiency of factor Xa with respect to thrombin formation (16).  
Initial cleavage of prothrombin at Arg320 that is absolutely factor Va-dependent and 
results in meizothrombin generation is required and sufficient for the formation of the 
active site of α-thrombin and complete exposure of ABE-I of the molecule (17-19).  
However, meizothrombin does not have a fully exposed ABE-II which is required for 
proper fibrinogen binding and timely fibrin formation.  Exposure of this exosite, which 
is partially covered by fragment 2 of prothrombin, requires cleavage at Arg271 (5,20,21).  
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As a consequence, most functions associated with ABE-II of thrombin are impaired in 
meizothrombin.  For this reason, meizothrombin has reduced fibrinogen clotting activity 
(22,23).   
Human factor V circulates in plasma as a 330,000 single-chain protein that consists 
of three domains in the order A1-A2-B-A3-C1-C2.  Proteolytic cleavage of the cofactor 
by α-thrombin occurs sequentially at Arg709, Arg1018, and Arg1045 to produce a 
heterodimer consisting of a heavy chain (Mr~105,000) and a light chain (Mr~74,000) 
associated through divalent metal ions (24-28) (Fig.2.1).  The heavy chain of the 
cofactor contains an acidic amino acid region that has been shown to be important for 
cofactor function (amino acid 680-709) (29).  Early data have suggested that this region 
is implicated in the productive interaction of factor Va with prothrombin (30-32).  
Various proteases can cleave this acidic region to produce a cofactor with a truncated 
heavy chain (33-36).  Gerads et al first showed that it is possible to selectively eliminate 
the acidic region from factor Va heavy chain by an enzyme purified from the venom of 
the snake Naja Naja Oxiana (33).  Using proteins of bovine origin, the authors showed 
that while elimination of the COOH-terminal region of factor Va results in a molecule 
with severely impaired clotting activity, incorporation of the truncated cofactor 
molecule into prothrombinase resulted in an increased kcat for the activation of 
prothrombin (33).  The same authors also showed that cleavage of the human factor Va 
heavy chain by the same enzyme results in a cofactor with impaired clotting activity 
(33). Subsequently, Bakker et al using the same purified enzyme identified the cleavage 
site of the enzyme at His682 in the human factor Va heavy chain (this amino acid is 
conserved in the bovine cofactor) and demonstrated that prothrombinase assembled with 
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a human factor Va molecule missing the Asp683-Arg709 portion has increased kcat for the 
activation of prothrombin (34).  Afterward, Camire et al using cathepsin G (CG) and 
human neutrophil elastase demonstrated that prothrombinase assembled with factor Va 
molecules missing the COOH-terminal domain of the heavy chain result in enzymes that 
consistently express higher kcat values suggesting that these molecules are “more active” 
cofactors than purified plasma factor Va activated with thrombin in an assay using 
purified reagents (35).  Surprisingly, and in line with the initial findings of Gerads et al 
(33) the same factor Va molecules showed a significant decrease in clotting activity 
(35).  More recently, using a purified enzyme from the snake venom of Naja Naja 
Nigricollis, we have also shown that a factor Va molecule missing a portion of the 
COOH-terminus of the heavy chain has decreased clotting activity (36).  Altogether 
these studies reveal that removal of the acidic COOH-terminal portion of factor Va 
heavy chain results in a cofactor molecule that is deficient in its clotting activity. 
However, prothrombinase assembled with cofactor molecules missing the acidic 
COOH-terminus produces significant higher kcat for prothrombin activation when 
assessed in assays using purified reagents and a chromogenic substrate specific for 
thrombin.  A molecular explanation for these paradoxical observations has not yet been 
provided.   
We have recently used overlapping peptides from the region 680-709 of the factor 
Va molecule to show that a pentapeptide with the sequence DYDYQ inhibits 
prothrombin activation by prothrombinase in a competitive manner with respect to 
substrate (36,37).  We have further demonstrated that DYDYQ inhibits prothrombinase 
activity by inhibiting meizothrombin generation (38).  Using data obtained with 
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recombinant proteins, Toso and Camire have recently suggested that the COOH-
terminal region of the factor Va heavy chain has no detectable effect on prothrombinase 
function (39).  This conclusion was surprising since their data showed that: 1) 
prothrombinase assembled with recombinant factor Va molecules missing a portion or 
the entire hirudin-like carboxyl- terminal end of the heavy chain have increased kcat for 
the activation of prothrombin (from 129%-150%) compared to prothrombinase 
assembled with the wild type molecule in an assay using purified reagents and a 
chromogenic substrate specific for thrombin; 2) initial velocity measurements using the 
same assay demonstrated a 20-25% increase in the rate of thrombin formation by 
prothrombinase assembled with the same recombinant mutant cofactor molecules that 
were truncated at their carboxyl-terminal end; and 3) a recombinant factor Va molecule 
that is missing 17 amino acids from the carboxy-terminal portion of the heavy chain had 
decreased clotting activity (39). All these data are in complete accord with all earlier 
findings using plasma-derived factor Va molecules truncated at their heavy chain and 
demonstrate a crucial but yet undetermined contribution of the acidic COOH-terminal 
region of the heavy chain of the cofactor to prothrombinase activity during prothrombin 
activation. 
It has been well established that while meizothrombin has poor clotting activity, its 
amidolytic activity is increased compared to thrombin towards small fluorescent and 
chromogenic substrates specifically used to assess thrombin activity (23,40).  A logical 
hypothesis to reconcile all the findings described above is that the acidic COOH-terminus 
of factor Va heavy chain, and more precisely the sequence DYDYQ, regulates 
meizothrombin concentration during the factor Xa catalyzed prothrombin activation by 
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prothrombinase.  Thus, activation of prothrombin by prothrombinase assembled with a 
cofactor that is missing the acidic region will result in increased and stable 
meizothrombin production.  This result will be translated by a factor Va molecule that is 
deficient in its clotting activity but produces an increase in kcat when introduced into 
prothrombinase.  In contrast, in the presence of an excess of the acidic region 
(represented by DYDYQ, (36-38)) no meizothrombin is produced by prothrombinase 
resulting in the generation of thrombin through the alternative pathway characterized by 
initial cleavage of prothrombin at Arg271.  The present work was undertaken to test these 
hypotheses and to elucidate the role of the acidic COOH-terminal portion of factor Va 
heavy chain during activation of prothrombin by prothrombinase. 
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Figure 2.1.  Mutants of human factor V.  Factor V is activated following three 
sequential cleavages by thrombin at Arg709, Arg1018, and Arg1545.  These cleavages release 
the active cofactor composed of heavy and light chains associated in the presence of 
divalent metal ions, and two activation fragments.  The COOH-terminus of the heavy 
chain contains an acidic hirudin-like amino acid region that is important for its cofactor 
functions.  The mutations (deletions and point mutations) within the heavy chain are 
indicated together with the designation for the recombinant mutant factor V molecules 
created and used throughout the manuscript.   
 
 34
 2.3 Experimental Procedures 
Materials reagents, and proteins.  Diisopropyl-fluorophosphate (DFP), O-
phenylenediamine –dihydrochloride (OPD), N-[2-Hydroxyethyl]piperazine-N'-2-
ethanesulfonic acid (Hepes), Trizma (Tris base), and Coomassie Blue R-250 were 
purchased from Sigma (St. Louis, Mo).  Factor V-deficient plasma was from Research 
Proteins Inc (Essex Junction VT).  L-α-phosphatidylserine (PS) and L-a-
phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).  Normal 
reference plasma and the chromogenic substrate H-D-Hexahydrotyrosol-alanyl-arginyl-p-
nitroanilide diacetate (Spectrozyme-TH) were purchased from American Diagnostica Inc. 
(Greenwich, CT).  H-D-Phenylalanyl-L-pipecolyl-L-arginyl-p-nitroaniline 
dihydrochloride (Chromogenix, S-2238) was purchased from Diapharma Group, Inc. 
(West Chester, OH) and its concentration in solution (water) was verified as described 
(41).  RecombiPlasTin for the clotting assays was purchased from Instrumentation 
Laboratory Company (Lexington, MA).  The reversible fluorescent α-thrombin inhibitor 
dansylarginine N,N-(3-ethyl-1,5-pentanediyl)amide (DAPA), human prothrombin, RVV-
V activator, and human α-thrombin, were from Haematologic Technologies Inc. (Essex 
Junction, VT).  Active-site blocked human meizothrombin (obtained following digestion 
of prothrombin with the purified component from the venom of the snake Echis 
Carinatus as described (42,43), FPR-meizothrombin) was provided by Dr. Rick Jenny 
(Haematologic Technologies Inc, Essex Junction VT).  Human factor Xa was from 
Enzyme Research Laboratories (South Bend, IN).  Human cathepsin G was from 
Calbiochem (EMD Chemicals, Inc. San Diego, CA).  All molecular biology and tissue 
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culture reagents and media were from Gibco, Invitrogen Corporation (Grand Island, NY).  
Human plasma factor V was purified and concentrated using methodologies previously 
described employing the monoclonal antibody αhFV#1 coupled to Sepharose (44).  
Digestion of factor Va by a-thrombin and cathepsin G (to obtain factor VaII/CG) and/or the 
purified enzyme from Naja Naja Nigricollis (factor VaNN) were performed as described 
(35,36).  The clotting activities of all factor Va preparations was measured by a clotting 
assay using factor V deficient plasma and standardized to the percentage of control as 
described (44) using an automated coagulation analyzer (START-4, Diagnostica Stago, 
Parsippany, NJ).  Recombinant wild type prothrombin and prothrombin rMZ-II that has 
only one cleavage site for factor Xa (i.e. Arg320) were prepared and purified as previously 
described (17,22,45,46). Phospholipid vesicles composed of 75% PC and 25% PS 
(referred to as PCPS vesicles throughout the manuscript) were prepared as previously 
described (47).   
Construction of Recombinant FV Molecules.  Mutant factor V with the 
substitutions 695DYDY698→AAAA (factor V4A) was constructed using the QuickChange 
II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the 
manufacturer’s instructions with the following primers (underlined nucleotides represent 
the mismatch): 5’-GATGAAGAGAGTGATGCTGCCGCTGCTGCCCAGAACAGA-
3’(sense) and 5’-TCTGTTCTGGGCAGCAGCGGCAGCATCACTCTCTTCATC-3’ 
(anti-sense).  The deletion mutant (factor VD680-709)) was constructed with the same kit.  
Primers for factor VD680-709 were 5’-
CCTCCAGAATCTACAGTCATGGCTACACGGTCATTCCGAAACTCATCATTGAA
TCAGG-3’ (sense) and 5’-
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CCTGATTCAATGATGAGTTTCGGAACGACCGTGTAGCCATGACTGTAGATTCT
GGAGG-3’ (anti-sense).  PCR products were transformed into competent E. Coli cells 
and positive ampicillin-resistant clones were selected.  Before transfection, all mutant 
constructs were verified following sequencing in the Cleveland State University DNA 
Analysis Facility using a Beckman Coulter CEQ 8000 Genetic Analysis System 
(Beckman, Fullerton CA) with factor-V sequence-specific primers.  The wild type pMT2-
FV and mutant pMT2-FV plasmids were isolated from the bacterial culture by the 
QIAfilter High Speed plasmid Midi Kit (Qiagen Inc., Valencia, CA). 
Expression of Recombinant Wild Type and Mutant Factor V in Mammalian 
Cells.  COS-7L and COS-7 cells (Invitrogen) were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, and 
antibiotics (100 μg/ml streptomycin and 100 IU/ml penicillin) in a humidified 
atmosphere of 5% CO2 and 95% air at 37°C.  Purified factor VWt, factor VD680-709, and 
factor V4A plasmids were transfected into the cells as described (48).  Purification of all 
recombinant factor V molecules was performed as described (49). The concentration of 
all molecules was assessed by ELISA as detailed (48).  The activity and integrity of the 
recombinant molecules was verified before and after activation with RVV-V activator or 
thrombin by clotting assays using factor V-deficient plasma and and in several 
experiments by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
followed by Western blotting using monoclonal and polyclonal antibodies. 
Analysis of Prothrombin Activation and FPR-Meizothrombin Cleavage at Arg271 
by Gel Electrophoresis.  Prothrombin (1.4μM) was incubated with PCPS vesicles 
(20μM), DAPA (50μM), and factor Va (10-30nM) in a buffer composed of 5 mM Ca2+ in 
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20 mM Tris, 0.15 M NaCl, pH 7.4.  The reaction was initiated with the addition of factor 
Xa (0.5-1nM) at room temperature over a 1 h time course.  Aliquots (50 μl ) from the 
reaction were removed at selected time intervals (as indicated in the legend to the figures) 
treated as described (38) and analyzed using 9.5% SDS-PAGE.  Prothrombin and 
prothrombin-derived fragments were visualized by Coomassie Blue staining.  Scanning 
densitometry and calculation of the rates of prothrombin consumption were performed as 
described (38,50,51).  FPR-meizothrombin cleavage at Arg271 was assessed in a similar 
manner.   
Gel Electrophoresis and Western Blotting.  SDS-PAGE analyses of recombinant 
proteins following activation were performed using 5-15% gradient gels according to the 
method of Laemmli (52).  Proteins were transferred to polyvinylidene difluoride (PVDF) 
membranes according to the method described by Towbin et al. (53).  After transfer to 
nitrocellulose, factor Va heavy and light chain(s) were detected using the appropriate 
monoclonal and polyclonal antibodies (54-57).  Immunoreactive fragments were 
visualized with chemiluminescence.   
Measurement of Rates of Thrombin Formation in a Prothrombinase Assay.  
rMZ-II and recombinant prothrombin were activated by prothrombinase prior to the 
experiment using conditions previously described (58).  Subsequent gel electrophoresis 
analyses under reducing conditions were performed to verify that both rMZ-II and the 
recombinant prothrombin preparations were activated to the same extent.  The enzymes 
(rMZ-IIa and recombinant a-thrombin) used for the titration of Spetrozyme-TH and S-
2238 were assayed at a constant concentration (4.3 nM), as previously described using 
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serial dilutions of chromogenic substrate (35,50,59,60).  The absorbance was monitored 
with a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA).   
Functionally defined apparent dissociation constants (KDapp) for factor Va binding to 
factor Xa-PCPS were obtained from plots measuring the rate of thrombin generation as a 
function of factor Va concentration in the presence of a limiting, (constant) concentration 
of factor Xa.  Throughout all experiments the assumption was n=moles of factor Xa 
bound/mole of factor Va at saturation; throughout this study 1=1; the stoichiometry of the 
factor Va-factor Xa interaction was fixed at 1.  The initial rate of the formation of 
thrombin (initial velocity in nM⋅IIa⋅min-1) was calculated, and the data were analyzed and 
plotted using the software Prizm (Graphpad Software Inc, San Diego CA) according to 
the one binding site model.  Dissociation constants were extracted directly from the 
graphs. 
The assay using purified reagents and verifying the activity of the recombinant factor 
V molecules was conducted under conditions where all factor Xa was saturated with 
factor Va, as described by measuring α-thrombin formation by the change in the 
absorbance of a chromogenic substrate at 405 nm (Spectrozyme-TH, 0.4 mM) (48).  All 
factor V molecules were activated with RVV-V or thrombin as described (36,37).  
Knowing the (KDapp) of each factor Va species for factor Xa, the amount necessary to 
saturate factor Xa was calculated using the quadratic equation described in the literature 
(61,62) before each experiment.  The total concentration of ligand (VaT) used was 
modified as appropriate to obtain between 95-98% saturation of the factor Xa molecule. 
The absorbance was monitored with a Thermomax microplate reader and compared to an 
α-thrombin standard prepared daily using purified plasma-derived α-thrombin (35,37,61-
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63).  The data were analyzed and plotted using the software Prizm according to the 
Michaelis-Menten equation.  Kinetic constants provided throughout the manuscript were 
extracted directly from the graphs. 
 40
2.4 Results 
Activation of Recombinant Human Factor V Molecules.  To ascertain the function 
of the acidic region from the COOH-terminus of factor Va heavy chain for cofactor 
activity, we constructed a molecule that is missing the entire amino acid region 680-709 
(factor VD680-709, Fig. 2.1).  We have also constructed a factor V molecule with the 
mutation 695DYDY698→AAAA (factor V4A).  The recombinant molecules were expressed 
in mammalian cells and purified to homogeneity as described (49).  Because factor 
VD(680-709) is missing Arg709 that is the activating cleavage site for thrombin (Fig.2.1), in 
the functional assays, the recombinant mutant molecule was activated with RVV-V 
activator.  In contrast, factor V4A was activated with either RVV-V activator or α-
thrombin.  SDS-PAGE analyses followed by immunoblotting with specific monoclonal 
antibodies to the heavy and light chain of the cofactor demonstrate that the mutant 
recombinant proteins were intact and homogeneous and migrated according to their 
expected molecular weights (Fig.2.2).   
Cofactor Function of Recombinant Human Factor Va Molecules.  Recent work 
using recombinant factor Va molecules demonstrated that all cofactors lacking portions 
or the entire acidic COOH-terminus of the heavy chain encompassing amino acid region 
680-709, had KDapp values for membrane-bound factor Xa that are similar to the values 
for the bimolecular interaction found with wild type or the intact plasma cofactor (39).  
These values are similar to the KDapp obtained with truncated plasma-derived factor Va 
molecules for factor Xa (35,36).  Our studies with factor VaD(680-709) also demonstrate that 
the mutant cofactor has similar affinity for plasma-derived factor Xa as the wild type 
molecule (Fig.2.3A).  Similar results were found for factor Va4A (not shown).  Thus, 
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elimination of the acidic COOH-terminal region of factor Va heavy chain has no 
consequence on the affinity of the cofactor for its interaction with factor Xa. 
We next evaluated the ability of all recombinant factor Va molecules to function as a 
cofactor for prothrombinase.  A clotting assay using factor V-deficient plasma and a α-
thrombin generation assay using spectrozyme-TH and purified reagents were employed.  
We have also followed the activation of prothrombin by gel electrophoresis.  Figure 2.3B 
show the fitted hyperbolic plots used to extract the kinetic constants obtained following 
plasma-derived prothrombin activation by prothrombinase assembled with all control or 
modified cofactor molecules, and summarized in Table 2.I.  Because we wanted to 
prevent the possibility that differences between prothrombinase assembled with factor 
VaWt and prothrombinase assembled with factor VaD680-709) or factor Va4A may be 
attributed to subtle differences in the KDapp of factor Va for factor Xa, which would result 
in a lesser amount of prothrombinase formed, all experiments described below were 
conducted under condition where more than 95% of factor Xa was saturated with factor 
Va.  The amount of factor Xa saturation by each cofactor was calculated using the 
quadratic equation provided in the literature (61,62).  The percent saturation of factor Xa 
by each cofactor species as well as the correlation coefficient (R2) of the hyperbolas used 
to extract the values of Vmax and Km, are provided in the legend to figure 2.3B together 
with the actual reagent concentrations used in each experiment.   
Factor VaRVVD680-709) had a 39.2% higher kcat (figure 2.3B, open circles) and 73% 
lower clotting activity than factor VaRVVWt (figure 2.3B, open inverse triangles), while 
factor VaIIa/CG had a 23.7% higher kcat and 62% lower clotting activity than factor 
VaIIaPLASMA.  In separate experiments, we have found that under similar experimental 
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conditions, factor VaIIa/NN that has 60% lower clotting activity than the plasma cofactor 
(36) had a 20.5% increased kcat than factor VaIIaPLASMA (Table 2.I).  All these data are in 
complete agreement with earlier and recent findings (33-36,39) and demonstrate that 
elimination of the COOH-terminal region of factor Va heavy chain produces a molecule 
with poor clotting activity yet, when the truncated cofactor is incorporated into 
prothrombinase, it produces an enzyme with increased catalytic efficiency for 
prothrombin activation as assessed in an assay using purified components and under 
conditions in which the majority of membrane-bound cofactor is bound to factor Xa.  
Overall the data shown in Table 2.I also demonstrate that the plasma and wild type 
molecule behave similarly following activation by either RVV-V activator or a-thrombin 
with respect to prothrombin activation.  Thus, the two molecules are interchangeable and 
throughout the manuscript control experiment were conducted with only one of the two 
molecules as indicated. 
We next assessed the capability of prothrombinase assembled with the truncated 
molecules to activate prothrombin by gel electrophoresis and the data are presented in 
figure 2.4.  Under the conditions employed, prothrombinase assembled with factor 
VaRVVWt activates prothrombin quickly, with meizothrombin as a short-lived intermediate 
as demonstrated by the brief half-life of fragment 1•2-A (Fig. 2.4A, panel A).  Scanning 
densitometry demonstrated a peak of meizothrombin early in the reaction at 80 sec and 
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Figure 2.2. Electrophoretic analyses of wild type factor V and recombinant 
factor V molecules. Panel A, factor VWt and factor V680-709) were activated with RVV-V 
activator as described (36); panel B, factor VWt and factor V4A were activated with 
thrombin as described in the “Experimental Procedures” section and analyzed by SDS-
PAGE. Following transfer to a PVDF membrane, immunoreactive fragments were 
detected with monoclonal antibodies αHFVaHC17 (recognizing an epitope on the heavy 
chain of the cofactor between amino acid residues 307-506) and αHFVaHC9 (recognizing 
the light chain). At the right the positions of the heavy/light chains of factor Va are 
shown.  
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Figure 2.3A.  Raw data used for the determination of the parameters of 
prothrombinase complex assembly and function.  Panel A. Determination of the 
affinity of recombinant factor Va molecules for plasma-derived factor Xa.  Initial rates of 
thrombin generation were determined as described under “Experimental Procedures”.  
Prothrombinase assembled with factor VaWt is shown by filled squares (R2 = 0.979) while 
prothrombinase assembled with FVaD(680-709) is depicted by filled triangles (R2 = 0.978)  
Titrations were carried out to 20 nM factor Va; however, for graphical purposes the data 
show the titration for up to 10 nM cofactor.  The solid lines represent a nonlinear 
regression fit of the data as detailed under “Experimental Procedures” using the software 
Prizm and the model for one binding site.  The apparent dissociation constant (KDapp) for 
each species was derived from each titration performed at least in triplicate with at least 
two different preparations of recombinant proteins and is listed in the inset.   
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Figure 2.3B. Panel B.  Determination of kinetic parameters of prothrombinase 
assembled with various factor Va species.  Initial rates of thrombin generation were 
determined using the KD for factor Xa found in panel A as described under 
“Experimental Procedures” in the presence of 20 uM PCPS vesicles.  The reaction was 
initiated by the addition of factor Xa (5 pM).  Prothrombinase assembled with two 
different concentrations of factor VaWtRVV is shown by open triangles (10 nM, 95% factor 
Xa saturation, R2 = 0.97) and open inverse triangles (20 nM, 97% factor Xa saturation, 
R2 = 97).  Prothrombinase assembled with two different concentrations of factor VaD(680-
709) is depicted by filled diamonds (10 nM, 96% factor Xa saturation, R2 = 0.98) and open 
circles (20 nM, 98% factor Xa saturation, R2 = 0.99) while prothrombinase assembled 
with factor VaIIaPLASMA is depicted by filled squares (10 nM, 98% factor Xa saturation, R2 
= 0.97) and factor VaRVVPLASMA is shown by open diamonds (10 nM, 98% factor Xa 
saturation, R2 = 0.97).  Prothrombinase assembled with factor VaRVV4A is depicted by 
filled inversed triangles (10 nM, 96.5% factor Xa saturation, R2 = 0.98).  The values of 
the Km and Vmax/ET (=kcat) extracted directly from these graphs are listed in Table 2.1.   
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 FVaIIaPLASMA FVaRVVPLASMA FVaIIaWt FVaRVVWt FVaRVVD(680-
709)
FVaIIa/CGd FVaIIa/NN FVaIIa4A FVaRVV4A
II 
Consumb
(moles • 
sec-1 • 
mole fXa-
1)
16.2 ± 1.8 ND 17.3 ± 1.2 15.8 ± 1.1 5.1 ± 0.54 5.9 ± 0.6 ND 4.4 ± 0.42 4.7 ± 0.4
Km (mM) 0.1 ± 0.011 0.24 ± 0.04 0.1 ± 0.013 0.22 ±
0.04
0.24 ± 0.03 0.26 ±
0.03
0.15 ±
0.07
0.31 ± 0.1 0.25 ±
0.03
kcat (min-
1)
1715 ± 45 1754 ± 84 1697 ± 48 1721 ± 90 2396 ± 71 2122 ± 62 2066 ± 86 2031 ± 81 2018 ± 75
Specific 
Activity 
(Units/mg)
c
3337 ± 480 2753 ± 267 2926 ± 340 3200 ±
550
869 ± 192 1280 ±
114
NDe 663 ± 210 640 ± 120
 
 
Table 2.I Characteristics of various factor Va molecules when assembled into 
prothrombinasea aThe rate of thrombin formation following activation of prothrombin by 
prothrombinase assembled with the various factor Va species was calculated as described in the 
“Experimental Procedures” section by knowing the dissociation constant of each factor Va 
species for factor Xa.  In each case more than 95% of factor Xa was saturated with factor Va.  
Some of the data in the table were extracted directly from the graphs shown in figure 2.3B. 
bThe rate of prothrombin consumption was determined following quantitative scanning 
densitometry of several gels stained with Coomassie Blue as described in the “Experimental 
Procedures” section.  Some of the gels used are shown in figure 2.4. 
cAll clotting activities were determined in a two-stage clotting assay following activation of factor 
V species by RVV-V activator or α-thrombin as described (58,59).   
dPlasma factor V was activated with α-thrombin and treated with cathepsin G (CG) as described 
(49). 
eThe clotting activity of the truncated cofactor is ~50% that of plasma-derived factor Va (50). 
ND, not determined in the present study. 
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no meizothrombin was detected following 180 sec (Fig.2.5).  In contrast, in the presence 
of prothrombinase assembled with factor VaD(680-709), prothrombin is activated with a rate 
that is approximately 3-fold slower than the rate of activation by prothrombinase 
assembled with the wild type molecule (Table 2.I), with persistence of meizothrombin as 
indicated by the lingering of fragment 1•2-A even at the late time-points of the reaction 
(Fig.2.4, panel B). The lower extent of prothrombin consumption most likely reflects the 
result of product inhibition by the accumulating meizothrombin.  Comparison of the data 
shown in figures 2.4, panels A and B demonstrates that meizothrombin was produced 
with similar initial rates but was more persistent.  Scanning densitometry demonstrated a 
peak of meizothrombin late in the reaction at 250 sec.  Meizothrombin persisted for up to 
6 minutes in the time course (Fig.2.5).  In addition, appearance of the B chain is also 
delayed when prothrombin is activated by prothrombinase assembled with factor VaD(680-
709), compared with the appearance of the B chain obtained following incubation of 
prothrombin with factor VaRVVWt.  Similar results were obtained with factor VaIIa/CG 
(Table 2.I).  In contrast, in the presence of DYDYQ, no meizothrombin is observed 
following prothrombin activation by prothrombinase assembled with factor VaD(680-709) 
and α-thrombin is formed through the alternate pathway characterized by initial cleavage 
at Arg271 and formation of prethrombin 2 as intermediate (Fig.2.5, panel C).  Overall, the 
data demonstrate that elimination of amino acid region 680-709 from factor Va results in 
a cofactor molecule that when incorporated into prothrombinase produces an enzyme 
responsible for persistence of meizothrombin during activation of prothrombin.   
In preliminary experiments using several preparations of recombinant proteins we 
observed that while the truncated factor Va molecules are impaired in their clotting 
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activity, factor Va4A is also deficient in its clotting activity.  To understand the properties 
of this molecule and the effect of the mutations on cofactor activity, we used the same 
preparation of recombinant protein to perform three different experiments.  Factor V4A 
was first activated with α-thrombin and the solution was split into three separate samples.  
One sample was used for assessment of clotting activity, one sample was used to measure 
the kinetic parameters of prothrombinase assembled with saturating concentration of 
factor VaIIa4A, and the third sample was used for analysis of prothrombin activation by gel 
electrophoresis.  The results reveal that while factor VaIIa4A is severely impaired in its 
clotting activity (~22% that of factor VaIIaWt), prothrombinase assembled with the mutant 
molecule shows a 19.7% increased kcat (Table 2.I).  Gel electrophoresis followed by 
scanning densitometry analysis demonstrated that prothrombinase assembled with factor 
VaIIa4A activates prothrombin with a rate that is approximately 3.8-fold slower that the 
rate of activation of prothrombin assembled with factor VaIIaWt (Fig.2.4 panels A andE, 
Table 2.1).  Scanning densitometry of several gels studying prothrombin activation by 
prothrombinase assembled with factor VaIIa4A revealed a peak of meizothrombin at 
approximately 240 sec with significant amounts of meizothrombin remaining for up to 10 
minutes into the time course (not shown).  These findings provide strong evidence in 
favor of our previous conclusion that amino acid sequence 695-699, regulates 
meizothrombin formation by prothrombinase (37,38).  These data also demonstrate that, 
in the presence of prothrombinase assembled with factor Va4A the excess meizothrombin 
formed as assessed functionally by clotting assays can compensate for the absence of α-
thrombin in the assay using purified reagents because the increased amidolytic activity of 
meizothrombin towards the chromogenic substrate is read as α-thrombin activity. 
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Figure 2.4. Analysis of the activation of plasma-derived prothrombin by 
prothrombinase.  Plasma-derived prothrombin (1.4 uM) was incubated in different mixtures 
with PCPS vesicles (20 nM), and prothrombinase assembled with either wild type factor Va 
(panel A, 10 nM) or factor VaD( 680-709) (panel B, 10 nM) as described in the “Experimental 
Procedures” section.  Panel C, prothrombinase assembled with factor Va680-709) in the presence 
of 20 uM DYDYQ (same conditions as in panel B); panel D, prothrombinase assembled with 
plasma-derived factor Va (10 nM); panel E, prothrombinase assembled with factor Va4A (10 nM).  
At selected time intervals aliquots of the reactions were withdrawn and treated as described in the 
“Experimental Procedures” section.  M represents the lane with the molecular weight markers 
(from top to bottom): Mr 98,000, Mr 64,000, Mr 50,000, Mr 36,000, Mr 22,000.  Lanes 1-19 
represent samples from the reaction mixture before (0 min) the addition of factor Xa and 20 sec, 
40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 220 sec, 240 sec, 5 
min, 6 min, 10 min, 20 min, 30 min, and 60 min respectively following the addition of factor Xa.  
The prothrombin derived fragments are shown as follows: II, prothrombin (amino acid residues 1-
579); prethrombin-1 (amino acid residues 156-579); F1•2-A, fragment 1•2-A chain (amino acid 
residues 1-320); F1•2, fragment 1•2 (amino acid residues 1-271); P2, prethrombin-2 (amino acid 
residues 272-579); P2’, prethrombin-2 cleaved at Arg284; B, B chain of α-thrombin (amino acid 
residues 321-579). 
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Figure 2.5. Reaction profiles for the activation of prothrombin by 
prothrombinase.  Progress curves for products and reactants for the activation of 
prothrombin by prothrombinase assembled with factor VaWt (panel A) or factor VaD(680-
709) (panel B) were obtained by quantitative densitometry of gels shown in Fig.2.4A and 
2.4B, as described in the “Experimental Procedures” section.  The graphs illustrate the 
disappearance of prothrombin (filled squares), the transient formation of meizothrombin 
(open circles), and the accumulation of the B chain of α-thrombin (filled circles).  There 
is a three-fold difference in the x-axis between the two panels, because prothrombinase 
assembled with factor VaD(680-709) consumes prothrombin with a ~3-fold slower rate than 
prothrombinase assembled with factor VaWt.  The lines for the disappearance of 
prothrombin were drawn according to the equation of a one phase exponential decay 
(factor VaWt, R2 = 0.985, and factor VaD(680-709), R2 = 0.968).  The lines depicting the 
formation of meizothrombin and the accumulation of the B chain of α-thrombin were 
arbitrarily drawn.  Additional data points extending to 1h of incubation (shown in figure 
4) have been omitted for clarity. 
 51
Role of the Acidic COOH-terminal Portion of Factor Va Heavy Chain: a 
Potential Mechanism.  The data obtained thus far with the mutant cofactor molecules 
indicate that meizothrombin is generated with similar rates, however the intermediate 
accumulates to more persistent levels and lingers throughout the time course.  
Appearance of the B-chain of α-thrombin also appears to be delayed when prothrombin is 
activated by prothrombinase assembled with the mutant cofactor (Fig.2.5).  
Consequently, analysis of the results suggests that cleavage of meizothrombin at Arg271 
by prothrombinase assembled with factor VaRVVD(680-709) maybe be slower than cleavage 
of meizothrombin at the same site by prothrombinase assembled with factor VaRVVWt 
resulting in less conversion of meizothrombin to α-thrombin.  Since during the course of 
the assay using plasma-derived prothrombin we are measuring the sum of meizothrombin 
and α-thrombin, a more rigorous test to verify which cleavage in prothrombin is affected 
by the deletion at the COOH-terminus of factor Va heavy chain, involves the study of  the 
activation of a prothrombin molecule that cannot be cleaved at Arg271 such as rMZ-II 
(22).  In addition, while cleavage of rMZ-II can be followed by gel electrophoresis, 
generation of rMZ-IIa can be also assessed with the chromogenic substrate used to assess 
α-thrombin formation.  We thus followed activation of rMZ-II by prothrombinase 
assembled with either factor VaRVVD(680-709) or factor VaRVVWt by gel electrophoresis (Fig. 
2.6A) and activity assays using spetrozyme-TH (Fig.2.6B).  Both sets of data demonstrate 
that there are no significant differences between the rates of activation of rMZ-II by 
either enzyme.  The rates of rMZ-II consumption were similar as assessed by scanning 
densitometry of the gels depicted in figure 2.6A (not shown), and the profiles of both 
titrations are coincident (similar Vmax and similar Km values of 91±9 mM and 121±18 
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mM, Fig.2.6B).  Comparable results were found in two independent measurements using 
two different preparations of recombinant factor Va molecules and two separate 
preparations of rMZ-II.  The data demonstrate that cleavage at Arg320 in prothrombin is 
not affected by the COOH-terminal portion of factor Va heavy chain. 
Earlier data has demonstrated that incorporation of factor Va in prothrombinase has a 
differential influence on the rates of cleavage of the two bonds responsible for the 
activation of prothrombin.  In particular, the binding of factor Va to factor Xa within 
prothrombinase results in an 3-5-fold increase in the rate of cleavage of meizothrombin at 
Arg271 as compared to cleavage at the same site by factor Xa alone (13,14).  We next 
compared the rate of cleavage of FPR-meizothrombin at Arg271 by prothrombinase 
assembled with various factor Va molecules (Fig.2.7).  The data demonstrate a delay for 
cleavage of FPR-meizothrombin at Arg271 by prothrombinase assembled with factor 
VaRVVD(680-709) (panel C) or factor VaRVV4A (panel D) as compared to the same reaction 
catalyzed by prothrombinase assembled with factor VaRVVPLASMA (panel B).  A direct 
comparison between the rates of cleavage of FPR-meizothrombin by membrane-bound 
factor Xa alone (panel A) and cleavage of the substrate by prothrombinase assembled 
with factor VaRVVD680-709) (panel C) or factor Va4A do not show any significant 
differences.  These data imply that following incorporation of factor Va in 
prothrombinase it is the COOH-terminal acidic hirudin-like portion of factor Va heavy 
chain and in particular amino acid sequence 695DYDY698 that is responsible for the 
increase in the rate of cleavage of meizothrombin at Arg271.  Quantitative scanning 
densitometry of fragment 1•2-A present on the gels shown in figure 2.7, demonstrated a 
~3-4-fold delay in cleavage of FPR-meizothrombin at Arg271 by either membrane-bound 
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factor Xa alone or prothrombinase assembled with the recombinant mutant factor Va 
molecules, compared to cleavage at Arg271 by prothrombinase assembled with the 
plasma-derived cofactor (Fig.2.7, panel E).  These data are in complete agreement with 
previous findings (13,14) and demonstrate that the lingering of meizothrombin during 
plasma-derived prothrombin activation by prothrombinase assembled with factor 
VaRVVD680-709) or factor Va4A is the result of impaired cleavage at Arg271.  Overall, the 
data suggest that amino acid sequence 695DYDY698, regulates meizothrombin 
concentration during activation of prothrombin by prothrombinase. 
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Figure 2.6A.  Analysis of the activation of rMZ-II.  Panel A.  Gel electrophoresis analyses.  
rMZ-II (1.4 µM) was incubated in different mixtures with PCPS vesicles (20 µM), DAPA (3 
µM), and factor VaWt (left panel, 20nM) or factor VaD( 680-709) (right panel, 20nM).  The reaction 
was started by the addition of factor Xa and the samples were treated as detailed in the 
“Experimental Procedures” section.  Lanes 1-9, represent samples of the reaction mixture 
following incubation of prothrombinase with rMZ-II, before (lane 1), or following 0.5 min, 1 
min, 2.5 min, 4min, 6min, 10min, 20min, and 30min incubation with factor Xa respectively.  
Positions of prothrombin-derived fragments are indicated at right as detailed in the legend to 
figure2.4.  For the easy reading of the manuscript, the factor Va species used for the 
reconstitution of prothrombinase are shown under each panel.   
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Figure 2.6B. Kinetic analyses of the activation of rMZ-II.  Initial rates of α-thrombin 
generation were determined as described under “Experimental Procedures” and the data were 
plotted according to the Michaelis-Menten equation.  Activation of rMZ-II by prothrombinase 
assembled with factor VaWt is shown by filled squares (R2 = 0.98) while activation of rMZ-II by 
prothrombinase assembled with factor VaD(680-709) is depicted by filled triangles (R2 = 0.96).  
Kinetic constants reported in the text were extracted directly from the graphs.   
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Figure 2.7.  Gel electrophoresis analyses for cleavage of FPR-meizothrombin.  FPR-
meizothrombin (1.4 µM) was incubated in different mixtures with PCPS vesicles (20 µM) and 
factor Va as described in the legend to figure 2.4.  The reaction and the samples were further 
treated as detailed in the “Experimental Procedures” section.  The gels were scanned and 
quantification of fragment 1•2-A was performed as described (65, 66).  Panel A, control, no 
factor Va (13.4 moles FPR-meizo consumed•s-1•mole factor Xa-1); panel B, factor VaRVVPLASMA 
(42.6 moles FPR-meizo consumed•s-1•mole factor Xa-1); panel C, factor VaRVVD(680-709) (8.4 moles 
FPR-meizo consumed•s-1•mole factor Xa-1); panel D, factor VaRVV4A (14.6 moles FPR-meizo 
consumed•s-1•mole factor Xa-1).  M represents the lane with the molecular weight markers (from 
top to bottom): Mr 50,000, Mr 36,000, Mr 22,000.  Lanes 1-19 represent samples from the 
reaction mixture before (0 min) the addition of factor Xa and 20 sec, 40 sec, 60 sec, 80 sec, 100 
sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 220 sec, 240 sec, 5 min, 6 min, 10 min, 20 min, 
30 min, and 60 min respectively following the addition of factor Xa.  The prothrombin derived 
fragments are shown as detailed in the legend to figure 2.4.  For the easy reading of the 
manuscript, the factor Va species used for the reconstitution of prothrombinase are also shown 
under each panel. 
 57
2.5 Discussion 
Our data demonstrate that the acidic COOH-terminus of factor Va heavy chain is 
responsible for coordinate activation of prothrombin resulting in timely a-thrombin 
formation at the place of vascular injury.  Furthermore, our findings appear to resolve 
many apparently conflicting results and explain the observation that was initially reported 
15 years ago (33) and verified several times with either truncated plasma-derived factor 
Va (34-36) or more recently with recombinant factor Va molecules (39).  Namely, 
incorporation of cofactor molecules with a truncated heavy chain into prothrombinase 
results in enhanced stability of meizothrombin during prothrombin activation.  Our 
findings assign an important physiological role to the COOH-terminus of factor Va heavy 
chain for efficient prothrombin activation and demonstrate that the sequence 695DYDY698, 
regulates meizothrombin formation by factor Xa within prothrombinase.  In addition, we 
have recently demonstrated that meizothrombin formation by prothrombinase assembled 
with the plasma-derived cofactor is inhibited in the presence of an excess of an acidic 
region from the carboxyl-terminal portion of factor Va (represented by mM 
concentrations of DYDYQ).  Since meizothrombin formation by prothrombinase 
assembled with factor VaD(680-709) is also completely inhibited by an excess of DYDYQ, 
the combined findings demonstrate that this amino acid sequence is solely responsible for 
the regulation of meizothrombin processing, and provide a logical explanation for the 
anticoagulant effect of the DYDYQ peptide, (explicitly, the acidic pentapeptide controls 
meizothrombin concentration during prothrombin activation).  Keeping in mind the data 
shown in figure 2.7, we can thus speculate that DYDYQ inhibits meizothrombin 
generation by accelerating the cleavage rate at Arg271.  These findings are in complete 
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accord with our recent data demonstrating that DYDYQ increases the rate of cleavage of 
prothrombin by factor Xa alone with accumulation of prethrombin 2 (38), and warrant the 
need for further investigation of the mode of action and site of interaction with 
prothrombin of the pentapeptide as well as of the molecular mechanism of inhibition of 
prothrombinase by DYDYQ. 
Approximately 35 years ago Heldebrant and Mann first demonstrated that incubation 
of fragment 2 with α-thrombin results in a significant increase in the esterolytic activity 
of the enzyme towards Tos-L-Arg-OMe (TAME) as compared to the activity of α-
thrombin alone towards the same substrate (66).  This increase in the esterase activity of 
a-thrombin was concomitant with a decrease in its clotting activity (66).  Subsequently, 
Franza et al (65), Morita et al (67) and Kornalik and Blombäck (68) reported that 
meizothrombin (and meizothrombin desfragment 1) generated by a component purified 
from the venom of Echis Carinatus has poor clotting activity and very high hydrolytic 
activity towards TAME.  Franza et al specifically demonstrated that the meizothrombin 
species generated by Echis Carinatus has much higher hydrolytic activity towards TAME 
than α-thrombin (between 30-50% higher activity) (65).  Concomitantly, Myrmel et al 
provided complete evidence demonstrating that addition of fragment 2 to α-thrombin 
increases significantly the catalytic efficiency of the enzyme towards TAME, compared 
to the efficiency of α-thrombin alone against the same substrate (69).  All these findings 
were later corroborated by two independent studies using either TAME or S-2238 that 
reported that meizothrombin has higher catalytic efficiency than α-thrombin towards 
small peptidyl substrates (43,70), and it was hypothesized that there may be subtle but 
significant differences between the active sites of α-thrombin and meizothrombin (70).  
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This conclusion was strengthened by earlier findings demonstrating that while DAPA 
interacts with prethrombin 2 with an affinity that is ~30-times lower than that for α-
thrombin, the inhibitor doesn’t bind prothrombin and prethrombin 1 (64), suggesting an 
important effect of cleavage at Arg271 on the progressive formation of the active-site of α-
thrombin.  More recently, using electron spin resonance to probe the active sites of 
meizothrombin and α-thrombin, significant conformational differences between the 
apolar binding region of the active-site of the two enzymes have been reported (71).   
Abundant structural data obtained in recent years from the crystal structure of several 
prothrombin derivatives, has established that meizothrombin is impaired in its clotting 
activity because it has not yet exposed ABE-II (which is covered by fragment 2).  
Exposure of this site that is required for optimum fibrinogen binding and processing, 
necessitates cleavage of meizothrombin at Arg271 resulting in the release of fragment 2 
(5,20,21,72).  Several studies have shown independently that plasma-derived or 
recombinant meizothrombin has 25-60% higher catalytic efficiency towards S-2238 
(15,23,40,73,74) or TAME (43), and 25-50% higher fluorescence intensity with DAPA 
(14,64).  The data shown in Fig.2.6B confirm all previous findings obtained using 
recombinant or plasma-derived meizothrombin, and demonstrate that rMZ-IIa has higher 
catalytic efficiency than α-thrombin towards the peptidyl substrates generally used to 
assess for α-thrombin activity (75-77).  At this point, it is important to underline the fact 
that while a sulfated peptide representing the last 12 amino acids of hirudin (Hir54-65(SO3-
)) is a very potent inhibitor of α-thrombin’s function in vivo and in vitro because it 
interacts with ABE-I of the enzyme with high affinity (78), the dodecapeptide increases 
considerably the activity of α-thrombin towards peptidyl chromogenic substrates 
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(between 30%-50%, (4,79)).  The correlation of this observation with the increased 
activity of meizothrombin towards small peptidyl chromogenic and fluorescent substrates 
as compared to the activity of α-thrombin alone against the same synthetic substrates 
remains to be established.  Nevertheless, the bulk of published data strongly supports the 
concept that any interaction of ABE-I and/or ABE-II of α-thrombin with their respective 
ligands will result in allosteric modulations of the active site of the enzyme (80,81).  It is 
thus expected that meizothrombin as well as meizothrombin desfragment 1 (ABE-II 
occupied by fragment 2) may have a different configuration of the active-site than the 
active-site of α-thrombin. 
Blood clotting enzymes, with the exception of factor IX and prothrombin, are 
activated following single proteolytic cleavage (1).  It is thus assumed that results 
obtained following the activation of a zymogen either by gel electrophoresis or by assays 
that measure the generation of enzymatic activity with chromogenic substrates should be 
concordant.  However, prothrombin activation is different from other zymogens 
activation because: 1) prothrombin can be activated through two different pathways that 
have different requirements and significantly different rates; and 2) activation of 
prothrombin through the meizothrombin pathway generates an intermediate that has 
higher amidolytic activity than α-thrombin towards chromogenic substrates that are used 
to assess for a-thrombin generation.  Thus, while following prothrombin activation by 
both gel electrophoresis and activity assays simultaneously may appear to be a 
duplication of the same result, drawing conclusions from activity assays alone without 
analyzing the pathway to prothrombin activation and the intermediates formed, is an 
oversimplification that can lead to erroneous conclusions. 
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Two assays are used worldwide for the determination of factor Va cofactor activity: a 
clotting assay using factor V-deficient plasma and an assay using purified reagents.  The 
former assay is performed at low (limiting) concentrations of factor Va, while the latter 
assay is conducted with high (saturating) concentrations of factor Va with respect to 
factor Xa.  Both assays indirectly report on factor Va cofactor activity through the 
activation of prothrombin to α-thrombin assuming that α-thrombin is the final and main 
product of the reaction.  The clotting time measures fibrin formation in factor V-deficient 
plasma, while the prothrombinase assay measures α-thrombin’s amidolytic activity as it 
is generated towards a chromogenic substrate.  Initial cleavage of prothrombin at Arg320 
by prothrombinase, which is absolutely factor Va-dependent, results in rapid 
meizothrombin generation.  Depending on the ratio of meizothrombin to α-thrombin 
formed at the moment the measurement is taken, the results reflect the clotting or 
amidolytic activity of either α-thrombin, or meizothrombin, or the sum of both.  Thus, if 
generation of α-thrombin is slower than formation of meizothrombin, the measurements 
will mostly reflect the properties of meizothrombin (i.e. impaired clotting and increased 
chromogenic activity).   
Work performed independently in several laboratories worldwide has demonstrated 
that while elimination of the COOH-terminal region of factor Va heavy chain results in a 
cofactor molecule with poor clotting activity (retaining 20-40% clotting activity of 
normal factor Va), the same molecule as part of prothrombinase produces a substantial 
increase in the kcat of the enzyme in an assay using a chromogenic substrate to assess α-
thrombin generation (33-36) (Table 2.II).  Similar results were recently obtained with 
recombinant factor Va molecules missing portions of the COOH-terminus of factor Va 
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heavy chain (39).  All these results could be partially explained if the truncated cofactor 
molecules had diminished binding capabilities for membrane-bound factor Xa.  However, 
earlier data has demonstrated that all truncated factor Va molecules have similar KD for 
factor Xa as the plasma-derived cofactor (35,36), and recent experiments with 
recombinant factor Va molecules missing the entire hirudin-like COOH-terminal portion 
of factor Va heavy chain (amino acids 679-709, rFVa678) confirm our findings shown in 
Fig.2.3A with factor VaD(680-709), and demonstrate that the recombinant mutant cofactor 
binds factor Xa with similar affinity as the wild type molecule (39).  Thus, while every 
study performed (worldwide) was remarkably consistent in showing poor clotting and 
increased kcat for the same truncated factor Va molecules (up to ~50% higher kcat, Table 
2.II), no satisfactory explanation has been yet provided to explain this seeming paradox at 
best (33-35), or at worst the observations were simply discarded as relatively modest 
changes (39).  Our data, put in the context of the literature, provide a logical explanation 
for these observations and clearly demonstrate that the acidic COOH-terminal portion of 
factor Va heavy chain controls the rate of α-thrombin generation by factor Xa within 
prothrombinase.   
Crystallographic evidence has determined that cleavage at Arg320 in prothrombin is 
required to induce the conformational transitions for the conversion of the zymogen to 
proteinase (82,83).  In meizothrombin, the two factor Xa cleavage sites are separated by 
36 Å (21).  Before cleavage at Arg320, the two cleavage sites in prethrombin 1 are 
separated by 42 Å (79).  These combined findings alone verify the change in  
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Table 2.II 
Summary of results obtained with factor Va molecules truncated at the COOH-
terminus of the heavy chain in a clotting assay and in a prothrombinase assay 
Impaired Clottinga Increased kcatb
Gerads et al (ref.18) + + (17%)c
Bakker et al (ref.19) +d + (12%)e
Camire et al (ref.20) + + (18-23%)
Kalafatis et al (ref.21) + + (19%)f
Toso and Camire (ref.37) + + (29-50%)g
 
aThe plus sign indicates that the molecules missing part or the entire COOH-terminal 
portion of the heavy chain are impaired in clotting activity. 
bThe plus sign indicates that the factor Va molecules missing part or the entire COOH-
terminal portion of the heavy chain have increase catalytic efficiency when assembled in 
prothrombinase.  In parenthesis is the % increase in kcat compared to prothrombinase 
assembled with plasma-derived factor Va or to wild type recombinant factor Va reported 
in each study. 
cAll results reported were obtained with proteins of bovine origin. 
dFrom reference 18; the authors also report results obtained with human factor Va and 
clotting assays with factor V-deficient plasma  
eAll work was performed with proteins of human origin and are complementary to the 
work reported in reference 18. 
fThe kcat of factor VaIIa/NN in the assay for using purified reagents and a chromogenic 
substrate to assess for α-thrombin formation is reported in the present manuscript (Table 
2.I)gAll results were obtained with recombinant proteins. The factor V construct used 
expression was missing a major portion of the B domain of the molecule.
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conformation associated with cleavage of prothrombin at Arg320 since we can expect that 
the two scissile bonds are separated by ~42 Å in intact prothrombin.  We show that while 
rMZ-II is cleaved with equivalent rates by either, prothrombinase assembled with factor 
VaWt or prothrombinase made with factor VaD(680-709), active-site blocked meizothrombin 
was processed with a slower rate by prothrombinase assembled with factor VaD(680-709) or 
factor Va4A, compared to prothrombinase assembled with factor VaPLASMA.  Altogether, 
these findings demonstrate that the rate of the first cleavage in prothrombin (i.e. Arg320) 
does not appear to be significantly affected by the deletion of the COOH-terminal portion 
of factor Va heavy chain.  The data rather suggest that in the presence of prothrombinase 
assembled with factor VaD(680-709) (or factor Va4A), meizothrombin has a different 
conformation than meizothrombin formed by prothrombinase assembled with factor VaWt 
since the molecule is not cleaved with equivalent rates by the two enzymes.  These data 
confirm earlier findings showing a 4-5-fold increase in the rate of cleavage of 
meizothrombin by prothrombinase at Arg271 as compared to cleavage of the same 
substrate by factor Xa alone (13,14), and clearly demonstrate that the COOH-terminal 
acid region from factor Va heavy chain alone is responsible for the acceleration of the 
rate of cleavage of prothrombin at Arg271 by prothrombinase. 
Recently, it has been shown that following cleavage at Arg320, meizothrombin 
undergoes ratcheting prior to cleavage at Arg271, whereby, meizothrombin changes 
conformation prior to subsequent processing to product by prothrombinase (84).  A 
prothrombin molecule with the mutations Ile321-Val322-Glu323→Thr-Ala-Thr 
(prothrombinTAT) was impaired in the ratcheting process and meizothrombinTAT persisted 
throughout the prothrombinase-mediated activation process.  Remarkably, these latter 
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data resemble our data shown in figure 2.4 Panels B and E obtained with factor 
VaRVVD(680-709) and factor VaIIa4A.  However, ratcheting and efficient cleavage at Arg271 in 
meizothrombinTAT could be restored in the presence of an excess of DAPA (64,84), 
implying that the active site of meizothrombin is involved in the conformational change 
of the molecule required for efficient cleavage at Arg271.  Furthermore, an incomplete 
conversion of conformationally activated prothrombin bound to FPRck, from zymogen to 
proteinase, was observed in the presence of an excess of DAPA , most likely because 
DAPA interaction with the active-site involves both the site occupied by FPR-ck and the 
site that is available on prethrombin 2 (64) in order for the complete transition 
(ratcheting) to occur.  Since it is not clear yet whether it is the ratcheting of 
meizothrombin from the zymogen to proteinase form, or cleavage at Arg271 per se, or 
both, that induce a change in the active site of α-thrombin resulting in an enzyme with 
diminished kcat for peptidyl chromogenic and fluorescent substrates as compared to 
meizothrombin, our data put in the context of the literature suggest that slow ratcheting 
and/or impaired cleavage at Arg271 are the cause of meizothrombin lingering during 
activation of prothrombin by prothrombinase assembled with factor VaRVVD680-709).   
Our data provide strong evidence pointing to the fact that the COOH-terminal acidic 
region of factor Va heavy chain is crucial for efficient α-thrombin generation at the place 
of vascular injury.  Bearing in mind the poor fibrinogen clotting properties of 
meizothrombin, we can hypothesize that following injury individuals with a factor Va 
molecule lacking the COOH-terminal region of the heavy chain will produce more 
meizothrombin, rather than α-thrombin at the place of vascular injury resulting in 
bleeding tendencies.  This hypothetical situation is verified by clinical data obtained from 
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patients that are homozygous for an amino acid substitution in the prothrombin gene at 
Arg271 (85-89).  All these patients that have a prothrombin molecule unable to be cleaved 
at Arg271 circulating in their plasma, were identified because of their hemorrhagic 
syndrome clinically resembling mild hemophilia.  Thus, while meizothrombin can 
competently substitute for most of α-thrombin’s procoagulant/anticoagulant functions 
locally at the place of vascular injury in the presence of an adequate membrane surface 
(22,40,58,90-93), the molecule still lacks the ultimate procoagulant function (i.e. efficient 
fibrin formation).  All these observations together with the fact that prothrombin can be 
activated through two distinct pathways that differ in terms of rate constants and 
intermediates, may allow for the design of novel anticoagulant molecules with the 
potential to act as a control switch and able to modulate specific events during α-
thrombin (and meizothrombin) formation according to a precise need.  DYDYQ may be 
the prototype for such a class of anticoagulants and we have recently reported that 
DYDYQ inhibits prothrombin activation on the surface of endothelial cells (79) attesting 
of its physiological potency.  Thus, if the requirement for anticoagulant therapy is to slow 
down generation of α-thrombin activity without eliminating its production, a low 
concentration of DYDYQ will be enough to alleviate α-thrombin formation through the 
meizothrombin pathway (38).  In contrast, if complete arrest of α-thrombin formation is 
required, higher concentrations of DYDYQ will completely eliminate α-thrombin 
generation through the prethrombin 2 pathway as well.  In conclusion, pentapeptide 
DYDYQ provides an ideal backbone for exosite directed anticoagulant molecules that 
could attenuate or fully suppress α-thrombin formation in individuals with thrombotic 
tendencies.  
 67
2.6 Reference List 
1. Kalafatis, M., Egan, J. O., van't Veer, C., Cawthern, K. M., and Mann, K. G. 
(1997) Crit. Rev. Eukar. Gene. 7, 241-280 
2. Mann, K. G., and Kalafatis, M. (2003) Blood 101(1), 20-30 
3. Anderson, P. J., and Bock, P. E. (2003) J. Biol. Chem. 278, 44489-44495 
4. Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000) J. 
Biol. Chem. 275, 16435-16442 
5. Anderson, P. J., Nesset, A., and Bock, P. E. (2003) J. Biol. Chem. 278, 44482-
44488 
6. Chen, L., and Rezaie, A. R. (2004) J. Biol. Chem. 279, 17869-17874 
7. Chen, L., Yang, L., and Rezaie, A. R. (2003) J. Biol. Chem. 278, 27564 - 27569 
8. Mann, K. G., Bajaj, S. P., Heldebrant, C. M., Butkowski, R. J., and Fass, D. N. 
(1973) Sem Haematol. 6, 479-493 
9. Heldebrant, C. M., Butkowski, R. J., Bajaj, S. P., and Mann, K. G. (1973) J. Biol. 
Chem. 248, 7149-7163 
10. Esmon, C. T., Owen, W. G., and Jackson, C. M. (1974) J. Biol. Chem. 249, 8045-
8047 
11. Esmon, C. T., and Jackson, C. M. (1974) J. Biol. Chem. 249, 7782-7790 
 68
12. Rosing, J., Tans, G., Govers-Riemslag, J. W., Zwaal, R. F., and Hemker, H. C. 
(1980) J. Biol. Chem. 255, 274-283 
13. Nesheim, M. E., and Mann, K. G. (1983) J. Biol. Chem. 258, 5386-5391 
14. Krishnaswamy, S., Church, W. R., Nesheim, M. E., and Mann, K. G. (1987) J. 
Biol. Chem. 262, 3291-3299 
15. Brufatto, N., and Nesheim, M. E. (2003) J. Biol. Chem. 278, 6755-6764 
16. Nesheim, M. E., Taswell, J. B., and Mann, K. G. (1979) J. Biol. Chem. 254, 
10952-10962 
17. Côté, H. C. F., Bajzar, L., Stevens, W. K., Samis, J. A., Morser, J., MacGillivray, 
R. T. A., and Nesheim, M. E. (1997) J. Biol. Chem. 272, 6194-6200 
18. Rosing, J., Zwaal, R. F. A., and Tans, G. (1986) J. Biol. Chem. 261, 4224-4228 
19. Van de Locht, A., Stubbs, M., Bauer, M., and Bode, W. (1996) J. Biol. Chem. 
271, 3413–3416 
20. Arni, R. K., Padmanabhan, K., Padmanabhan, K. P., Wu, T. P., and Tulinsky, A. 
(1993) Biochemistry 32, 4727-4737 
21. Martin, P. D., Malkowski, M. G., Box, J., Esmon, C. T., and Edwards, B. F. 
(1997) Structure 5, 1681-1693 
22. Côté, H. C. F., Stevens, W. K., Bajzar, L., Banfield, D. K., Nesheim, M. E., and 
MacGillivray, T. A. (1994) J. Biol. Chem. 269, 11374-11380 
 69
23. Shim, K., Zhu, H., Westfield, L. A., and Sadler, J. E. (2004) Blood 104, 415-419 
24. Esmon, C. T. (1979) 254(3), 964-973 
25. Nesheim, M. E., Foster, W. B., Hewick, R., and Mann, K. G. (1984) J. Biol. 
Chem. 259, 3187-3196 
26. Suzuki, K., Dahlbäck, B., and Stenflo, J. (1982) J. Biol. Chem. 257, 6556-6564 
27. Adams, T. E., Hockin, M. F., Mann, K. G., and Everse, S. J. (2004) Proc. Natl. 
Acad. Sci. U.S.A. 101, 8918–8923 
28. Orban, T., Kalafatis, M., and Gogonea, V. (2005) Biochemistry 44, 13082-13090 
29. Hortin, G. L. (1990) Blood 76, 946-952 
30. Esmon, C. T., Owen, W. G., Duiguid, D. L., and Jackson, C. M. (1973) Biochim 
Biophys Acta 310(1), 289-294 
31. Guinto, E. R., and Esmon, C. T. (1984) J. Biol. Chem. 259, 13986-13992 
32. Luckow, E. A., Lyons, D. A., Ridgeway, T. M., Esmon, C. T., and Laue, T. M. 
(1989) Biochemistry 28, 2348-2354 
33. Gerads, I., Tans, G., Yukelson, L. Y., Zwaal, R. F., and Rosing, J. (1992) Toxicon 
30(9), 1065-1079 
34. Bakker, H. M., Guido, T., Thomassen, M. C. L. G. D., Yukelson, L. Y., Ebberink, 
R., Hemker, H. C., and Rosing, J. (1994) J. Biol. Chem. 269(12), 20662-20667 
 70
35. Camire, R. M., Kalafatis, M., and Tracy, P. B. (1998) Biochemistry 37, 11896-
11906 
36. Kalafatis, M., Beck, D. O., and Mann, K. G. (2003) J. Biol. Chem. 278(35), 
33550-33561 
37. Beck, D. O., Bukys, M. A., Singh, L. S., Szabo, K. A., and Kalafatis, M. (2004) J. 
Biol. Chem. 279, 3084-3095 
38. Bukys, M. A., Kim, P. Y., Nesheim, M. E., and Kalafatis, M. (2006) J. Biol. 
Chem. 281, 39194-39204 
39. Toso, R., and Camire, R. M. (2006) J. Biol. Chem. 281, 8773-8779 
40. Doyle, M. F., and Mann, K. G. (1990) J. Biol. Chem. 265(18), 10693-10701 
41. Lottenberg, R., and Jackson, C. M. (1983) Biochim Biophys Acta 742(3), 558-564 
42. Morita, T., Iwanaga, S., and Suzuki, T. (1976) J. Biochem. (Tokyo) 79, 1089-1108 
43. Morita, T., and Iwanaga, S. (1981) Methods in Enzymology 90, 303-311 
44. Nesheim, M. E., Katzmann, J. A., Tracy, P. B., and Mann, K. G. (1980) Methods 
Enzymol. 80, 243-275 
45. Stevens, W. K., Côté, H. C. F., MacGillivray, R. T. A., and Nesheim, M. E. 
(1996) J. Biol. Chem. 271, 8062-8067 
46. Yan, S. C., Razzano, P., Chao, Y. B., Walls, J. D., Berg, D. T., McClure, D. B., 
and Grinnell, B. W. (1990) Biotechnology (NY) 8(7), 655-661 
 71
47. Barenholz, Y., Gibbs, D., Litmann, B. J., Goll, J., Thompson, T., and Carlson, D. 
(1977) Biochemistry 16, 2806-2910 
48. Singh, L. S., Bukys, M. A., Beck, D. O., and Kalafatis, M. (2003) J. Biol. Chem. 
278(30), 28335-28345 
49. Erdogan, E., Bukys, M. A., Orfeo, T., Mann, K. G., and Kalafatis, M. (2007) 
Thromb Haemost 98, 998-1006 
50. Bukys, M. A., Blum, M. A., Kim, P. Y., Brufatto, N., Nesheim, M. E., and 
Kalafatis, M. (2005) J. Biol. Chem. 280, 27393-27401 
51. Kim, P. Y., and Nesheim, M. E. (2007) J. Biol. Chem. 282(45), 32568-32581 
52. Laemmli, U. K. (1970) Nature 227, 680-685 
53. Towbin, H., Staehlin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. 76, 4350-
4354 
54. Kalafatis, M., Bertina, R. M., Rand, M. D., and Mann, K. G. (1995) J. Biol. 
Chem. 270, 4053-4057 
55. Kalafatis, M., Haley, P. E., Lu, D., Bertina, R. M., Long, G. L., and Mann, K. G. 
(1996) Blood 87, 4695-4707 
56. Van"t Veer, C., Kalafatis, M., Bertina, R. M., Simioni, P., and Mann, K. G. 
(1997) J. Biol. Chem. 272, 20721-20729 
57. Van"t Veer, C., Golden, N. J., Kalafatis, M., and Mann, K. G. (1997) J. Biol. 
Chem. 272, 7983-7994 
 72
58. Bukys, M. A., Orban, T., Kim, P. Y., Beck, D. O., Nesheim, M. E., and Kalafatis, 
M. (2006) J. Biol. Chem. 280, 27393-27401 
59. Krishnaswamy, S., and Walker, R. K. (1997) Biochemistry 36, 3319-3330 
60. Camire, R. M. (2002) J. Biol. Chem. 277(40), 37863-37870 
61. Krishnaswamy, S., Williams, E. B., and Mann, K. G. (1986) J. Biol. Chem. 261, 
9684-9693 
62. Krishnaswamy, S. (1992) J. Biol. Chem. 267, 23696-23706 
63. Singh, L. S., Bukys, M. A., Beck, D. O., and Kalafatis, M. (2003) J. Biol. Chem. 
278, 28335-28345 
64. Hibbard, L. S., Nesheim, M. E., and Mann, K. G. (1982) Biochemistry 1982(21), 
2285-2292 
65. Franza, B. R. J., Aronson, D. L., and Finlayson, J. S. (1975) J. Biol. Chem. 250 
66. Heldebrant, C. M., and Mann, K. G. (1973) J. Biol. Chem. 248(10), 3642-3652 
67. Morita, T., Iwanaga, S., and Suzuki, T. (1976) Thromb Res 8(2 suppl), 59-65 
68. Kornalik, F., and Blombäck, B. (1975) Thromb Res 6, 57-63 
69. Myrmel, K. H., Lundblad, R. L., and Mann, K. G. (1976) Biochemistry 15, 1767-
1773 
70. Doyle, M. F., and Haley, P. E. (1993) Methods in Enzymology 222, 299-313 
71. Boxrud, P. D., and Berliner, L. J. (1996) J. Prot. Chem. 15(2), 231-242 
 73
72. Bode, W., Mayr, I., Baumann, U., Huber, R., Stone, S. R., and Hofsteenge, J. 
(1989) EMBO J. 8, 3467-3475 
73. Orcutt, S. J., and Krishnaswamy, S. (2004) J. Biol. Chem. 279, 54927-54936 
74. Tans, G., Janssen-Claessen, T., Hemker, H. C., Zwaal, R. F., and Rosing, J. 
(1991) J. Biol. Chem. 266(32), 21864-21873 
75. Lottenberg, R., Christensen, U., Jackson, C. M., and Coleman, P. L. (1981) 
Methods in Enzymology 80, 341-361 
76. Coleman, P. L., Perry, J. F., and Wehrly, J. A. (1983) Clin. Chem. 29, 603-608 
77. Sonder, S. A., and Fenton, J. W. n. (1986) Clin. Chem. 32, 934-937 
78. Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000) J. 
Biol. Chem. 275, 16428-16434 
79. Bukys, M. A., Orban, T., Kim, P. Y., Nesheim, M. E., and Kalafatis, M. (2008) 
Thromb Haemost  
80. Fredenburgh, J. C., Stafford, A. R., and Weitz, J. I. (1997) J. Biol. Chem. 272, 
25493-25499 
81. Verhamme, I. M., Olson, S. T., Tollefsen, D. M., and Bock, P. E. (2002) J. Biol. 
Chem. 277, 6788-6798 
82. Vijayalakshmi, J., Padmanabhan, K. P., Mann, K. G., and Tulinsky, A. (1994) 
Protein Sci. 3, 2254-2271 
 74
83. Khan, A. R., and James, M. N. G. (1998) Protein Sci. 7, 815-836 
84. Bianchini, E. P., Orcutt, S. J., Panizzi, P., Bock, P. E., and Krishnaswamy, S. 
(2005) Proc. Natl. Acad. Sci. U S A. 102(29), 10099-10104 
85. Rabiet, M. J., Benarou, R., Labie, D., and Josso, F. (1978) FEBS Lett. 87(1), 132-
134 
86. Diuguid, D. L., Rabiet, M. J., Furie, B. C., and Furie, B. (1989) Blood 74, 193-
200 
87. Rabiet, M. J., Furie, B. C., and Furie, B. (1986) J. Biol. Chem. 261, 15045-15048 
88. Miyata, T., Zheng, Y. Z., Kato, A., and Kato, H. (1995) Brit J Haemat 90, 688-
692 
89. Guillin, M. C., and Bezeaud, A. (1981) Annals NY Acad Sci 370, 414-425 
90. Orfeo, T., Brufatto, N., Nesheim, M. E., Xu, H., Butenas, S., and Mann, K. G. 
(2004) J. Biol. Chem. 279, 19580-19591 
91. Tans, G., Nicolaes, G. A. F., Thomassen, M. C. L. G. D., Hemker, H. C., van 
Zonneveld, A.-J., Pannekoek, H., and Rosing, J. (1994) J. Biol. Chem. 269, 
15969-15972 
92. Kroh, H. K., Tans, G., Nicolaes, G. A., Rosing, J., and Bock, P. E. (2007) J. Biol. 
Chem. 82, 16095-16104 
93. Hackeng, T. M., Tans, G., Koppelman, S. J., de Groot, P. G., Rosing, J., and 
Bouma, B. N. (1996 Oct 15;319 ( Pt 2):399-405) Biochem. J. 319 ( Pt 2), 399-405 
 75
  
 76
  
 
 
 
 
 
 
Chapter III 
AMINO ACID REGION 659-663 OF FACTOR VA HEAVY CHAIN IS 
INDISPENSABLE FOR OPTIMAL ACTIVITY OF FACTOR XA 
WITHIN PROTHROMBINASE 
 
3.1 Abstract 
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 Factor Va, the cofactor of prothrombinase, is composed of heavy and light chains 
associated non-covalently in the presence of divalent metal ions.  The COOH-terminal 
region of the heavy chain contains acidic amino acid clusters that are important for 
cofactor activity.  We have investigated the role of amino acid region 659-663 that 
contains five consecutive acidic amino acid residues.  To ascertain the function of this 
region site-directed mutagenesis was performed to generate factor V molecules in which 
all residues were mutated to either lysine (factor V5K) or alanine (factor V5A).  We have 
also constructed a mutant molecule with this region deleted (factor VΔ659-663).  The 
recombinant molecules along with wild type factor V (factor VWT) were transiently 
expressed in COS7L cells, purified, and assessed for cofactor activity.  Two-stage 
clotting assays revealed that the mutant molecules had reduced clotting activities 
compared to factor VaWT.  Kinetic analyses studying prothrombinase assembled with the 
mutant molecules demonstrated diminished kcat values, while the affinity of all mutant 
molecules for factor plasma-derived Xa was similar to factor VaWT.  Gel electrophoresis 
analyzing plasma-derived and recombinant mutant prothrombin activation demonstrated 
delayed cleavage of prothrombin at both Arg320 and Arg271 by prothrombinase assembled 
with the mutant molecules.  However, cleavage at Arg271 by prothrombinase assembled 
with factor VaΔ659-663, factor Va5K and factor V5A was slower compared to cleavage at 
Arg320 by prothrombinase assembled with the same recombinant cofactor molecules, 
resulting in lingering of meizothrombin throughout the activation process.  These results 
were confirmed following analysis of the cleavage of FPR-meizothrombin by 
prothrombinase assembled with the mutant cofactor molecules.  Our data suggest that 
amino acid region 659-663 from factor Va heavy chain plays an important role during 
prothrombin activation by prothrombinase. 
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 3.2 Introduction 
 The proteolytic conversion of prothrombin to thrombin is catalyzed by the 
prothrombinase complex composed of the enzyme, factor Xa, and the cofactor, factor Va, 
assembled on a membrane surface in the presence of Ca2+ (1, 2). Factor Xa alone can 
activate prothrombin following sequential cleavages at Arg271 and Arg320 yielding the 
transient inactive intermediate prethrombin 2.  However, the interaction of factor Va with 
factor Xa on a membrane/cell surface in the presence of divalent metal ions and 
formation of the prothrombinase complex results in the reversal of the order of cleavages 
and a 300,000-fold increase in the catalytic efficiency of factor Xa for thrombin 
generation.  A first cleavage of prothrombin by prothrombinase at Arg320 produces the 
active intermediate meizothrombin, while the second cleavage at Arg271 produces 
thrombin (3-6).  Thrombin and prothrombin contain two positively charged binding 
regions (anion binding exosite I, ABE-I and anion binding exosite II, ABE II), that are 
crucial for protein function.  Initial cleavage of prothrombin at Arg320 by prothrombinase 
which is absolutely factor Va dependent, entirely exposes (pro)exosite I (7).  Factor Va is 
required for the specific recognition of prothrombinase by (pro)exosite I of prothrombin 
(8, 9).  Proteolytic elimination of fragment 1 of prothrombin eliminates the accelerating 
effect of the membrane surface for initial cleavage at Arg320 by prothrombinase (10, 11).   
Coagulation factor V circulates in plasma at a concentration of 20 nM, as a single 
chain inactive precursor of Mr 330,000 consisting of three subdomains in the order A1-
A2-B-A3-C1-C2) (Fig.3.1).  The molecule is activated by thrombin following sequential 
cleavages at Arg709, Arg1018, and Arg1545 to generate the active cofactor (factor Va) 
78 
 
composed of a heavy chain of Mr 105,000 (A1-A2 domains) and a light chain of Mr 
74,000 (A3-C1-C2 domains).  The two chains are associated via non-covalent bonds in 
the presence of divalent metal ions (12).  The light chain contains the domains that 
interact with the cell membrane surface at the place of vascular injury while the heavy 
chain possesses specific amino acid motifs that are involved in prothrombinase complex 
formation and function.  We have demonstrated that a binding site for factor Xa is 
contained within the heavy chain of the cofactor (13, 14) and we have recently shown 
that two residues from the central portion of the heavy chain of factor Va (amino acid 
residues 334-335) are crucial for cofactor function (15).   
The COOH-terminal region of factor Va heavy chain is involved in the interaction 
with prothrombin (16, 17).  We have recently demonstrated that a factor Va molecule 
lacking the last 30 amino acids from the carboxyl-terminal end of the heavy chain (amino 
acid residues 680-709) displayed a reduction in clotting activity and a delay in 
prothrombin consumption, leading to the accumulation of the intermediate 
meizothrombin during prothrombin activation.  Prothrombinase assembled with the same 
mutant also demonstrated an increased kcat for prothrombin activation when compared to 
prothrombinase assembled with wild-type factor Va (18).  We have established that this 
acidic region is essential for optimal expression of cofactor activity because it promotes a 
productive interaction with prothrombin regulating the rate of cleavage at Arg271 by 
prothrombinase (18-21).  This region of the cofactor is highly acidic in nature and 
contains several tyrosine residues that have been shown to be involved in factor V 
activation by α-thrombin and proper cofactor function (22).  This part of the molecule 
and, more precisely, the motif DYDYQ (amino acid residues 695-699) is highly 
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conserved in 20 different mammal species (Fig.3.2).  The heavy chain of the cofactor 
contains another cluster of acidic amino acids (DDDED, amino acid region 659-663) that 
may also be involved in the regulation of prothrombinase activity.  This region is also 
conserved among species a likely indicator of its physiological significance (Fig.3.2).  
The present study was undertaken to evaluate the importance of amino acid region 659-
663 of factor Va heavy chain for prothrombinase complex assembly and function.  Our 
results show that this region exerts a profound and unexpected effect on prothrombin 
activation by prothrombinase. 
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Figure 3.1. Factor V structure and mutant Molecules. The procofactor, factor V, is 
composed of three A domains (red), a connecting B region, and two C domains (blue). 
Factor Va is generated following three sequential cleavages of factor V by α-thrombin at 
Arg
709
, Arg
1018
, and Arg
1545
. The mutations within the acidic, hirudin-like COOH-
terminus region of the heavy chain (amino acid residues 659-653), are indicated together 
with the designation of the recombinant mutant factor V molecules created and used 
throughout the manuscript. The acidic region 680-709, recently shown to be involved in 
factor Va cofactor function is also illustrated (18). 
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             656   660               670                      680                         690                        700                710 
      |     |                      |                            |                          |                              |                         | 
Humf5.Pep               CIP--DDDEDSYEI--FEPPESTVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRS 
chimpf5_pep_          CIP--DDDEDSYEI--FEPPESTVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRS 
orangf5tot_pep_       CIP--DDDEDSYEI--FEPPESTVMATRKMHDRLEPEDEESDADYDYQNRLAAALGIRS 
nomaleucf5_pep_     CIP--DDDEDSYEI--FEPPESTVMATRKMHDRLEPEDEESDADYDYQSRLAAALGIRS 
macacaf5.pep_          CIT--DDDEDSYEI--FEPPESTVIATRKMHDPLETEDEESDTDYDYQSRLAAALGIRS 
papiohamaf5_pep_   CIT--DDDEDSYEI--FEPPESTVIATRKMHDRLETEDEEGDTDYDYQSRLAAALGIRS 
calljaccf5.pep_         CIR--DDYEDSYEI--YEPLESSVTATRKMHTPSENEDEESDADYDYQTRLASALGIRS 
otogarf5.pep_           CIL--DDGDNSYEI--YEPPSFTPMETRKMHDFPDYEDEETKIEDYYQYMLASEFGIRS 
Bovf5.Pep                 CIR--NDDDDSYEI-IYEPSGSTAMTTKKIHDSSE-IEDENDADSDYQDELALILGLRS 
pigf5.pep_                CIR--DDDEDSYEI-IYEPSSSTTLTTRKMHDSSENKEEENDDEYDYQDLLASVLGIRS 
dogf5.pep_               CIR--DDYEDSYEI-IYESLAPTVMTTRKMRDSPEDNGDENDADYDYQNNLASWLGIRS 
myotlucif5_pep_      CNR--NDENEEYEFEIYKPPPSTPMTTRKVHEFPENQGEIDETEDDYDSHLASLYGIRS 
horsef5_pep_           CIL--DDGEGSYEF-IFQPPESTAITTRKMHDSSENSNEEFDADYDYQNRLASLFGIRS 
dasnovf5_pep_        CIR-DYDDEDSYQI-IYEHKTSSTMDTRKMHDSSEDKSEMDDTDSDYQDTLASLLGIRS 
elephf5.pep_           CIR--DDYEGSYEI-MYGPPTSIPMDTRKMHDSLENKSGEDATEYDYQDSLASSLGIRS 
dipordif5_pep_        CNRNDDDNDDSY-I--YKPVESTVMETRKMRYSAENEQEEDDNESDYQDELATSLGIRS 
rabbitf5_pep_          CNR--DDDDDSYEI--YQPPTSSPIDTRKMRDSSENRDEEYDAEYDYQNSLASSLGIRS 
caviaf5_pep_           CIG--DDDEDSYKI-YAPPEVSTPMDVRKIKFPSENEHEEINPDDDYQDDLASALGLRS 
Musf5.Pep               CNR-DYDNEDSYEI-YEPP-APTSMTTRRIHDSLENEFGIDNEDDDYQYLLASSLGIRS 
ratf5_pep_              CNRNDDDDEDSYEI-YQPL-EPTSMTTRKIHDSVENDFGIENEDDDYQYELASTLGIRS 
 
 
 
 
 
 
 
Figure 3.2. Comparison of the acidic COOH-terminal amino acid sequences 659-
663 and 695-698 from factor Va heavy chain among species (numbering from the 
human molecule, top sequence).  Sequences were derived from various database 
sources, such as GenBank and the NCBI Trace Archive. The species shown are as 
follows (from top to bottom):  Homo sapiens, human; Pan troglodytes, chimpanzee; 
Pongo pygmaeus, orangutan; Nomascus leucogenys, white-cheeked gibbon; Macaca 
mulatta, rhesus monkey; Papio hamadryas, hamadryas baboon; Callithrix jacchus, white-
tufted-ear marmoset; Otolemur garnettii, small-eared galago; Bos taurus, cattle; Sus 
scrofa, pig; Canis lupus familiaris, dog; Myotis lucifugus, little brown bat;  Equus 
caballus horse; Dasypus novemcinctus, nine-banded armadillo; Loxodonta africana, 
African elephant; Dipodomys ordii, Ord’s kangaroo rat; Oryctolagus cuniculus, rabbit; 
Cavia porcellus, domestic guinea pig; Mus musculus, western European house mouse; 
Rattus norvegicus, Norway rat. 
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3.3 Experimental Procedures 
 Materials and Reagents. Diisopropyl-fluorophosphate (DFP), O-
phenylenediamine (OPD)-dihydrochloride, and Coomassie Blue R-250, were purchased 
from Sigma (St. Louis, MO).  Factor V-deficient plasma was from Research Protein Inc. 
(Essex Junction, VT).  Secondary anti-mouse and anti-sheep IgG coupled to peroxidase 
was purchased from Southern Biotechnology Associates Inc. (Birmingham, AL).  L-α-
phosphatidylserine (PS) and L-α-phosphatidylcholine (PC) were obtained from Avanti 
Polar Lipids (Alabaster, AL).  Chemiluminescent reagent ECL+ and Heparin–Sepharose 
were obtained from AmershamPharmacia Biotech Inc. (Piscataway, NJ).  Normal 
reference plasma and the chromogenic substrate H-D-Hexahydrotyrosol-alanyl-arginyl-p-
nitroanilide diacetate (Spectrozyme-TH) were purchased from American Diagnostica Inc. 
(Greenwich, CT).  RecombiPlasTin used in the clotting assays was purchased from 
Instrumentation Laboratory Company (Lexington, MA).  The reversible fluorescent α-
thrombin inhibitor dansylarginine-N- (3-ethyl-1,5-pentanediyl) amide (DAPA), human α-
thrombin, human prothrombin and active-site blocked human meizothrombin (obtained 
following digestion of prothrombin with the purified component from the venom of the 
snake Echis Carinatus as described (23), FPR-meizothrombin) were purchased from 
Haematologic Technologies Inc. (Essex Junction, VT).  Human factor Xa was from 
Enzyme Research Laboratories (South Bend, IN).  Human factor V cDNA was obtained 
from American Type Tissue Collection (ATCC# 40515 pMT2-V, Manassas, VA).  All 
restriction enzymes were obtained from New England Biolabs (Beverly, MA).  All 
molecular biology and tissue culture reagents, specific primers, and medium were 
purchased from Gibco, Invitrogen Corp. (Grand Island, NY) or as indicated.  
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Recombinant wild type prothrombin, prothrombin rMZ-II that has only one cleavage site 
for factor Xa (i.e. Arg320) and prothrombin rP2-II that has only one cleavage site for 
factor Xa (i.e. Arg271) were prepared and purified as previously described (24) and 
provided by Dr. Michael Nesheim (Queen’s University, Kingston, Ontario Canada).  
Human factor V monoclonal antibodies (αHFVHC17 and αHFVLC9) used for 
immunoblotting experiments and monoclonal antibody αHFV1 coupled to Sepharose 
used to purify plasma and recombinant factor V molecules were provided by Dr. Kenneth 
G. Mann (Department of Biochemistry, University of Vermont, Burlington, VT). 
Mutagenesis and Transient Expression of Recombinant Factor V Molecules.  
The factor V cDNA consists of a 6,909 bp long fragment inserted into the pMT2 
mammalian expression vector at the SalI site.  Mutant factor V molecules consisting of 
point mutations and various deletions to the COOH-terminus of the heavy chain were 
synthesized using the QuickChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, 
CA, USA) according to the manufacturer’s instructions.  The mutagenic primers used for 
the deletions were 58-base pair primers on the sense and antisense strands of the 
recombinant factor V molecule.  The primers for factor V5K were 5’-
TGAGGCTGAAATTCAGGGATGTTAAATGTATCCCAAAGAAGAAGAAAAAGTC
ATATGAGATTTTTGAACCTCCAGAATC-3’ (sense) and 5’-
GATTCTGGAGGTTCAAAAATCTCATATGACTTTTTCTTCTTCTTTGGGATACAT
TTAACATCCCTGAATTTCAGCCTCA-3’ (antisense).  Primers for factor V659-663 were, 
5’-
AGGCTGAAATTCAGGGATGTTAAATGTATCCCATCATATGAGATTTTTGAACC
TC-3’ (sense), and 5’-
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GAGGTTCAAAAATCTCATATGATGGGATACATTTAACATCCCTGAATTTCAGC
CT-3’ (antisense).  Primers for factor V5A were 5’-
GCTGAAATTCAGGGATATTAAATGTATCCCAGCGGCGGCGGCGGCGTCATAT
GAGATTTTTGAACCTCCAGA-3’ (sense), 5’-
TCTGGAGGTTCAAAAATCTCATATGACGCCGCCGCCGCCGCTGGGATACATTT
AACATCCCTGAATTTCAGC-3’ (antisense), respectively.  The mutagenized primers 
were transformed into competent E.coli cells and positive ampicillin-resistant clones 
were selected to screen for mutants.  Wild-type factor V and mutant factor V clones were 
cultured and isolated using the PureLink Quick Plasmid miniprep Kit (Invitrogen, 
Carlsbad, CA).  The incorporation of the mutations in the cDNA was verified by DNA 
sequence analysis, using factor V-specific primers.  Transfection and harvesting of the 
media was performed as described in detail by our laboratory (14, 25).  All media 
containing the recombinant factor V molecules were concentrated using the Vivaflow 50 
Complete System (Vivascience AG, Hannover, Germany) according to manufacturer’s 
instructions.  All recombinant factor V molecules were purified according to the detailed 
protocol previously described by our laboratory (25).  The concentration of the 
recombinant proteins was determined by ELISA as previously described (14).  The 
activity and integrity of the recombinant molecules was verified before and after 
activation with thrombin by clotting assays using factor V-deficient plasma and by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by 
Western Blotting using both monoclonal and polyclonal antibodies.  In some instances 
factor Va fragments were also visualized following staining with silver. 
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Gel Electrophoresis and Western Blotting.  SDS-PAGE analyses of recombinant 
factor V molecules were performed using 4-12% gradient gels according to the method of 
Laemmli (26).  Proteins were transferred to polyvinylidene difluoride (PVDF) 
membranes according to the method described by Towbin et al.(27).  After transfer to 
PVDF, factor V heavy and light chain(s) were detected using the appropriate monoclonal 
and polyclonal antibodies (28, 29).  Immunoreactive fragments were visualized with 
chemiluminescence.  In several instances recombinant factor V and factor Va fragments 
obtained following activation of the procofactor with thrombin were visualized following 
staining of the gels with silver as described (30). 
Analysis of Prothrombin or Recombinant Mutant Prothrombin Activation and 
FPR-Meizothrombin Cleavage at Arg271 by Gel Electrophoresis.  Prothrombin or 
recombinant mutant prothrombin molecules (1.4μM) were incubated with PCPS vesicles 
(20μM), DAPA (50μM), and factor Va (10-20nM) in the presence of 5 mM Ca2+ in 20 
mM Tris, 0.15 M NaCl, pH 7.4.  The reaction was initiated upon addition of factor Xa 
(0.5-1 nM) at room temperature over the time course indicated in the legend to the 
figures.  Aliquots (50 μl ) from the reaction were removed at selected time intervals (as 
indicated in the legend to the figures), diluted into 2 volumes of 0.2 M glacial acetic acid 
and concentrated using a Centrivap concentrator attached to a Centrivap cold trap 
(Labconco, Kansas City, MO).  The dried samples were dissolved in 0.1 M Tris-base, pH 
6.8, 1% SDS, 1% β-mercaptoethanol, heated for exactly 75s at 90°C, mixed, and 
subjected to SDS-PAGE using 9.5% gels prepared according to the method of Laemmli 
(26); 6μg of protein per lane was applied.  FPR-meizothrombin cleavage at Arg271 was 
assessed in a similar manner using 12% SDS-PAGE.  Protein bands were visualized 
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following staining with Coomassie Brilliant Blue R and destained by diffusion in a 
methanol/acetic acid/water solution.   
Scanning densitometry of SDS-PAGE and calculation of the rate of prothrombin 
consumption.  Scanning densitometry of the gels was performed as described (31).  
Briefly, the stained gels were scanned and imported into the software UN-SCAN-IT gel 
(Silk Scientific, Orem UT).  The numbers were normalized to the initial concentration of 
prothrombin (1.4 μM) and adjusted for the capability of each fragment to be stained by 
Coomassie as described (32).  Following scanning densitometry, the data representing 
prothrombin consumption as a function of time (sec) were subsequently plotted using 
nonlinear regression analysis and the equation representing a first-order exponential 
decay using the software Prizm (GraphPad, San Diego, CA).  The apparent first-order 
rate constant, k (s-1), obtained directly from the fitted data was divided by the molar 
concentration of factor Xa used in each experiment.  The number obtained was 
subsequently multiplied by the starting concentration of prothrombin.  The final numbers 
reported throughout the manuscript characterizing the effect of the mutations on plasma-
derived prothrombin consumption by prothrombinase assembled with various 
recombinant factor Va molecules, represent moles of prothrombin consumed per mole of 
factor Xa per second for a given experiment.  The consumption rates reported in the 
manuscript are representative of experiments performed at least in triplicate using 2-4 
different preparations of recombinant proteins.  All constants reported in Tables 3.II and 
3.III were extracted directly from the fitted data.  The tables also report the standard 
deviation for each measurement.  In the legend to the figures we are also providing the 
goodness of the fit to the equation representing a first-order exponential decay (R2). 
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Measurement of Rates of Thrombin Formation in a Prothrombinase Assay.  All 
factor V molecules, both recombinant and plasma, were activated with human α-
thrombin as described (33).  The assay verifying the activity of the recombinant 
molecules was conducted as described by measuring thrombin formation by the change in 
the absorbance of a chromogenic substrate at 405 nm (Spectrozyme-TH) monitored with 
a Thermomax microplate reader (Molecular Devices, Sunnyvale, CA) (14, 20).  
Absorbance at 405 nm was compared with a standard curve prepared daily using purified 
thrombin (0-50 nM). 
For the functional calculation of the apparent dissociation constants (KDapp) between 
the recombinant factor Va molecules and factor Xa, experiments were performed in the 
presence of a limited concentration of factor Xa (15 pM) and varying concentrations of 
factor Va (between 30 pM and 5 nM).  Throughout all experiments the assumption was 
=moles of factor Xa bound/mole of factor Va at saturation; throughout this study n = 1; 
the stoichiometry of the factor Va-factor Xa interaction was fixed at 1.  The initial rate of 
thrombin formation was calculated, and the data were analyzed and plotted using 
nonlinear regression analysis and the software Prizm (Graphpad, GraphPad, San Diego, 
CA) according to the one binding site model.  Dissociation constants reported in the 
manuscript were extracted directly from the fitted data.  In the legend to the figures we 
are also providing the goodness of the fit to the one binding site model (R
n
2). 
The assay using purified reagents and verifying the cofactor activity of the 
recombinant factor V molecules for prothrombin activation was conducted under 
conditions where all factor Xa was saturated with factor Va, as described by measuring 
α-thrombin formation by the change in the absorbance of a chromogenic substrate at 405 
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nm (Spectrozyme-TH, 0.4 mM) (14).  All factor V molecules were activated with 
thrombin as described (19, 20).  Knowing the KDapp of each factor Va species for factor 
Xa, the amount necessary to saturate factor Xa was calculated using the quadratic 
equation described in the literature (34) before each experiment.  The absorbance was 
monitored with a Thermomax microplate reader and compared to a α-thrombin standard 
prepared daily using purified plasma-derived α-thrombin.  The data were analyzed and 
plotted using nonlinear regression analysis and the software Prizm according to the Henri 
Michaelis-Menten equation.  Kinetic constants provided throughout the manuscript were 
extracted directly from the fitted data.  In addition, in the legend to the figures we are 
reporting the goodness of the fit to the Henri Michaelis-Menten equation (R2). 
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3.4 Results 
Transient Expression and Activation of Recombinant Factor V Molecules.  In 
order to assess the importance of amino acid region 659-663 from the heavy chain of 
factor Va, we constructed three mutant molecules. We prepared recombinant factor VΔ659-
663, factor V5A, and factor V5K (Fig.3.1).  Recombinant factor VWT and the mutant 
molecules were expressed in mammalian cells and purified by immunoaffinity 
chromatography as previously described in detail by our laboratory (25).  All 
recombinant mutant molecules were activated with thrombin.  Figure 3.3 illustrates a 
typical quality control procedure performed prior to all experiments.  Panels A-C show 
the subunit composition the recombinant molecules prior and after activation by 
thrombin.  SDS-PAGE analyses followed by immunoblotting with specific monoclonal 
antibodies to the heavy and light chain of the cofactor demonstrate that the mutant 
recombinant proteins are intact and composed of heavy and light chains that migrated in 
accord with their expected molecular weights (panel D).  In addition, experiments using a 
polyclonal antibody to factor V demonstrate that all factor V molecules were fully 
activated prior to use (not shown).   
The recombinant molecules were assessed for their clotting activity in a two-stage 
clotting assay.  Thrombin activation of factor VWT resulted in a cofactor with similar 
clotting activity as the plasma-derived molecule (Table 3.I).  Under similar experimental 
conditions factor VaΔ659-663, factor Va5K and factor V5A displayed 3.5-, 10-, and 24-fold 
less clotting activities respectively compared to the clotting activity of factor VaWT (Table 
3.I).  These data demonstrate that amino acid region 659-663 is important for expression 
of optimal factor Va clotting activity. 
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Kinetic Analyses of Recombinant Factor Va Molecules.  We next examined the 
capability of the recombinant factor Va molecules to bind factor Xa and to assemble in 
prothrombinase using an assay employing purified reagents and a chromogenic substrate 
to probe for thrombin generation.  The assay was performed under conditions of limiting 
factor Xa concentrations while varying the concentration of recombinant factor Va 
molecules.  Figure 3.4A and Table 3.I show the results of the kinetic studies.  The data 
demonstrate that under the experimental conditions used, factor VaWT has similar affinity 
for the enzyme, factor Xa, as its plasma counterpart.  Likewise, the three recombinant 
mutant factor Va molecules have similar affinities for plasma-derived factor Xa which 
are indistinguishable from the affinity of factor VaWT for factor Xa.  These results are in 
complete accord with our recent findings (18) and demonstrate that the acidic hirudin-like 
amino acid regions from the COOH-terminal of the heavy chain of factor Va do not 
participate in the interaction of the cofactor with plasma-derived factor Xa (Table 3.I).   
We subsequently evaluated the effect of the mutations on the Km and kcat of 
prothrombinase.  The raw data are displayed in Figure 3.4B, the values of the kcat and Km 
for each set of titration are reported in Table 3.I, and a comparison of the second order 
rate constants is displayed in figure 3.4C.  Since we wanted to prevent the possibility that 
differences between prothrombinase assembled with factor VaWT and prothrombinase 
assembled with the two recombinant mutant factor Va molecules may be attributed to 
subtle differences in the KDapp of factor Va for factor Xa, which would result in a lesser 
amount of prothrombinase formed, all experiments shown in figure 3.4B were conducted 
under conditions where factor Xa was saturated with factor Va.  Calculations were 
performed using the dissociation constants of all recombinant molecules for factor Xa 
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shown in Table 3.I as extensively described (34).  Under the experimental conditions 
employed the mutations had no significant effect on the Km of the reaction, while the 
catalytic efficiencies of prothrombinase assembled with the three mutant recombinant 
cofactor molecules were decreased compared to the catalytic efficiency of 
prothrombinase assembled with factor VaWT (Fig. 3.4B, Table 3.I).  The data show that 
prothrombinase assembled with factor Va5K or factor Va5A have approximately 50% 
reduced catalytic efficiency when compared to the catalytic efficiency of factor VaWT, 
while factor VaΔ659-663 has a 40% reduced catalytic efficiency, compared to the value 
obtained for prothrombinase assembled with the wild type cofactor.  Comparison of the 
second-order rate constant between prothrombinase assembled with the recombinant 
mutant molecules (kcat/Km) with the second-order rate constant obtained with 
prothrombinase assembled with the wild type or the plasma-derived cofactor 
demonstrates that the turnover number for prothrombinase assembled with the mutant 
molecules is 40-50% reduced (Fig.3.4C).  The inability of prothrombinase assembled 
with the mutant cofactor molecules to function optimally coupled to the lack of effect of 
the mutations on the dissociation constant of the recombinant mutant cofactor molecules 
for plasma factor Xa, can be explained by the inability of factor Xa to efficiently convert 
prothrombin to thrombin because of diminished productive collisions between the 
enzyme and prothrombin.  Overall, the data demonstrate that amino acid region 659-663 
of factor Va has an important regulatory role during prothrombin activation by factor Xa 
within prothrombinase. 
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Figure 3.3. Electrophoretic analyses of wild type factor V and recombinant factor V 
molecules. Factor V
WT
, factor V
Δ659-663
, factor V
5K
, and factor V
5A 
were activated with 
thrombin as described in the “Experimental Procedures” section and analyzed by SDS-
PAGE followed by staining with silver (panels A-C). Lane 1, factor V prior to activation 
by thrombin; lane 2, recombinant molecules following incubation with thrombin. Panel 
D, following SDS-PAGE and transfer to a PVDF membrane, immunoreactive fragments 
were detected with monoclonal antibodies αHFVa
HC
17 (recognizing an epitope on the 
heavy chain of the cofactor between amino acid residues 307-506) and αHFVa
HC
9 
(recognizing the light chain). At the right of all panels the positions of factor V as well as 
of the heavy/light chains of factor Va are shown.  
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Figure 3.4A.  Factor Va titrations to determine the affinity of the recombinant factor 
Va molecules for factor Xa. Thrombin generation experiments were carried out as described 
under “Experimental Procedures”. Factor V
WT
, factor V
Δ659-663
, factor V
5K
, and factor V
5A 
were activated by thrombin and assayed for factor Xa binding as described in the 
“Experimental Procedures”. The solid lines represent a nonlinear regression fit of the data 
using Prizm GraphPad software according to the equation of a one binding site (hyperbola) 
model. Prothrombinase complex was assembled with varying concentrations of 
recombinant factor Va
WT 
(filled squares, R
2
=0.98), factor Va
Δ659-663 
(filled circles, 
R
2
=0.96), factor Va
5A 
(filled diamonds, R
2
=0.99) and factor Va
5K 
(filled inverse triangles, 
R
2
=0.97). The dissociation constants reported in Table 3.1 were extracted directly from 
the fitted data.  
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Figure 3.4B.  Prothrombin titration to determine the kinetic parameters of 
prothrombinase assembled with various recombinant factor Va species.   Thrombin 
generation experiments were carried out as described under “Experimental Procedures” 
by varying the substrate concentration (25 nM to 4 μM) with factor Xa saturated with 
each of the recombinant factor Va species. Factor V
WT
, factor V
PLASMA
, factor V
Δ659-663
, 
factor V
5K
, and factor V
5A 
were activated with thrombin as described in the 
“Experimental Procedures” section. The solid lines represent the nonlinear regression fit 
of the data using Prizm GraphPad software according to the Henri Michaelis-Menten 
equation. Prothrombinase was assembled with recombinant factor Va
WT 
(filled squares, 
R
2
=0.99), factor Va
PLASMA 
(filled triangles, R
2
=0.97), factor Va
Δ659-663 
(filled circles, 
R
2
=0.94), factor Va
5K 
(filled inverse triangles, R
2
=0.97), and factor Va
5A 
(filled 
diamonds, R
2
=0.98). The data with factor Va
WT
, factor Va
PLASMA
, factor Va
Δ659-663
, and 
factor V
5K 
show the average results obtained from at least three different titrations with 
three different preparations of purified proteins. The data with factor Va
5A 
are 
representative of two titrations obtained in duplicate using two different preparations of 
recombinant protein. Kinetic constants reported in the text and in Table 3.I were 
extracted directly from fitted data.  
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Figure 3.4C.  Determination of the kinetic parameters of prothrombinase assembled 
with the various recombinant factor Va species. Second-order rate constants for 
prothrombinase assembled with all cofactor molecules (M
-1 
• s
-1
).  
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Table 3.I 
 
Functional properties of various factor Va molecules 
 
Factor Va 
Species 
 
Clotting 
Activity 
(U/mg)a
KDapp 
(nM)b
kcat
(min-1)c
Km
(μM)c
Factor VaPLASMA
 
3124 ± 413 0.70 ± 0.1 2287 ± 87 0.3 ± 0.04 
Factor VaWTa
 
2926 ± 320 0.81 ± 0.1 2397 ± 37 0.2 ± 0.01 
Factor VaΔ659-663
 
823 ± 180 1.0 ± 0.2 1493 ± 58 0.2 ± 0.03 
Factor Va5K
 
275 ± 92 0.8 ± 0.2 1135 ± 36 0.3 ± 0.03 
Factor Va5A 
 
120 ± 30 0.8 ± 0.1 1074 ± 51 0.3 ± 0.05 
 
Table 3.I aTwo-stage clotting assays of recombinant factor V molecules was performed 
as described in the “Experimental Procedures” section. 
bApparent dissociation constants of recombinant factor Va for plasma-derived factor Xa 
(KDapp) were determined as described in the “Experimental Procedures” section at 
limiting factor Xa concentrations (15 pM) according to the binding model assuming one 
binding site using the software Prizm.  Dissociation constants were derived directly from 
the fitted data.   
cThe Km and kcat of prothrombinase assembled with saturating concentrations of 
recombinant factor Va molecules were determined as described in the “Experimental 
Procedures” section according to the Michaelis-Menten equation using the software 
Prizm.  Kinetic constants were derived directly from the fitted data.   
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The findings obtained thus far suggest that prothrombin cleavage and activation by 
prothrombinase assembled with the recombinant mutant molecules is deficient.  These 
data indicate that the rate of one or both of the two prothrombin activation cleavages are 
impaired when prothrombinase is assembled with a cofactor molecule mutated at the 659-
663 amino acid region of the heavy chain.   
To better understand the deficiency in prothrombin cleavage and activation by 
prothrombinase assembled with the recombinant mutant cofactor molecules, we have 
studied prothrombin activation by gel electrophoresis.  The results demonstrate a delay in 
prothrombin activation by prothrombinase assembled with either VaΔ659-663, factor Va5K, 
or factor Va5A as compared to the activation of prothrombin by prothrombinase 
assembled with either factor VaPLASMA or factor VaWT (Fig. 3.5, panels A-E).  Scanning 
densitometry of the gels shown in figure 3.5 demonstrated a 3- and 7-fold delay in 
prothrombin consumption by prothrombinase assembled with factor VaΔ659-663 and factor 
Va5K respectively, as compared to the consumption of prothrombin assembled with factor 
VaWT(Fig.3.6 and Table 3.II). Interestingly, prothrombin consumption by prothrombinase 
assembled with factor Va5A was most severely impaired and no meizothrombin was 
visible during the activation process (Figs 3.5E).  In addition, when prothrombin is 
activated by prothrombinase assembled with either factor VaΔ659-663 or factor Va5K, there 
is persistence (lingering) of meizothrombin throughout the activation process (Figs 3.5C 
and 3.5D).  Scanning densitometry demonstrated that a peak for meizothrombin is 
observed at 120 sec when prothrombin is activated by prothrombinase assembled with 
factor VaWT, while a peak for meizothrombin is detected at 200 sec and 360 sec when 
prothrombin is activated by prothrombinase assembled with either factor VaΔ659-663 or  
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Figure 3.5. Analysis of the activation of plasma-derived prothrombin by 
prothrombinase assembled with various mutant factor Va molecules. Plasma-derived 
prothrombin (1.4 μM) was incubated in different mixtures with PCPS vesicles (20 μM), 
and prothrombinase assembled with either factor Va
WT 
(panel A) or factor Va
PLASMA 
(panel B) as described in the “Experimental Procedures” section. Panel C, 
prothrombinase assembled with factor Va
Δ659-663
; panel D, prothrombinase assembled 
with factor Va
5K
; panel E, prothrombinase assembled with factor Va
5A
. The reactions 
were started by the addition of factor Xa. At selected time intervals aliquots of the 
reaction mixtures were withdrawn and treated as described in the “Experimental 
Procedures” section. M represents the lane with the molecular weight markers (from top 
to bottom): M
r 
98,000, M
r 
64,000, M
r 
50,000, M
r 
36,000. Lanes 1-19 represent samples 
from the reaction mixture before (0 min) the addition of factor Xa and 20 sec, 40 sec, 60 
sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 220 sec, 240 sec, 5 min, 
6 min, 10 min, 20 min, 30 min, and 60 min respectively following the addition of factor 
Xa.  
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Figure 3.6. Analysis of prothrombin consumption by prothrombinase assembled 
with recombinant factor Va molecules. The gels shown in figure 3.5 were scanned and 
prothrombin consumption was recorded as described in the “Experimental Procedures” 
section. Following scanning densitometry, the numbers were normalized to the initial 
concentration of prothrombin (1.4 μM). The data representing prothrombin consumption 
(μM) as a function of time (sec) were subsequently plotted using non-linear regression 
analysis according to the equation representing a first-order exponential decay using the 
software Prizm (GraphPad, San Diego, CA). Prothrombinase was assembled with 
recombinant factor Va
WT 
(filled triangles, R
2
=0.98), factor Va
PLASMA 
(filled circles, 
R
2
=0.98), factor Va
Δ659-663 
(filled squares, R
2
=0.99), factor Va
5K 
(open squares, 
R
2
=0.93), and factor Va
5A 
(open inverse triangles, the data were not a good fit to a first 
order exponential decay model, see Table 3.2). The apparent first-order rate constant, k 
(s
-1
), obtained directly from the fitted data was divided by the molar concentration of 
factor Xa used in each experiment. The number obtained was subsequently multiplied by 
the starting concentration of prothrombin. The resulting numbers representing 
prothrombin consumption are reported in Table 3.II.  
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Table 3.II 
 
 
Rate of activation of native plasma-derived prothrombin and recombinant mutant 
rMZ-II in the presence of prothrombinase assembled with various recombinant 
factor Va species 
 
 
Enzyme 
Plasma-derived 
Prothrombin* (Initial 
cleavage at Arg320) 
(moles consumed • sec-1 • 
mole factor Xa-1) 
rMZ-II*
(Cleavage at Arg320) 
(moles consumed • sec-1 • mole 
factor Xa-1) 
Membrane-bound 
factor Xa alone 
 
-- 0.023 ± 0.017 
Prothrombinase 
assembled with factor 
VaPLASMA
19 ± 1.5 14.0 ± 0.8 
Prothrombinase with  
factor VaWT
21.8 ± 1.9 11.2 ± 1.1 
Prothrombinase with  
factor VaΔ659-663
7.7 ± 0.5 6.4 ± 0.6 
Prothrombinase with  
factor Va5K
3.3 ± 0.9 2.8 ± 0.8 
Prothrombinase with  
factor Va5A
NFa NSCb
 
 
 
 
 
Table 3.II. The rates of plasma-derived prothrombin and recombinant mutant 
prothrombin rMZ-II consumption were obtained following scanning densitometry of gels 
shown in Figs.3.5 and 3.7 respectively.  The final rate of prothrombin consumption in the 
presence of prothrombinase assembled with various factor Va species, was extracted 
following plotting of the data according to the equation representing a first-order 
exponential decay as described in the “Experimental Procedures” section (Figs.3.6 and 
3.9).  The apparent first-order rate constants were obtained directly from the fitted data. 
aNF, no fit; the data could not be fitted to a first-order exponential decay (R2 = 0.0049).  
The concentration of plasma-derived prothrombin varied from 1400 nM at time 0 to 200 
nM following 1h incubation with prothrombinase assembled with factor Va5A. 
bNSC, not significant consumption.  The concentration of rMZ-II varied from 1400 nM at 
time 0 to 1260 nM following 2h incubation with prothrombinase assembled with factor 
Va5A
104 
 
factor Va5K respectively.  It is important to note, that in the latter case the detrimental 
effect of the mutations is more pronounced on prothrombin activation than when amino 
acid sequence 659-663 is deleted.  However, mutating all amino acids from this region to 
alanine appears to abolish the capability of factor Xa within prothrombinase for cleavage 
of prothrombin at Arg320.  These data are in complete accord with the data obtained in the 
clotting assays and the combined data suggest that both prothrombin activation cleavages 
(Arg320 and Arg271) appear to be affected to various degrees when prothrombinase is 
assembled with factor VaΔ659-663, factor Va5K, or factor Va5A  However, because 
meizothrombin lingers throughout the activation process, it appears that the rate of 
cleavage of prothrombin at Arg271 is considerably more affected by a deletion of the 659-
663 amino acid region or a D→K substitution, than the rate of cleavage of prothrombin at 
Arg320.  In contrast, the D→A substitution in the hirudin-like acidic 659-663 region 
appears to be equally detrimental to prothrombinase for cleavage of prothrombin at either 
Arg320 or Arg271.  Overall, the data demonstrate that 1) amino acid region 659-663 is 
important for optimum activity of prothrombinase and 2) the nature of the mutations in 
this region has an impact on the pathway and rate of prothrombin activation by 
prothrombinase. 
Activation of Recombinant Mutant Prothrombin by Prothrombinase Assembled 
with Mutant Factor Va molecules.  The data obtained thus far studying plasma-derived 
prothrombin activation by prothrombinase assembled with the mutant cofactor molecules, 
demonstrate that 1) meizothrombin lingers throughout the time course, 2) appearance of 
the B-chain of thrombin is also delayed when prothrombin is activated by prothrombinase 
assembled with two of the three mutant cofactor molecules; and 3) initial cleavage of 
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prothrombin by prothrombinase assembled with factor Va5A is severely impaired.  In 
order to verify which cleavage in prothrombin is specifically affected by the 
modifications in the 659-663 amino acid region of factor Va heavy chain, we first used 
prothrombin molecules that cannot be cleaved at either Arg271 such as rMZ-II (Fig.3.7) or 
at Arg320 (rP-II, Fig.3.8) (24).  
The data demonstrate that there is a significant difference between the rates of 
activation of rMZ-II by prothrombinase assembled with factor VaΔ659-663, factor Va5K, or 
factor Va5A as compared to rMZ-II activated by prothrombinase made with factor VaWT 
or factor VaPLASMA (Fig.3.7).  Scanning densitometry of the gels shown in figure 3.7 
demonstrate that cleavage at Arg320 of rMZ-II is delayed by ~2-fold when 
prothrombinase is assembled with factor VaΔ659-663 and 4-fold when prothrombinase is 
assembled with factor Va5K compared to cleavage of the recombinant mutant 
prothrombin molecule by prothrombinase assembled with factor VaWT (Table 3.II, and 
Fig.3.9).  In contrast, no significant prothrombin consumption was observed when rMZ-II 
was incubated with prothrombinase assembled with factor Va5A (Fig.3.7)  The data 
confirm our overall findings with plasma-derived prothrombin and demonstrate that 
prothrombinase-mediated cleavage at Arg320 in prothrombin is affected by the 
modifications/deletion of amino acids 659-663 from the COOH-terminal portion of factor 
Va heavy chain. 
The data shown in figures 3.8 and 3.9, and in Table 3.III demonstrate that the rate of 
cleavage of rP2-II at Arg271 by prothrombinase assembled with factor VaΔ659-663, factor 
Va5K, or factor Va5A is undetectable compared to the rate of cleavage of rP2-II at Arg271 
by prothrombinase assembled with either factor VaWT or factor VaPLASMA.  In fact, these 
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mutations in factor Va heavy chain practically abolish the capability of prothrombinase 
assembled with any of the mutant cofactor molecules to cleave rP2-II at Arg271.  Overall, 
the data shown in figures 3.5-3.9 demonstrate that mutations in the acidic amino acid 
segment 659-663 differentially affect the rate of the two activating cleavage sites of 
prothrombin by prothrombinase.  These data demonstrate that this portion of factor Va 
heavy chain controls the catalytic efficiency of factor Xa within the enzymatic complex. 
Activation of FPR-Meizothrombin by Prothrombinase Assembled with Mutant 
Factor Va molecules.  Analysis of the results obtained thus far with plasma-derived and 
recombinant prothrombin suggests that activation of prothrombin by prothrombinase 
assembled with factor VaΔ659-663, factor Va5K, and factor Va5A is severely impaired 
compared to cleavage of the recombinant molecule by prothrombinase assembled with 
factor VaWT because of delayed cleavage at both Arg320 and Arg271 resulting in both slow 
prothrombin consumption and less conversion of meizothrombin to thrombin.  It has been 
shown that a change in conformation of meizothrombin is associated with cleavage of 
prothrombin at Arg320 (35).  To ascertain the effect of the mutations of the factor Va 
heavy chain on the cleavage of prothrombin at Arg271 following the transition that occurs 
after cleavage at Arg320, we compared the rate of cleavage of FPR-meizothrombin by 
prothrombinase assembled with either factor VaWT or the recombinant mutant cofactor 
molecules (Fig.3.10). The data demonstrate a delay for cleavage of FPR-meizothrombin 
at Arg271 by prothrombinase assembled with factor VaΔ659-663 (panel B), factor Va5K 
(panel C), or factor Va5A (panel D) as compared to the same reaction catalyzed by 
prothrombinase assembled with factor VaWT (panel A).  Quantitative scanning 
densitometry of fragment 1•2-A present on the gels shown in figure 3.10, demonstrated a 
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~2-fold delay in cleavage of FPR-meizothrombin at Arg271 by prothrombinase assembled 
with all mutant cofactor molecules, compared to cleavage at Arg271 by prothrombinase 
assembled with factor VaWT (Fig.3.11, Table 3.III).  However, the rates for cleavage of 
FPR-meizothrombin at Arg271 are 2-fold faster than the rate of cleavage of FPR-
meizothrombin by factor Xa alone.  Thus, deletion or substitutions of amino acid residues 
within region 659-663 has a similar effect on prothrombinase, namely, significantly 
impedes acceleration of the rate of cleavage at Arg271 of meizothrombin attributed to the 
interaction of factor Va with factor Xa (3, 36).  These data are in complete agreement 
with all the findings presented herein and overall our data demonstrate that amino acid 
sequence 659DDDED663 from the factor Va heavy chain is indispensable for optimal rates 
of thrombin formation during activation of prothrombin by prothrombinase. 
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 Figure 3.7. Electrophoretic analyses of the activation of rMZ-II by prothrombinase 
assembled with mutant factor Va molecules. rMZ-II was incubated in different 
mixtures with PCPS vesicles, DAPA, and various factor Va molecules. The reaction was 
started by the addition of factor Xa and the samples were treated as detailed in the 
“Experimental Procedures” section. The gels were scanned and quantified as detailed 
under “Experimental Procedures”. Lanes 1-9, represent samples of the reaction mixture 
following incubation of prothrombinase with rMZ-II, before (lane 1), or following 1min, 
3min, 5min, 10min, 20min, 45min, 60min, and 120min incubation with factor Xa 
respectively; Panel A, prothrombinase assembled with factor Va
WT
; panel B 
prothrombinase assembled with plasma-derived factor Va; panel C, prothrombinase 
assembled with factor Va
Δ659-663
; panel D, prothrombinase assembled with factor Va
5K
; 
panel E, prothrombinase assembled with factor Va
5A
; panel F, is a schematic of the 
recombinant prothrombin molecule used (rMZ-II). This molecule is a triple mutant with 
only one cleavage site for prothrombinase remaining at Arg
320
. Positions of prothrombin-
derived fragments are indicated at right as detailed in the legend to figure 3.5. The factor 
Va species used for the reconstitution of prothrombinase are shown under each panel.  
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 Figure 3.8. Electrophoretic analyses of the activation of rP2-II by prothrombinase 
assembled with mutant factor Va molecules. rP2-II was incubated in different mixtures 
with PCPS vesicles, DAPA, and various factor Va molecules. The reaction was started by 
the addition of factor Xa and the samples were treated as detailed in the “Experimental 
Procedures” section. The gels were scanned and quantified as detailed under 
“Experimental Procedures”. Lanes 1-9, represent samples of the reaction mixture 
following incubation of prothrombinase with rP2-II, before (lane 1), or following 1min, 
3min, 5min, 10min, 20min, 45min, 60min, and 120min incubation with factor Xa 
respectively; Panel A, prothrombinase assembled with factor Va
WT
; panel B 
prothrombinase assembled with plasma-derived factor Va; panel C, prothrombinase 
assembled with factor Va
Δ659-663
; panel D, prothrombinase assembled with factor Va
5K
; 
panel E, prothrombinase assembled with factor Va
5A
; panel F, is a schematic of the 
recombinant prothrombin molecule used (rP2-II). This molecule is a triple mutant with 
only one cleavage site for prothrombinase remaining at Arg
271
. Positions of prothrombin-
derived fragments are indicated at right as detailed in the legend to figure 3.5. The factor 
Va species used for the reconstitution of prothrombinase are shown under each panel.  
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Figure 3.9. Analysis of recombinant prothrombin consumption by prothrombinase 
assembled with recombinant factor Va molecules. The gels shown in figures 3.7 and 
3.8 were scanned and prothrombin consumption was recorded as described in the 
“Experimental Procedures” section. Following scanning densitometry, the data 
representing recombinant mutant prothrombin consumption as a function of time (sec) 
were plotted using non-linear regression analysis according to the equation representing a 
first-order exponential decay using the software Prizm (GraphPad, San Diego, CA) as 
described in the legend to figure 6. Prothrombinase was assembled with recombinant 
factor Va
WT 
(filled triangles), factor Va
PLASMA 
(filled circles), factor Va
Δ659-663 
(filled 
squares), factor Va
5K 
(open squares), and factor Va
5A 
(open inverse triangles). The 
apparent first-order rate constant, k (s
-1
) was obtained directly from the fitted data. The 
resulting numbers representing recombinant mutant prothrombin consumption are 
reported in Table 3.2 and table 3.3. Panel A; shows the data obtained following cleavage 
of rMZ-II: factor Va
WT
, R
2
=0.99, factor Va
PLASMA
, R
2
=0.99, factor Va
Δ659-663
, R
2
=0.99, 
and factor Va
5K
, R
2
=0.94. Panel B; shows the data obtained following cleavage of rP2-II: 
factor Va
WT
, R
2
=0.99, factor Va
PLASMA
, R
2
=0.98.  
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Figure 3.10. Gel electrophoresis analyses for cleavage of FPR-meizothrombin. FPR-
meizothrombin (1.4 μM) was incubated in different mixtures with PCPS vesicles (20 μM) 
and factor Va as described in the legend to figure 3.5. The reactions were started by the 
addition of factor Xa and the samples were further treated, scanned and quantified as 
detailed in the “Experimental Procedures” section. Panel A, factor Va
WT
; panel B, factor 
Va
Δ659-663
; panel C, factor Va
5K
, panel D, factor Va
5A
, M represents the lane with the 
molecular weight markers (from top to bottom): M
r 
50,000, M
r 
36,000, M
r 
22,000. Lanes 
1-19 represent samples from the reaction mixture before (0 min) the addition of factor Xa 
and 20 sec, 40 sec, 60 sec, 80 sec, 100 sec, 120 sec, 140 sec, 160 sec, 180 sec, 200 sec, 
220 sec, 240 sec, 5 min, 6 min, 10 min, 20 min, 30 min, and 60 min respectively 
following the addition of factor Xa. The prothrombin derived fragments are shown as 
detailed in the legend to figure 3.5. The recombinant factor Va species used for the 
reconstitution of prothrombinase are shown under each panel.  
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Figure 3.11. Analysis of FPR-meizothrombin consumption by prothrombinase 
assembled with recombinant factor Va molecules. The gels shown in figure 3.10 were 
scanned and FPR-meizothrombin consumption was recorded as described in the 
“Experimental Procedures” section. Following scanning densitometry, the data 
representing prothrombin consumption as a function of time (sec) were plotted using non-
linear regression analysis according to the equation representing a first-order exponential 
decay using the software Prizm (GraphPad, San Diego, CA) as described in the legend to 
figure 3.6. The apparent first-order rate constant, k (s
-1
) was obtained directly from the 
fitted data. Prothrombinase was assembled with recombinant factor Va
WT 
(filled 
triangles), factor Va
Δ659-663 
(filled squares), factor Va
5K 
(open squares), and factor Va
5A 
(open inverse triangles). The resulting numbers representing FPR-meizothrombin 
consumption are reported in Table 3.III.  
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Table 3.III 
 
Rates of activation of recombinant prothrombin rP2-II and plasma-derived FPR-
Meizothrombin in the presence of various recombinant factor Va species 
 
Enzyme  
 
 
rP2-II*
(Cleavage at Arg271) 
(moles of rP2-II consumed • 
sec-1 • mole factor Xa-1) 
FPR-Meizothrombin* 
(Cleavage at Arg271) 
(moles of fragment 1•2-A 
consumed • sec-1 • mole factor Xa-
1) 
Factor Xa alone 0.048 ± 0.013 13.5a
Prothrombinase 
with factor 
VaPLASMA
3.3 ± 0.4 42.6a
Prothrombinase 
with factor 
VaWT
3.4 ± 0.5 52.2 ± 14 
Prothrombinase 
with factor 
VaΔ659-663
NSCb 23.5 ± 2.1 
Prothrombinase 
with factor Va5K
NSCc 20.1 ± 4.3 
Prothrombinase 
with factor Va5A
NSCd 26.1 ± 2.2 
 
Table 3.3.  *Rates of rP2-II consumption in the presence of wild-type or plasma factor Va 
and recombinant mutant factor VaΔ659-663, factor Va5K and factor Va5A were measured 
following scanning densitometry of gels shown in Fig.3.8.  Calculation of the apparent 
first-order rate constant was achieved as detailed in “Experimental Procedures”.  The rate 
of fragment 1•2-A consumption in the presence of prothrombinase assembled with factor 
VaWT, factor VaΔ659-663, factor Va5K and factor Va5A was measured following scanning 
densitometry of the gels shown in Fig.3.10 and calculation of the apparent first-order rate 
constant as detailed in “Experimental Procedures”.  The rates of rP2-II and fragment 1•2- 
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A consumption were extracted from the fitted data (shown in Figs. 3.9 and 3.11 
respectively).   
aFrom reference (18). 
bNSC, not significant consumption.  The concentration of rP2-II varied from 1400 nM at 
time 0 to 1250 nM following 2h min incubation with prothrombinase assembled with 
factor VaΔ659-663. 
cNSC, not significant consumption.  The concentration of rP2-II varied from 1400 nM at 
time 0 to 1220 nM following 2h min incubation with prothrombinase assembled with 
factor Va5K. 
dNSC, not significant consumption.  The concentration of rP2-II varied from 1400 nM at 
time 0 to 1100 nM following 2h min incubation with prothrombinase assembled with 
factor Va5A. 
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3.5 Discussion 
 Our data demonstrate that the acidic region 659-663 located at the COOH-
terminus of factor Va heavy chain is responsible for coordinated activation of 
prothrombin by prothrombinase resulting in timely thrombin formation at the place of 
vascular injury.  To our knowledge, this is the first time that the role of this specific 
amino acid region of the cofactor has ever been investigated.  The data presented here, 
assign an important physiological role to the acidic region 659-663 from the COOH-
terminus of factor Va heavy chain for efficient prothrombin activation.  Namely, amino 
acid sequence 659DDDED663 regulates the rate of cleavage of prothrombin by 
prothrombinase at Arg320 and Arg271.  This acidic amino acid sequence together with 
sequence 695DYDYQ699 (18, 20, 21) are both located on the surface of the factor Va 
molecule (37), and are conserved among species (Fig.3.2) attesting to their physiological 
significance.  Since both sequences have no effect on the direct interaction between factor 
Va and factor Xa, our findings are consistent with the interpretation that these acidic 
amino acid sequences contribute significantly to the macromolecular substrate 
recognition of prothrombin by prothrombinase and demonstrate that factor Va indeed 
regulates the activity of factor Xa within the enzymatic complex. 
Proteolytic inactivation of factor Va by activated protein C (APC) following 
cleavages at Arg506, Arg306, and Arg679 (38, 39) results in the arrest of the contribution of 
the cofactor to the catalytic efficiency of factor Xa.  Earlier data have demonstrated that 
factor Xa and prothrombin protect the cofactor from APC inactivation (40-42).  
Functional data obtained with plasma or natural and/or recombinant mutant factor Va 
molecules have established that cleavages at Arg306 and Arg506 result in the dissociation 
of the A2 domain of the cofactor from the rest of the molecule (37, 43-46).  The A2 
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domain of factor Va contains the major factor Xa binding domains (13, 14, 47, 48).  
Thus, dissociation of the A2 domain from the rest of the molecule results in impaired 
factor Xa-factor Va interaction.  However, a specific role for cleavage at Arg679 has not 
been yet determined and has been mystifying scientists since the initial identification of 
the specific inactivating cleavage sites of the human cofactor approximately 15 years ago 
(39).  Our data demonstrate that the acidic hirudin-like sequences from the COOH-
terminal portion of the heavy chain of factor Va direct the rate of prothrombin activation 
by factor Xa because they are part of a regulatory group of amino acids from the cofactor 
controlling the rate of the two prothrombin activation cleavage sites.  Our data put in the 
context of the literature suggest that cleavage of the cofactor by APC at Arg679 
destabilizes the structure of the COOH-terminus of the heavy chain of factor Va and 
eliminates its regulatory role on the two prothrombin activation cleavages, resulting in 
uncontrolled meizothrombin generation by the prothrombinase complex.  This conclusion 
is also strengthened by the fact that the acidic regions from the COOH-terminal region of 
factor Va heavy chain together with the Arg679 APC-cleavage site are conserved among 
species (Fig.3.2).  Overall, the data strongly suggest that proteolytic inactivation of factor 
Va by APC results in the inability of the cofactor to bind factor Xa and to provide a 
productive regulatory interaction with prothrombin.  Thus, our findings also offer for the 
first time a logical explanation for the role of cleavage of factor Va by APC at Arg679.   
Data obtained with plasma-derived prothrombin show delay in prothrombin 
consumption when prothrombinase was assembled with factor VaΔ659-663, factor Va5K, or 
factor Va5A, compared to plasma-derived prothrombin activation by prothrombinase 
assembled with factor VaWT.  Clotting assays using factor VaΔ659-663, factor Va5K, and 
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factor Va5A showed a comparable decrease in clotting activity compared to the activity of 
factor VaWT.  Similarly, experiments using rMZ-II demonstrate that cleavage at Arg320 
and rMZ-II consumption is delayed significantly when prothrombinase is assembled with 
factor VaΔ659-663, factor Va5K, and factor Va5A, as compared to cleavage of rMZ-II by 
prothrombinase assembled with factor VaWT.  These data together with the data shown in 
figures 3.8 and 3.10 demonstrating that elimination of the amino acid region 659-663 in 
factor Va heavy chain or substitution of all amino acids from this region by either lysine 
or alanine, result in the elimination of the acceleration of the rate of cleavage of rP2-II 
and FPR-meizothrombin at Arg271 due to the interaction of factor Va with factor Xa.  
These data suggest that lingering of meizothrombin during prothrombin activation by 
prothrombinase assembled with the mutant cofactor molecules is the consequence of 
delayed cleavage at and Arg271.  However, we must note a differential effect of the 
mutations on the two prothrombin activation cleavage sites.  Thus, while prothrombinase 
assembled with factor Va5A is severely impaired for initial cleavage at Arg320 of 
prothrombin or rMZ-II as compared to cleavage of the two molecules by prothrombinase 
assembled with either factor VaΔ659-663 or factor Va5K, prothrombinase assembled with 
factor Va5A has similar activity for cleavage of either rP2-II or FPR-meizothrombin as 
prothrombinase assembled with factor VaΔ659-663 or factor Va5K.  Overall, our findings 
convincingly demonstrate that prothrombinase assembled with factor VaΔ659-663 is a better 
enzyme than prothrombinase assembled with factor Va5K, which in turn is a better 
enzyme than prothrombinase assembled with factor Va5A for cleavage at Arg320.  These 
data strongly suggest a differential effect of the mutations within amino acid region 659-
663 of factor Va heavy chain on the rate of the two prothrombin activating cleavage sites.   
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It is well established that cleavage of prothrombin at Arg271 has an important effect on 
the progressive formation of the active site of thrombin (49, 50), and that meizothrombin 
has higher amidolytic activity than thrombin towards several chromogenic substrates 
usually employed to assess thrombin esterase activity (23, 51-53).  In addition, it has 
been demonstrated following analysis of the crystal structure of meizothrombin, that 
ABE-II of meizothrombin has not yet been exposed, because it is covered by fragment 2 
(54).  This fact alone explains the poor clotting activity of meizothrombin since ABE-II is 
part of the binding site of thrombin for fibrinogen and is required for optimal rate of 
fibrin formation during blood clotting.  ABE-II is exposed following cleavage of 
meizothrombin at Arg271 and release of fragment 2.  However, the catalytic activity of 
prothrombinase when assembled with the mutant cofactor molecules is only moderately 
affected by the mutations, when the activity of factor Va is measured in an assay using a 
chromogenic substrate to assess for thrombin activity (half to 1/3 of the values found with 
prothrombinase assembled with the wild type cofactor).  Indeed, the kcat and second order 
rate constants of prothrombinase assembled with the mutant factor Va molecules are 
approximately 50% of that of prothrombinase assembled with factor VaPLASMA or factor 
VaWT.  In contrast, the clotting activity of the mutant cofactor molecules is severely 
impaired and gel electrophoresis experiments combined with densitometric analyses 
reveal a significant delay in prothrombin activation with meizothrombin being more 
stable throughout the activation process when prothrombinase is assembled with the 
mutant molecules as compared to prothrombin activation by prothrombinase assembled 
with either factor VaWT or factor VaPLASMA.  The data demonstrate a delay in prothrombin 
activation and thrombin generation because of impaired rates of cleavage at both Arg320 
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and Arg271 with the rate of cleavage at Arg271 being affected the most, and with the 
659DDDED663→AAAAA substitution being the most detrimental to factor Va cofactor 
activity.  The findings presented herein are entirely consistent with earlier findings 
obtained with plasma-derived proteins (55-57), recent findings obtained with 
recombinant proteins (58) and our data (18, 19).  Explicitly, when prothrombinase is 
assembled with a factor Va molecule possessing a heavy chain which is truncated at the 
acidic hirudin-like COOH-terminal region, a discrepancy is observed between the activity 
of factor Va measured by clotting assay as compared to the activity of the cofactor 
measured in an assay using a chromogenic substrate to assess for thrombin activity.  The 
data provided herein and in our recent manuscript detailing the properties of factor VΔ680-
709 (18), explain these paradoxical findings.  Because we have studied prothrombin, rMZ-
II, rP2-II, and FPR-meizothrombin activation by gel electrophoresis, we can conclude 
that meizothrombin lingers throughout the activation of prothrombin by prothrombinase 
assembled with the recombinant mutant molecules.  The excess meizothrombin present in 
the assays while having poor clotting activity can compensate for the lack of thrombin 
activity because of its increased amidolytic activity towards chromogenic substrates (51, 
52) that are usually employed to assess thrombin activity, thus creating the false 
impression that the mutations have a minimal effect on prothrombinase activity.  As a 
consequence, and because factor Va is a cofactor molecule devoid of enzymatic activity, 
when studying recombinant mutant factor Va molecules, drawing conclusions from 
activity assays only, without visualizing the pathway to thrombin generation, would lead 
to incorrect interpretations of the prothrombin intermediates formed and the rate of the 
specific prothrombin activating cleavages.  We therefore conclude that following the 
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activity of various recombinant mutant factor Va molecules by clotting assays, gel 
electrophoresis analyses, and assays using chromogenic substrates is by no means 
redundant and prevents oversimplification that in turn might lead to flawed conclusions.   
 
 
 
 
 
 
123 
 
3.6 Reference List 
1. Kalafatis, M., Egan, J. O., van't Veer, C., Cawthern, K. M., and Mann, K. G. 
(1997) The regulation of clotting factors, Crit. Rev. Eukar. Gene. 7, 241-280. 
2. Mann, K. G., and Kalafatis, M. (2003) Factor V: a combination of Dr Jekyll and 
Mr Hyde, Blood 101, 20-30. 
3. Nesheim, M. E., and Mann, K. G. (1983) The kinetics and cofactor dependence of 
the two cleavages involved in prothrombin activation, J. Biol. Chem. 258, 5386-
5391. 
4. Nesheim, M. E., Taswell, J. B., and Mann, K. G. (1979) The contribution of 
bovine factor V and factor Va to the activity of prothrombinase, J. Biol. Chem. 
254, 10952-10962. 
5. Heldebrant, C. M., Butkowski, R. J., Bajaj, S. P., and Mann, K. G. (1973) The 
activation of prothrombin. II. Partial reactions, physical and chemical 
characterization of the intermediates of activation, J. Biol. Chem. 248, 7149-7163. 
6. Esmon, C. T., Owen, W. G., and Jackson, C. M. (1974) A plausible mechanism 
for prothrombin activation by factor Xa, factor Va, phospholipid, and calcium 
ions, J. Biol. Chem. 249, 8045-8047. 
7. Anderson, P. J., and Bock, P. E. (2003) Role of prothrombin fragment 1 in the 
pathway of regulatory exosite I formation during conversion of human 
prothrombin to thrombin, J. Biol. Chem. 278, 44489-44495. 
8. Anderson, P. J., Nesset, A., Dharmawardana, K. R., and Bock, P. E. (2000) Role 
of proexosite I in factor Va-dependent substrate interactions of prothrombin 
activation, J. Biol. Chem. 275, 16435-16442. 
124 
 
9. Chen, L., Yang, L., and Rezaie, A. R. (2003) Proexosite-1 on prothrombin is a 
factor Va-dependent recognition site for the prothrombinase complex, J. Biol. 
Chem. 278, 27564 - 27569. 
10. Walker, R. K., and Krishnaswamy, S. (1994) The activation of prothrombin by 
the prothrombinase complex. The contribution of the substrate-membrane 
interaction to catalysis, J. Biol. Chem. 269, 27441-27450. 
11. Bukys, M. A., Orban, T., Kim, P. Y., Nesheim, M. E., and Kalafatis, M. (2008) 
The interaction of fragment 1 of prothrombin with the membrane surface is a 
prerequisite for optimum expression of factor Va cofactor activity within 
prothrombinase, Thromb Haemost 99, 511-522. 
12. Adams, T. E., Hockin, M. F., Mann, K. G., and Everse, S. J. (2004) The crystal 
structure of Activated Protein C-inactivated bovine factor Va: Implications for 
cofactor function, Proc. Natl. Acad. Sci. U.S.A. 101, 8918–8923. 
13. Kalafatis, M., and Beck, D. O. (2002) Identification of a binding site for blood 
coagulation factor Xa on the heavy chain of factor Va. Amino acid residues 323-
331 of factor V represent an interactive site for activated factor X, Biochemistry 
41, 12715-12728. 
14. Singh, L. S., Bukys, M. A., Beck, D. O., and Kalafatis, M. (2003) Amino acids 
Glu323, Tyr324, Glu330, and Val331 of factor Va heavy chain are essential for 
expression of cofactor activity, J. Biol. Chem. 278, 28335-28345. 
15. Barhoover, M. A., Orban, T., Beck, D. O., Bukys, M., and Kalafatis, M. (2008) 
Contribution of Amino Acid Region 334-335 from Factor Va Heavy Chain to the 
Catalytic Efficiency of Prothrombinase, Biochemistry 47, 6840-6850. 
125 
 
16. Esmon, C. T., Owen, W. G., Duiguid, D. L., and Jackson, C. M. (1973) The 
action of thrombin on blood clotting factor V: conversion of factor V to a 
prothrombin-binding protein, Biochim Biophys Acta 310, 289-294. 
17. Luckow, E. A., Lyons, D. A., Ridgeway, T. M., Esmon, C. T., and Laue, T. M. 
(1989) Interaction of clotting factor V heavy chain with prothrombin and 
prethrombin 1 and role of activated protein C in regulating this interaction: 
analysis by analytical ultracentrifugation, Biochemistry 28, 2348-2354. 
18. Hirbawi, J., Bukys, M., Barhoover, M. A., Erdogan, E., and Kalafatis, M. (2008) 
Role of the acidic hirudin-like COOH-terminal amino acid region of factor Va 
heavy chain in the enhanced function of prothrombinase, Biochemistry 47, 7963-
7974. 
19. Kalafatis, M., Beck, D. O., and Mann, K. G. (2003) Structural requirements for 
expression of factor Va activity, J. Biol. Chem. 278, 33550-33561. 
20. Beck, D. O., Bukys, M. A., Singh, L. S., Szabo, K. A., and Kalafatis, M. (2004) 
The contribution of amino acid region ASP695-TYR698 of factor V to 
procofactor activation and factor Va function, J. Biol. Chem. 279, 3084-3095. 
21. Bukys, M. A., Kim, P. Y., Nesheim, M. E., and Kalafatis, M. (2006) A control 
switch for prothrombinase: characterization of a hirudin-like pentapeptide from 
the COOH terminus of factor Va heavy chain that regulates the rate and pathway 
for prothrombin activation, J. Biol. Chem. 281, 39194-39204. 
22. Pittman, D. D., Tomkinson, K. N., Michnick, D., Selighsohn, U., and Kaufman, 
R. J. (1994) Posttranslational sulfation of factor V is required for efficient 
126 
 
thrombin cleavage and activation and for full procoagulant activity, Biochemistry 
33, 6952-6959. 
23. Morita, T., and Iwanaga, S. (1981) Prothrombin activator from Echis carinatus 
venom, Methods in Enzymology 90, 303-311. 
24. Côté, H. C. F., Stevens, W. K., Bajzar, L., Banfield, D. K., Nesheim, M. E., and 
MacGillivray, T. A. (1994) Characterization of a stable form of human 
meizothrombin derived from recombinant prothrombin (R155A, R271A, and 
R284A), J. Biol. Chem. 269, 11374-11380. 
25. Erdogan, E., Bukys, M. A., Orfeo, T., Mann, K. G., and Kalafatis, M. (2007) 
Identification of an inactivating cleavage site for α-thrombin on the heavy chain 
of factor Va, Thromb Haemost 98, 998-1006. 
26. Laemmli, U. K. (1970) Cleavage of structural proteins during the assembly of the 
head of bacteriophage T4, Nature 227, 680-685. 
27. Towbin, H., Staehlin, T., and Gordon, J. (1979) Electrophoretic transfer of 
proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some 
applications, Proc. Natl. Acad. Sci. U S A. 76, 4350-4354. 
28. van 't Veer, C., Golden, N. J., Kalafatis, M., and Mann, K. G. (1997) Inhibitory 
mechanism of the protein C pathway on tissue factor-induced thrombin 
generation. Synergistic effect in combination with tissue factor pathway inhibitor, 
J. Biol. Chem. 272, 7983-7994. 
29. Kalafatis, M., Haley, P. E., Lu, D., Bertina, R. M., Long, G. L., and Mann, K. G. 
(1996) Proteolytic events that regulate factor V activity in whole plasma from 
127 
 
normal and activated protein C (APC)-resistant individuals during clotting: an 
insight into the APC-resistance assay, Blood 87, 4695-4707. 
30. Merril, C. R., Dunau, M. L., and Goldman, D. (1981) A rapid sensitive silver stain 
for polypeptide in polyacrylamide gels, Analytical Biochemistry 110, 201-207. 
31. Bukys, M. A., Orban, T., Kim, P. Y., Beck, D. O., Nesheim, M. E., and Kalafatis, 
M. (2006) The structural integrity of anion binding exosite-I of thrombin is 
required and sufficient for timely cleavage and activation of factor V and factor 
VIII, J. Biol. Chem. 281, 18569-18580. 
32. Kim, P. Y., and Nesheim, M. E. (2007) Further evidence for two functional forms 
of prothrombinase each specific for either of the two prothrombin activation 
cleavages, J. Biol. Chem. 282, 32568-32581. 
33. Erdogan, E., Bukys, M. A., and Kalafatis, M. (2008) The contribution of amino 
acid residues 1508-1515 of factor V to light chain generation, J Thromb Haemost. 
6, 118-124. 
34. Krishnaswamy, S., Williams, E. B., and Mann, K. G. (1986) The binding of 
activated protein C to factors V and Va, J. Biol. Chem. 261, 9684-9693. 
35. Bianchini, E. P., Orcutt, S. J., Panizzi, P., Bock, P. E., and Krishnaswamy, S. 
(2005) Racheting of the substrate from the zymogen to proteinase conformations 
directs the sequential cleavage of prothrombin by prothrombinase, Proc. Natl. 
Acad. Sci. U S A. 102, 10099-10104. 
36. Krishnaswamy, S., Church, W. R., Nesheim, M. E., and Mann, K. G. (1987) 
Activation of human prothrombin by human prothrombinase. Influence of factor 
Va on the reaction mechanism, J. Biol. Chem. 262, 3291-3299. 
128 
 
37. Orban, T., Kalafatis, M., and Gogonea, V. (2005) Completed three-dimensional 
model of human coagulation factor Va. Molecular dynamics simulations and 
structural analyses, Biochemistry 44, 13082-13090. 
38. Kalafatis, M., and Mann, K. G. (1993) Role of the membrane in the inactivation 
of factor Va by activated protein C, J. Biol. Chem. 268, 27246-27257. 
39. Kalafatis, M., Rand, M. D., and Mann, K. G. (1994) The mechanism of 
inactivation of human factor V and human factor Va by Activated Protein C, J. 
Biol. Chem. 269, 31869-31880. 
40. Nesheim, M. E., Canfield, W. M., Kisiel, W., and Mann, K. G. (1982) Studies of 
the capacity of factor Xa to protect factor Va from inactivation by activated 
protein C, J. Biol. Chem. 257, 1443-1447. 
41. Solymoss, S., Tucker, M. M., and Tracy, P. B. (1988) Kinetics of inactivation of 
membrane-bound factor Va by activated protein C. Protein S modulates factor Xa 
protection, J. Biol. Chem. 263, 14884-14890. 
42. Smirnov, M. D., Safa, O., Esmon, N. L., and Esmon, C. T. (1999) Inhibition of 
activated protein C anticoagulant activity by prothrombin, Blood 94, 3839-3846. 
43. Rosing, J., Hoekema, L., Nicolaes, G. A., Thomassen, M. L. G. D., Hemker, H. 
C., Varadi, K., Schwartz, H. P., and Tans, G. (1995) Effects of Protein S and 
factor Xa on peptide bond cleavages during inactivation of factor Va and factor 
VaR506Q by Activated Protein C, J. Biol. Chem. 270, 27852-27858. 
44. Tran, S., Norstrøm, E., and Dahlbäck, B. (2008) Effects of prothrombin on the 
individual activated protein C-mediated cleavages of coagulation factor Va, J. 
Biol. Chem. 283, 6648-6655. 
129 
 
45. Yegneswaran, S., Nguyen, P. M., Gale, A. J., and Griffin, J. H. (2009) 
Prothrombin amino terminal region helps protect coagulation factor Va from 
proteolytic inactivation by activated protein C, Thromb Haemost 101, 55-61. 
46. Mann, K. G., Hockin, M. F., Begin, K. J., and Kalafatis, M. (1997) Activated 
Protein C cleavage of factor Va leads to dissociation of the A2 domain, J. Biol. 
Chem. 272, 20678-20683. 
47. Bukys, M. A., Blum, M. A., Kim, P. Y., Brufatto, N., Nesheim, M. E., and 
Kalafatis, M. (2005) Incorporation of factor Va into prothrombinase is required 
for coordinated cleavage of prothrombin by factor Xa, J. Biol. Chem. 280, 27393-
27401. 
48. Heeb, M. J., Kojima, Y., Hackeng, T. M., and H., G. J. (1996) Binding sites for 
blood coagulation factor Xa and protein S involving residues 493-506 in factor 
Va, Protein Sci. 9, 1883-1889. 
49. Hibbard, L. S., Nesheim, M. E., and Mann, K. G. (1982) Progressive development 
of a thrombin inhibitor binding site, Biochemistry 1982, 2285-2292. 
50. Boxrud, P. D., and Berliner, L. J. (1996) Comparison of the active-site 
conformations of bovine a-thrombin and meizothrombin(desF1) by electron spin 
resonance, J. Prot. Chem. 15, 231-242. 
51. Doyle, M. F., and Mann, K. G. (1990) Multiple active forms of thrombin.  
Relative activities of meizothrombins, J. Biol. Chem. 265, 10693-10701. 
52. Doyle, M. F., and Haley, P. E. (1993) Meizothrombin: active intemediate formed 
during prothrombin-catalyzed activation of prothrombin, Methods in Enzymology 
222, 299-313. 
130 
 
53. Shim, K., Zhu, H., Westfield, L. A., and Sadler, J. E. (2004) A recombinant 
murine meizothrombin precursor, prtothrombin R157A/R268A, inhibits 
thrombosis in a model of acute carotide artery injury, Blood 104, 415-419. 
54. Martin, P. D., Malkowski, M. G., Box, J., Esmon, C. T., and Edwards, B. F. 
(1997) New insights into the regulation of the blood clotting cascade derived from 
the X-ray crystal structure of bovine meizothrombin des F1 in complex with 
PPACK, Structure 5, 1681-1693. 
55. Gerads, I., Tans, G., Yukelson, L. Y., Zwaal, R. F., and Rosing, J. (1992) 
Activation of bovine factor V by an activator purified from the venom of Naja 
naja oxiana, Toxicon 30, 1065-1079. 
56. Bakker, H. M., Tans, G., Thomassen, M. C. L. G. D., Yukelson, L. Y., Ebberink, 
R., Hemker, H. C., and Rosing, J. (1994) Functional properties of human factor 
Va lacking Asp683-Arg709 domain of the heavy chain, J. Biol. Chem. 269, 
20662-20667. 
57. Camire, R. M., Kalafatis, M., and Tracy, P. B. (1998) Proteolysis of factor V by 
cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor 
function by facilitating factor Xa binding, Biochemistry 37, 11896-11906. 
58. Toso, R., and Camire, R. M. (2006) Role of Hirudin-like factor Va heavy chain 
sequences in prothrombinase function, J. Biol. Chem. 281, 8773-8779. 
 
131 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER IV 
 
THE COFACTOR EFFECT OF AMINO ACIDS 695 AND 696 OF 
FACTOR VA HEAVY CHAIN ON THE ENZYMATIC ACTIVITY OF 
THE PROTHROMBINASE COMPLEX 
 
4.1 Abstract 
 
Blood coagulation is initiated after vascular injury, promoting formation of the 
fibrin clot.  Without the proper regulation of this process, serious life threatening 
conditions, such as DVT (deep vein thrombosis), can occur.  The proteolytic conversion 
of prothrombin to thrombin is catalyzed by the prothrombinase complex composed of the 
enzyme, factor Xa (fXa), the cofactor, factor Va (fVa), assembled on a membrane surface 
in the presence of Ca2+ [1].  The incorporation of fVa into the prothrombinase complex 
results in a 300,000-fold increase in the catalytic efficiency of fXa for thrombin 
generation.  Prothrombinase activates prothrombin through initial cleavage at Arg320 
followed by cleavage at Arg271 to yield human alpha-thrombin [2].  This pathway is 
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responsible for the generation of a transient intermediate, meizothrombin, which is 
enzymatically active with increased chromogenic substrate activity, but yields poor 
clotting activity [3].  Factor Va is composed of heavy and light chains that play a crucial 
role during thrombin formation.  Portions of the fVa heavy chain have been found to act 
as fXa binding sites and to interact with proexosite 1 (pro1) of prothrombin to increase 
prothrombinase activity [4, 5].  It has been recently demonstrated that deletion of the 
COOH-terminal region of the factor Va heavy chain causes accumulation of 
meizothrombin due to delayed cleavage of prothrombin at Arg271 [3].  Site-directed 
mutagenesis was performed to generate recombinant mutant molecules to identify the 
specific amino acids of this terminal region that regulate cleavage.  Mutants with the 
695DYDY698→ DFDY(fVaDFDY), KFDY(fVaKFDY), DEDE(fVaDEDE), DFDF(fVaDFDF) 
substitutions were constructed.  SDS-PAGE analyses of prothrombin activation time 
courses revealed that the overall cleavage of prothrombin by prothrombinase assembled 
with fVaKFDY and fVaDFDY was delayed, while fVaDEDE, and fVaDFDF had no significant 
effects when compared to fVaWT.  Two- stage clotting assays (PT times) revealed that 
prothrombinase assembled with fVaKFDY had reduced clotting activity when compared to 
fVaWT, while fVaDEDE, fVaDFDY, and fVaDFDF gave similar clotting results as fVaWT.  
Determination of kcat values for prothrombinase assembled with the various recombinant 
molecules revealed that fVaKFDY and fVaDFDY lead to an increase in the catalytic 
efficiency of the enzyme, while fVaDEDE, and fVaDFDF gave values that were normal.  The 
data presented suggests that the 695DY696 portion of the acidic cluster found in the 
COOH-terminus of the fVa heavy chain plays a significant role in enzyme-substrate 
interaction during thrombus formation. 
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4.2 Introduction 
The penultimate goal of the coagulation response is the generation of thrombin, 
which in turn converts fibrinogen to fibrin to produce a fibrin plug.  This cascade of 
enzymatic reactions begins immediately after vascular injury and is a tightly regulated 
process involving a multitude of proteins and enzyme complexes. The proteolytic 
conversion of prothrombin to thrombin is catalyzed by the prothrombinase complex 
composed of the enzyme, factor Xa, its cofactor, factor Va, assembled on a membrane 
surface in the presence of divalent metal ions [6].  Although factor Xa can activate 
prothrombin with an initial cleavage at Arg271 followed by cleavage at Arg320 to yield the 
intermediates Fragment 1.2 and Prethrombin 2, incorporation of factor Va into the 
prothrombinase complex results in a reversal of cleavages and a 300,000-fold increase in 
the catalytic efficiency of factor Xa for thrombin generation [7].  A first cleavage of 
prothrombin by prothrombinase at Arg320 produces the active intermediate 
meizothrombin (Fragment 1.2A), while the second cleavage at Arg271 produces thrombin. 
 The incorporation of factor Va into the prothrombinase complex is of absolute 
importance to the production of thrombin during the coagulation response.   It exists in 
the human body at a physiological concentration of 20nM and presents itself as a single 
chain protein with a Mr of 330,000 [8].  The cofactor is composed of three protein 
domains (A, B, & C) that are arranged in the order of A1-A2-B-A3-C1-C2. It is cleaved 
by α-thrombin (fIIa) at Arg709, Arg1018, and Arg 1545 to release the B domain (containing a 
large number of asparagine-linked oligosaccharides) and generate an active cofactor 
(fVaIia) composed of a light chain of Mr 74 kDa (A3-C1-C2 domains) and a heavy chain 
of Mr 105 kDa (A1-A2 domains) [9, 10].  It has been frequently demonstrated that factor 
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Va will increase the efficiency of factor Xa by decreasing the Km by 100-fold and 
increasing Kcat values by 3,000-fold [11].  This decrease in Km is due to tighter binding of 
factor Xa to the membrane surface, allowing higher concentrations of the enzyme to 
localize while the Kcat value is improved due to factor Va interaction with factor Xa [12].   
 Although the factor Va heavy chain interacts with factor Xa and anion exosite I of 
prothrombin during its conversion to thrombin, the exact mechanism by which this 
occurs has not been clarified [13].  Anion exosite I is known to be rich in basic amino 
acid residues that may interact with the factor Va molecule [14].  The carboxy-terminal 
region of the factor Va heavy chain contains small clusters of acidic amino acids, which 
are believed to play a role in the cofactor effect of the molecule on the prothrombinase 
complex [15].  We recently showed that amino acid region 680-709 of the heavy chain 
regulates proteolytic cleavage of the substrate, prothrombin, at Arg 271 by decreasing the 
rate of cleavage [3, 16].  In addition, a pentapeptide (DYDYQ) consisting of the region 
Asp695-Gln699 was also found to inhibit prothrombinase function as well as inhibiting 
activation of factor V by human alpha thrombin.  The following studies were undertaken 
to further understand the importance of the COOH-terminal region of the factor Va heavy 
chain during proteolytic cleavage of prothrombin by prothrombinase.  
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4.3 Experimental Procedures 
Materials reagents, and proteins.  Diisopropyl-fluorophosphate (DFP), O-
phenylenediamine –dihydrochloride (OPD), N-[2-Hydroxyethyl]piperazine-N'-2-
ethanesulfonic acid (Hepes), Trizma (Tris base), and Coomassie Blue R-250 were 
purchased from Sigma (St. Louis, Mo).  Factor V-deficient plasma was from Research 
Proteins Inc (Essex Junction VT).  L-α-phosphatidylserine (PS) and L-a-
phosphatidylcholine (PC) were from Avanti Polar Lipids (Alabaster, AL).  Normal 
reference plasma and the chromogenic substrate H-D-Hexahydrotyrosol-alanyl-arginyl-p-
nitroanilide diacetate (Spectrozyme-TH) were purchased from American Diagnostica Inc. 
(Greenwich, CT).  H-D-Phenylalanyl-L-pipecolyl-L-arginyl-p-nitroaniline 
dihydrochloride (Chromogenix, S-2238) was purchased from Diapharma Group, Inc. 
(West Chester, OH) and its concentration in solution (water) was verified as described 
(41).  RecombiPlasTin for the clotting assays was purchased from Instrumentation 
Laboratory Company (Lexington, MA).  The reversible fluorescent α-thrombin inhibitor 
dansylarginine N,N-(3-ethyl-1,5-pentanediyl)amide (DAPA), human prothrombin, RVV-
V activator, and human α-thrombin, were from Haematologic Technologies Inc. (Essex 
Junction, VT).  Active-site blocked human meizothrombin (obtained following digestion 
of prothrombin with the purified component from the venom of the snake Echis 
Carinatus as described). FPR-meizothrombin was provided by Dr. Rick Jenny 
(Haematologic Technologies Inc, Essex Junction VT).  Human factor Xa was from 
Enzyme Research Laboratories (South Bend, IN).  Human cathepsin G was from 
Calbiochem (EMD Chemicals, Inc. San Diego, CA).  All molecular biology and tissue 
culture reagents and media were from Gibco, Invitrogen Corporation (Grand Island, NY).  
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Human plasma factor V was purified and concentrated using methodologies previously 
described employing the monoclonal antibody αhFV#1 coupled to Sepharose.  Digestion 
of factor Va by a-thrombin and cathepsin G (to obtain factor VaII/CG) and/or the purified 
enzyme from Naja Naja Nigricollis (factor VaNN) were performed as described.  The 
clotting activities of all factor Va preparations was measured by a clotting assay using 
factor V deficient plasma and standardized to the percentage of control as described  
using an automated coagulation analyzer (START-4, Diagnostica Stago, Parsippany, NJ).  
Recombinant wild type prothrombin and prothrombin rMZ-II that has only one cleavage 
site for factor Xa (i.e. Arg320) were prepared and purified as previously described 
Phospholipid vesicles composed of 75% PC and 25% PS (referred to as PCPS vesicles 
throughout the manuscript) were prepared as previously described.   
Construction of Recombinant FV Molecules.  Mutant factor V with the 
substitutions 695DYDY698→DEDE (factor VDEDE) was constructed using the 
QuickChange II XL site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA) 
according to the manufacturer’s instructions with the following primers (underlined 
nucleotides represent the mismatch): 5’-GAGAGTGATGCTGACGAAGATGAACAG  
3’(sense) and 5’-CTGTTCATCTTCGTCAGCATCACTCTC-3’ (anti-sense).  The 
deletion mutant (factor VDFDF)) was constructed with the same kit.  Primers for factor 
VDFDF were 5’-GAGAGTGATGCTGACTTTGATTTCCAG-3’ (sense) and 5’-
CTGGAAATCAAAGTCAGCATCACTCTC-3’ (anti-sense).  In addition, the mutant 
factor VKFDY with the following primers was constructed: 5’-
GAGAGTGATGCTAAGTTTGATTACCAG-3’ (sense) and 5’-
CTGGTAATCAAACTTAGCATCACTCTC  -3’ (antisense).  One more mutant was also 
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made, factor VDFDY with primers: 5’-GAGAGTGATGCTGACTTTGATTACCAG-3’ 
(sense) and 5’-CTGGTAATCAAAGTCAGCATCACTCTC-3’ (antisense).   PCR 
products were transformed into competent E. Coli cells and positive ampicillin-resistant 
clones were selected.  Before transfection, all mutant constructs were verified following 
sequencing in the Cleveland State University DNA Analysis Facility using a Beckman 
Coulter CEQ 8000 Genetic Analysis System (Beckman, Fullerton CA) with factor-V 
sequence-specific primers.  The wild type pMT2-FV and mutant pMT2-FV plasmids 
were isolated from the bacterial culture by the QIAfilter High Speed plasmid Midi Kit 
(Qiagen Inc., Valencia, CA). 
Expression of Recombinant Wild Type and Mutant Factor V in Mammalian 
Cells.  COS-7L and COS-7 cells (Invitrogen) were maintained in Dulbecco’s modified 
Eagle’s medium supplemented with 10% fetal bovine serum, 2mM L-glutamine, and 
antibiotics (100 μg/ml streptomycin and 100 IU/ml penicillin) in a humidified 
atmosphere of 5% CO2 and 95% air at 37°C.  Purified factor VWt, factor VD680-709, and 
factor V4A plasmids were transfected into the cells as described.  Purification of all 
recombinant factor V molecules was performed as described. The concentration of all 
molecules was assessed by ELISA as detailed.  The activity and integrity of the 
recombinant molecules was verified before and after activation with thrombin by clotting 
assays using factor V-deficient plasma and and in several experiments by sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western blotting 
using monoclonal and polyclonal antibodies. 
Analysis of Prothrombin Activation and FPR-Meizothrombin Cleavage at Arg271 
by Gel Electrophoresis.  Prothrombin (1.4μM) was incubated with PCPS vesicles 
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(20μM), DAPA (50μM), and factor Va (10-30nM) in a buffer composed of 5 mM Ca2+ in 
20 mM Tris, 0.15 M NaCl, pH 7.4.  The reaction was initiated with the addition of factor 
Xa (0.5-1nM) at room temperature over a 1 h time course.  Aliquots (50 μl) from the 
reaction were removed at selected time intervals (as indicated in the legend to the figures) 
treated as described and analyzed using 9.5% SDS-PAGE.  Prothrombin and 
prothrombin-derived fragments were visualized by Coomassie Blue staining.  Scanning 
densitometry and calculation of the rates of prothrombin consumption were performed as 
described.  FPR-meizothrombin cleavage at Arg271 was assessed in a similar manner.   
Gel Electrophoresis and Western Blotting.  SDS-PAGE analyses of recombinant 
proteins following activation were performed using 5-15% gradient gels according to the 
method of Laemmli.  Proteins were transferred to polyvinylidene difluoride (PVDF) 
membranes according to the method described by Towbin et al.  After transfer to 
nitrocellulose, factor Va heavy and light chain(s) were detected using the appropriate 
monoclonal and polyclonal antibodies.  Immunoreactive fragments were visualized with 
chemiluminescence.   
Measurement of Rates of Thrombin Formation in a Prothrombinase Assay.  
rMZ-II and recombinant prothrombin were activated by prothrombinase prior to the 
experiment using conditions previously described.  Subsequent gel electrophoresis 
analyses under reducing conditions were performed to verify that both rMZ-II and the 
recombinant prothrombin preparations were activated to the same extent.  The enzymes 
(rMZ-IIa and recombinant a-thrombin) used for the titration of Spetrozyme-TH and S-
2238 were assayed at a constant concentration (4.3 nM), as previously described using 
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serial dilutions of chromogenic substrate.  The absorbance was monitored with a 
Thermomax microplate reader (Molecular Devices, Sunnyvale, CA).   
Functionally defined apparent dissociation constants (KDapp) for factor Va binding to 
factor Xa-PCPS were obtained from plots measuring the rate of thrombin generation as a 
function of factor Va concentration in the presence of a limiting, (constant) concentration 
of factor Xa.  Throughout all experiments the assumption was n=moles of factor Xa 
bound/mole of factor Va at saturation; throughout this study n=1; the stoichiometry of the 
factor Va-factor Xa interaction was fixed at 1.  The initial rate of the formation of 
thrombin (initial velocity in nM⋅IIa⋅min-1) was calculated, and the data were analyzed and 
plotted using the software Prizm (Graphpad Software Inc, San Diego CA) according to 
the one binding site model.  Dissociation constants were extracted directly from the 
graphs. 
The assay using purified reagents and verifying the activity of the recombinant factor 
V molecules was conducted under conditions were all factor Xa was saturated with factor 
Va, as described by measuring a-thrombin formation by the change in the absorbance of a 
chromogenic substrate at 405 nm (Spectrozyme-TH, 0.4 mM).  All factor V molecules 
were activated with thrombin as describe.  Knowing the (KDapp) of each factor Va species 
for factor Xa, the amount necessary to saturate factor Xa was calculated using the 
quadratic equation described in the literature before each experiment.  The total 
concentration of ligand (VaT) used was modified as appropriate to obtain between 95-
98% saturation of the factor Xa molecule. The absorbance was monitored with a 
Thermomax microplate reader and compared to an a-thrombin standard prepared daily 
using purified plasma-derived a-thrombin.  The data were analyzed and plotted using the 
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software Prizm according to the Michaelis-Menten equation.  Kinetic constants provided 
throughout the manuscript were extracted directly from the graphs. 
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4.4 Results 
 Expression of Recombinant Factor V Molecules and Activation.  To analyze 
the importance of amino acids 695 and 696 of the heavy chain of factor V, four 
recombinant mutant molecules were synthesized using site-directed mutagenesis.  Factor 
VDEDE and factor VDFDF (DY696DY698→DEDE, DFDF) were constructed along with 
factor V KFDY and factor VDFDY (D695FDY→KFDY, DFDY) (Fig. 4.1).  These 
recombinant factor V molecules along with wild-type factor V were transiently expressed 
in COS 7L cells and the recombinant proteins were harvested and purified.  The 
concentration of the various proteins was determined by ELISA [11].   
Western blot analysis was first done to determine the integrity of the recombinant 
proteins using anti-factor V antibodies that recognize an epitope on the light (α-fV #9) 
and heavy (α-fV #17) chains of the factor V molecule (Fig.4.2).  All molecules were 
activated with human α-thrombin and clotting activity was assessed in a two-stage 
clotting assay (Table 4.1).  Factor Vwild-type (fVWT) showed clotting activity that was 
normal along with factor VDFDF (fVDFDF), factor VDFDY, and factor VDEDE (fVDEDE ).  In 
contrast, fVKFDY had clotting activity that was decreased and resulted in a prolonged 
clotting time (30.3s)(Table 4.I).  The results obtained indicate that the mutations at amino 
acid residues D695Y696→KF have a profound effect on the cofactor.   
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A3 C1 C2 COOHA1 A2NH2
B Domain
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FVDEDE ,FVDFDF,FVDFDY,FVKFDY
Arg709 Arg1545Arg1018
(α‐IIa) (α‐IIa)
(RVV‐V) (RVV‐V)
1 2196
 
 
Figure 4.1.  Factor V structure and mutant Molecules.  The procofactor, factor 
V, is composed of three A domains, a connecting B region, and two C domains.  Factor 
Va is generated following three sequential cleavages of factor V by α-thrombin at Arg709, 
Arg1018, and Arg1545.  The mutations within the acidic hirudin-like COOH-terminus 
region of the heavy chain (amino acid residues 695-698) are indicated together with the 
designation of the recombinant mutant factor V molecules created and used throughout 
the manuscript. 
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Figure 4.2. Electrophoretic analyses of wild type factor V and recombinant 
factor V molecules.  Factor VWt, factor VKFDY, factor VDFDY, factor VDFDF, and factor 
VDEDE were activated with thrombin as described in the “Experimental Procedures” 
section and analyzed by SDS-PAGE. Following transfer to a PVDF membrane, 
immunoreactive fragments were detected with monoclonal antibodies αHFVaHC17 
(recognizing an epitope on the heavy chain of the cofactor between amino acid residues 
307-506) and αHFVaHC9 (recognizing the light chain). At the right the positions of the 
heavy/light chains of factor Va are shown.  
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Factor Va Clotting Time(s)
FVaWT 14.0±2.02
FVaDEDE 19.8±0.39
FVaDFDF 14.4±0.43
FVaDFDY 13.6±1.11
FVaKFDY 30.3±4.60
 
 
 
 
 
Table 4.I.  Clotting assay with factor VaWT and recombinant mutant 
molecules.  Two-stage clotting assays of recombinant factor V molecules was performed 
as described in the “Experimental Procedures” section.  As seen above, FVaDFDF, and 
FVaDFDY, and FVaDEDE all had clotting times that were in the normal range as compared 
to FVaWT, while FVaKFDY revealed a prolonged clotting time. 
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 Kinetic Analysis of Prothrombinase Assembled with Recombinant Factor Va 
molecules.  The cofactor effect on prothrombin activation when assembled in the 
prothrombinase complex has been a topic of heated discussion for the past decade.   It has 
been repeatedly shown by our lab that the factor Va carboxy-terminal region of the heavy 
chain contains acidic amino acid residues that are important for interaction of 
prothrombinase with its substrate, prothrombin [16, 3].  The exact mechanism of how this 
takes place is still not known. To establish what specific effects the residues at 695 and 
696 of the heavy chain have on prothrombinase activity, the following kinetic assays 
were performed.   
 Factor Va titrations were performed using a limiting amount of factor Xa (15 pM) 
to assess the ability of the factor Va mutants to bind factor Xa (fXa) during 
prothrombinase complex formation.  Varying concentrations of fVa were titrated in a 
mixture consisting of all components of the prothrombinase complex and the substate, 
prothrombin.  Thrombin generation was measured by cleavage of a chromogenic 
substrate.  The data obtained demonstrates that fVaWT has an affinity for fXa that is the 
same as plasma-derived fVa.  In analyzing results for fVaDEDE, fVaDFDF, fVaDFDY, and 
fVaKFDY, it was discovered that all of these mutant fVa molecules also have the same 
affinity for fXa as wild-type with Kd values that were less than 1.0 nM (Fig. 4.3).  These 
results indicate that mutation of these critical amino acids does not have any effect on 
fVa-fXa binding.   
 To further evaluate the effect of the mutations on the heavy chain of the fVa 
molecules, prothrombin titrations were performed to determine Kcat and Km values. A 
limiting concentration of fXa (10 pM) was combined with 20 nM fVa in the presence of 
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varying amounts of prothrombin (25nM-4uM).  Experiments done with fVaWT showed 
that the catalytic efficiency of prothrombinase during proteolytic cleavage of prothrombin 
was normal when compared to values obtained with plasma fVa.  Titrations done with 
prothrombinase assembled with fVaDEDE, and fVaDFDF resulted in catalytic efficiencies 
that were normal when compared to wild-type values.  In contrast, studies performed 
with fVaKFDY and fVaDFDY revealed a catalytic efficiency that was increased by 15% and 
10%, respectively, when compared to fVaWT (Fig. 4.4).  Meizothrombin, one of the 
intermediates during prothrombin activation, has been found to cleave the substrate, 
Spectrozyme-TH, at a higher rate than thrombin.  Accumulation of this intermediate 
caused by fVaKFDY , leads to the increase in Kcat (2355 min-1) value that was observed.   
 Analysis of Prothrombin Activation by Prothrombinase Assembled with 
FVaWT, FVaDEDE, FVaDFDF, FVaDFDY, and FVaKFDY.  To visualize the activation of 
prothrombin by prothrombinase, assembled with the various recombinant factor V 
molecules, analysis by SDS-PAGE was done.  Each cofactor molecule was included in a 
mixture consisting of 1.4 uM prothrombin, a membrane surface (20 uM PC/PS), and 
calcium.  Factor Xa was added to start the reaction and 50 ul samples were pulled at time 
points over a 1 hour time course.  Results show that prothrombin activation occurred 
through the meizothrombin pathway for all of the recombinant fVa molecules (Fig. 4.5).  
This pathway is characterized by initial cleavage of prothrombin at Arg320 to reveal 
fragment 1.2A, also known as meizothrombin.  Gel analysis showed that proteolytic 
cleavage of prothrombin by prothrombinase assembled with fVaWT, fVaDEDE, and 
fVaDFDF occured in a timely fashion and was normal.  On the other hand, prothrombinase 
consisting of fVaKFDY and fVaDFDY resulted in accumulation of meizothrombin, 
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represented by fragment 1.2A, with fVaKFDY showing a more prominent effect and 
fVaDFDY showing slight accumulation.  These results lead to the conclusion that fVaKFDY 
leads to impairment of proteolytic processing of the prothrombin molecule. 
Analysis of Prothrombin Cleavage Rates by the Prothrombinase Assembled 
with Recombinant Mutant FVa Molecules.  To understand the effect of the mutations 
at amino acids 695-698 of the factor Va heavy chain on cleavage at Arg271 of 
prothrombin, FPR-meizothrombin activation was done by prothrombinase assembled 
with fVaWT and the recombinant mutant fVa molecules.  Experimental analysis of FPR-
meizothrombin cleaved with prothrombinase assembled with fVaWT, fVaDEDE, and 
fVaDFDF ,all revealed no effect on cleavage at Arg271, while the rate of cleavage by 
prothrombinase assembled with fVaKFDY and fVaDFDY was delayed as displayed in figure 
4.6.  The prolonged presence of fragment 1.2A during the reaction with fVaKFDY points to 
the fact that 695DY696 of the factor Va heavy chain has a regulating effect on proteolytic 
processing of the prothrombin intermediate at the Arg271 cleavage site, leading to a delay 
in thrombin formation.  From the data obtained through this assay, we can therefore 
conclude that mutation of amino acid residues 695 and 696 of the COOH-terminal region 
of the factor Va heavy chain has a negative effect on the proteolytic conversion of 
meizothrombin to human α-thrombin.  In addition, it can also be assumed that the 
sequence 695DY696 plays an important role in factor Va regulation of prothrombinase 
function towards the activation of prothrombin. 
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Figure 4.3.  Factor Va titrations to determine the affinity of the recombinant 
factor Va molecules for factor Xa.   Thrombin generation experiments were carried out 
as described under “Experimental Procedures”.  Prothrombinase complex was assembled 
with varying concentrations of recombinant factor VaWT (filled squares), factor VaDFDY 
(filled triangles), factor VaKFDY (filled inverse triangles), factor VaDEDE(filled diamonds), 
and fVaDFDF(filled circles).  The dissociation constants (Kd) were obtained using the 
GraphPad Prism software. 
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Figure 4.4.  Prothrombin titration to determine the kinetic parameters of 
prothrombinase assembled with various recombinant factor Va species.  Thrombin 
generation experiments were carried out as described under “Experimental Procedures” 
by varying the substrate concentration (25 nM to 4 µM) with 10 pM of factor Xa 
saturated with the factor Va species.  Prothrombinase complex was assembled with 
recombinant factor VaWT (filled squares), factor VaKFDY (filled triangles), factor VaDFDY 
(filled inverse triangles), factor VaDEDE(filled diamonds), and fVaDFDF(filled circles).  The 
solid lines represent a nonlinear regression fit of the data using Prizm GraphPad software 
for a one binding site model. 
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Figure 4.5. Analysis of the activation of plasma-derived prothrombin by 
prothrombinase.  Plasma-derived prothrombin (1.4 μM) was incubated in different 
mixtures with PCPS vesicles (20 μM), and prothrombinase assembled with either factor 
VaWT , factor VaKFDY , factor VaDFDY, factor VaDEDE, and factor VaDFDF as described in 
the “Experimental Procedures” section. 
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 Figure 4.6.  Gel electrophoresis analyses for cleavage of FPR-meizothrombin.  
FPR-meizothrombin (1.4 μM) was incubated in different mixtures with PCPS vesicles 
(20 μM) and factor Va (20 nM).  The reactions were started by the addition of factor Xa 
and the samples were further treated, scanned and quantified as detailed in the 
“Experimental Procedures” section. 
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4.5 Discussion 
 In retrospect, our data has demonstrated that the amino acids 695DY696 of the 
factor Va heavy chain play a significant role in prothrombinase activation of its substrate, 
prothrombin.  Through experimental analysis using kinetic studies and recombinant 
proteins, we have shown that this portion of the carboxy-terminal region of the heavy 
chain induces a delay in cleavage at Arg271 during prothrombin activation.  This sequence 
on the factor V molecule has been found to be highly conserved amongst various species 
including bovine, chimp, and mouse sequences, pointing out the significance of the 
region.  
There have been conflicting reports by other laboratories stating that the carboxy-
terminus of the factor Va heavy chain has no major impact on prothrombinase function 
[17]. In our lab, we have demonstrated that the COOH-terminal region of the factor Va 
heavy chain plays an important part on the complex’s function and regulates the amount 
of meizothrombin that lingers during prothrombin activation through delayed cleavage at 
Arg271.  In these studies, we determined that it is specifically amino acid residues 695 and 
696 who are responsible for timely cleavage of the substrate by the prothombinase 
complex.  In order for prothrombinase to properly align itself with prothrombin to have 
efficient cleavage, these two amino acids must be in presence.   
Kinetic analysis through fVa titration assays were done to determine the effects of 
mutations done to the fVa heavy chain.  Mutation of the sequence, 695DY696, did not 
affect the affinity of fVa to fXa when Kd values were determined.  In addition, 
prothrombin titration assays using varying concentrations of the substrate with all 
components of the prothrombinase complex resulted in Kcat values that were normal for 
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all recombinant mutants constructed except for fVaKFDY and fVaDFDY.  In the case of 
prothrombinase assembled with fVaKFDY and fVaDFDY, the catalytic efficiency of the 
enzyme complex was actually increased when thrombin generation was measured using a 
chromogenic substrate.  This can be explained due to the fact that these mutations cause 
the accumulation of the intermediate, meizothrombin during prothrombin activation.  It 
has bee previously determined that meizothrombin cleaves the chromogenic substrate, 
spectrozyme-TH, more efficiently than thrombin, leading to a higher Kcat value.   
As an overall conclusion, we have determined that the acidic cluster of amino acids, 
DYDYQ, at the carboxy-terminus of the factor Va heavy chain play a crucial role in 
thrombin generation by the prothrombinase complex and that this effect can be 
specifically attributed to the combined effects of amino acid residues 695 and 696. 
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CHAPTER V 
OVERALL CONCLUSION 
 
5.1 Conclusion 
 Heart disease is presently one of the leading causes of death around the world.  
Individuals treated with medications to relieve cardiovascular complications are exposed 
to various side effects.  Thrombin inhibitors are one type of drug that targets serine 
proteases, which are involved in the blood coagulation.  Although these inhibitors aid 
patients with their ailments, they are non-specific and cause complications such as, 
excessive bleeding after injury.  To develop new treatments for the numerous ailments 
associated with cardiovascular problems, a deeper understanding of the molecular 
mechanisms involved in the blood coagulation response must be obtained.   
 The ultimate goal of the coagulation cascade is to form a fibrin clot that is 
catalyzd by the serine protease, human α-thrombin.  The prothrombinase complex plays a 
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crucial role in the formation of thrombin.  The efficiency of factor Xa to cleave 
prothrombin is increased considerably by the inclusion of its cofactor, factor Va.  We 
have repeatedly confirmed in our lab, that factor Va serves to regulate prothrombinase 
function during hemostasis and may be the key to the development of a better anti-
coagulant drug.   
 There are two different pathways by which prothrombin activation can occur. 
Pathway I involves factor Xa alone that will cleave prothrombin initially at Arg271 
followed by cleavage at Arg320 to reveal thrombin.  Pathway II involves the incorporation 
of factor Va and results in a reversal of cleavages with initial cleavage of prothrombin ar 
Arg320   [1].  This pathway is characterized by formation of an intermediate, 
meizothrombin that has been shown to have catalytic properties and increases factor Xa 
efficiency towards prothrombin activation.  Our lab has recently established that the 
factor Va heavy chain contains a specific cluster of amino acids on the COOH-terminal 
end that interact with prothrombin/thrombin [2].  In addition, we also analyzed a peptide 
with the sequence 695DYDYQ699 that was shown to competitively inhibit prothrombinase 
function by competing for a binding site on prothrombin [3].  It has also been 
demonstrated that prothrombinase assembled with a factor Va molecule that was cleaved 
with cathepsin G or human neutrophil elastase lead to a truncated molecule at the COOH 
end that lead to a higher Kcat value and poor clotting activity  [4].  We synthesized a 
recombinant mutant fV molecule to determine the extent of the effects of this region.  
The deletion of amino acids 680-709 resulted in a recombinant protein that increased the 
catalytic efficiency of factor Xa in regards to proteolytic processing of prothrombin.  
These results were due to the accumulation of meizothrombin when prothrombinase was 
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assembled with the deletion mutant, fVa680-709.  The prolonged appearance of this 
intermediate was found to be due to a reduced rate of cleavage at Arg271.   These results 
pointed to the importance of the factor Va heavy chain for prothrombinase function. 
 In addtion to 695DYDYQ699, our lab also investigated amino acids 334-335 which 
also consist of the DY motif.  Mutations to these two residues resulted in impaired 
clotting activity and a reduced Kcat value for prothrombinase assembled with these 
recombinant fVa mutants.     [5].  To further investigate the important role that acidic 
amino acids of factor Va play during coagulation, we constructed recombinant mutants 
within amino acids 659-663.  A deletion mutant (fVa659-664) along with point mutations 
(fVa5K) were tested within prothrombinase to evaluate kinetic values and rates of 
cleavage of the substrate, prothrombin.  Results displayed that mutations to this small 
portion of the fVa heavy chain lead to a reduced rate of cleavage of prothrombin at both, 
Arg320 and Arg271.  In addition, the Kcat values for prothrombinase formed with these 
mutants were reduced and clotting times were impaired.  Overall, these experiments point 
to the important role that acidic amino acids play in the formation of thrombin. 
 To elucidate the effects of amino acid residues 695-698 on cofactor function 
during prothrombin activation and to determine which specidic amino acids in this 
sequence were responsible for optimal cofactor function, we created fV mutants VaDEDE, 
fVaDFDF, fVaDFDY, and VaKFDY.  From studies performed in our lab, we determined that 
695DY696 of this sequence were required for proper thrombin formation.  FVaKFDY was 
found to give prothrombinase an increased Kcat value, but resulted in impaired clotting 
activity due to the accumulation of the intermediate, meizothrombin.  All of the other 
recombinant mutants were normal when compared to fVaWT.  Tyrosine sulfation is an 
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important modification that occurs to the factor V molecule.  It is essential for proper 
cofactor activation and function.  Tyr696 , Tyr698, and Tyr1510  have been identified as 
potential sulfo-tyrosine sites of factor V [6].  Results obtained in our studies with 
fVaKFDY, indicate that Tyr696 of the factor Va heavy chain plays an important role in 
coafactor regulation of the prothrombinase complex. 
 Heart disease and stroke have enormous effects on the world population on hand.  
It is of great importance to initiate a method of therapy that will cut the number of current 
cases as well as ones that will develop in the future.  In order to do this, it is necessary to 
further investigate the effects of the coagulation cascade and its numerous members.  In 
particular, the cofactor, factor Va and its involvement in clot formation.  
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